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Over the past decades, platinum-based therapy remains one of the most commonly used 
broad spectrum anticancer drugs available. In some cancers, such as testicular cancer, 
cisplatin-based therapy has more than 90% cure rates, but in others, such as ovarian and 
lung cancer, the effectiveness of cisplatin is poor due to high incidence of cisplatin-
resistant tumors in these cancers. More importantly, these refractory tumors are 
notoriously difficult to treat, as the options of available chemotherapeutic regimens 
become very limited due to their cross resistance to other chemotherapeutic agents. 
Consequently, chemoresistance is one of the main reasons for chemotherapy failure. To 
address this problem, this study aims to understand the molecular mechanisms 
underlying cisplatin resistance. This allows us to identify specific targets that confer the 
resistance and thus design better chemotherapeutic action against these targets to 
combat the problem of resistance. 
In this regard, we develop a NSCLC cisplatin-resistant model to emulate the refractory 
disease condition in an effort to understand the mechanism of acquired resistance to 
cisplatin. Indeed, these cisplatin-resistant cells display cross resistance with other 
platinum drugs as well as other conventional chemotherapeutic agents. In this study, we 
found several alterations in the energy metabolism and mitochondrial function of the 
cisplatin-resistant cells and proposed that mitochondria could be a main driver for the 
acquisition of resistance to cisplatin. One of the main functions of mitochondria 
involves mediating apoptosis in response to chemotherapy-induced DNA damage and 
we provide evidence to show that the pathway is compromised in the cisplatin-resistant 
cells. These findings led us to explore other drugs that could induce cell death 
independent of the mitochondria in the cisplatin-resistant cells. We found that TRAIL 
xi 
 
can effectively induce apoptosis in the cisplatin-resistant cells in a mitochondria-
independent manner. Further investigations led us to unravel the inherent molecular 
mechanisms of cisplatin resistance that concomitantly that render these cells sensitivity 
to TRAIL. We found that prior treatment to cisplatin caused a redistribution of death 
receptors to the lipid rafts on the plasma membrane which greatly enhance TRAIL-
induced apoptotic signaling in the cisplatin-resistant cells. In addition, we discovered 
that TRAIL was able to induce caspase-dependent intracellular peroxynitrite 
production, which function as an important mediator of cell death, in the cisplatin-
resistant cells. We further confirm the dependence of TRAIL on peroxynitrite-medited 
cell death by demonstrating that TRAIL-induced cell death can be abrogated by 
eliminating peroxynitrite accumulation. Finally, our study also provides compelling 
evidence for TRAIL to be used as a second line treatment, either as a monotherapy or 
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1 Lung cancer 
Lung cancer is the leading cause of cancer-related deaths in the world. It is 
characterized by the dysregulated growth of normal cells in lung tissues and at later 
stages, the malignant cells can spread to other parts of the body by the process called 
metastasis. Lung cancer can be broadly classified into 2 main types; small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC) (Johnson DH, 2008). Since 
the two types of lung cancers are treated differently, accurate diagnosis and distinction 
between the two lung cancer types is critical. Standard diagnosis relies on 
histopathology, and immunohistochemical studies from biopsies to confirm the type 
of lung cancer (Rivera and Mehta, 2007). In recent years, genetic expression profiling 
studies have gained significant attention for identifying molecular signatures that 
differentiate between the histological subtypes of lung cancers (Meyerson et al., 2004; 
Yanaihara et al., 2006). 
For both SCLC and NSCLC, the extent of disease is routinely examined with 
computer tomography (CT), positron emission tomography (PET) and 
mediastinoscopy to determine how far the disease has spread. The stage of the tumors 
is then classified using the TNM
1
 classification system, which is one of the most 
robust and important prognostic factors for lung cancer (Goldstraw et al., 2007).  
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SCLC accounts for about 20% of the lung cancer cases and is more aggressive as 
compared to NSCLC. SCLC is a type of epithelial tumor characterized by small cells 
with scant cytoplasm, ill-defined cell borders, finely granular nuclear chromatin, and 
absent or inconspicuous nucleoli (van Meerbeeck et al., 2011). SCLC has strong 
association with smoking with more than 90% of patients with SCLC are current or 
past heavy smokers, with various pulmonary, cardiovascular, and metabolic 
comorbidities (De Ruysscher et al., 2009). Essentially, the risk for SCLC is positively 
correlated to duration and intensity of smoking (Devesa et al., 2005).  
Extensive studies have shown many specific genetic and molecular features 
commonly associated with SCLC (Meyerson et al., 2004). For example, in almost all 
SCLC cases, the tumor suppressor FHIT and RB genes are deleted. In addition, SCLC 
cancers have higher frequencies of tumor suppressor TP53 gene mutations as 
compared to NSCLC. Although these molecular features are insufficient to affect 
diagnostic methods, the information has been extremely helpful in understanding 
SCLC tumorigenesis. 
Treatment options for SCLC depend on the histology and stage of the patients (van 
Meerbeeck et al., 2011). Because of its highly aggressive nature, patients with SCLC 
often develop distant metastases at time of diagnosis. Hence, localized forms of 
treatment, such as surgical resection and radiotherapy are often designed with 
chemotherapy regimens. First-line standard chemotherapy for SCLC is platinum-
based regimens in combination with etoposide (Sundstrom et al., 2002). At the start of 
treatment, SCLC is highly responsive to chemotherapy and radiation therapy, which 
significantly improves patient outcomes, however, SCLC often recurs with resistant 
disease. The option for second-line treatment in SCLC is fairly limited. The only 
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currently approved drug for refractory SCLC is topotecan, which has low response 
rate but patients have seen a few months of survival benefit.  Regardless of stage, the 
current prognosis of SCLC is poor with overall survival at 5 years at only 5-10% 
(Lassen et al., 1995).  
 
1.2 NSCLC 
NSCLC comprises 80% of the lung cancer cases and does not grow and spread as fast 
as SCLC. It is poorly differentiated and consists of diverse histological subtypes 
including adenocarcinoma, bronchioloalveolar, squamous, large-cell carcinomas and 
poorly differentiated variants (Goldstraw et al., 2011). While smoking remains as the 
primary risk factor for NSCLC, studies have reported 10-40% of NSCLC cases in 
patients with no history of tobacco smoking (Subramanian and Govindan, 2007). In 
this regard, evidence have accrued to demonstrate that other factors such as 
environment (second-hand smoke and radiation), occupational exposures (asbestos 
and other chemicals) and genetic susceptibility have important contributions in the 
etiology of NSCLC (Govindan et al., 2012; Ng, 1994; Weiss, 1983; Yang et al., 
1999).  
The treatment option and prognosis for NSCLC essentially depends on the 
classification and stage of the histological subtypes. For early stage NSCLC with 
localized resectable tumors, surgery is the standard of care for these patients, often 
along with adjuvant chemotherapy. Patients who have undergone lobectomy often 
have increased long term survival. Despite efforts to develop early screening tools, 
majority (70%) of the NSCLC are detected at an advanced stage. For advanced stage 
NSCLC, the use of radiotherapy and chemotherapy are the treatment of choice. Due to 
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high incidence of chemoresistance, the prognosis for advanced NSCLC is usually 
unsatisfactory (Goldstraw et al., 2011; Molina et al., 2008).  
The recommended first-line chemotherapy for advanced NSCLC is platinum-based 
therapy (cisplatin and carboplatin) in combination with conventional genotoxic drugs 
such as pemetrexed, gemcitabine (Breathnach et al., 2001; Scagliotti et al., 2009). 
These drugs bind indiscriminately to DNA, which interfere with DNA synthesis 
resulting in genotoxic stress and eventual cell death. Although this traditional 
chemotherapeutic approach has shown better patient response their use has been 
limited by the high incidence of drug resistance and severe toxicity in patients.  
Until recently, the selection of therapy for NSCLC is not based on histological 
subtype of NSCLC and it is largely empirical. Histological-based treatments have 
revolutionized the treatment of NSCLC, gearing towards a more patient-oriented as 
well as targeted therapeutic approach. Rapid advances using molecular and genetic 
approaches have identified change in expressions or alterations in proteins and 
signaling pathways crucial for the maintenance and metastasis of the different 
subtypes of NSCLC tumors. These discoveries allowed us to refine the therapeutic 
regimens as well as identify specific molecular targets for therapy which have shown 
to significantly improve long-term survival rates with less toxicity in molecularly 
selected subgroup of patients. These include: 
1) The discovery of epidermal growth factor receptor (EGFR) mutations in a 
subset of NSCLC patients has led to improved response to EGFR tyrosine 
kinase inhibitors (TKI) in these patients (Fukuoka et al., 2003; Gridelli et al., 
2011; Lynch et al., 2004; Mok et al., 2009).  
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2) The discovery of VEGF inhibitors, bevacizumab, which inhibits angiogenesis, 
has shown high toxicity profile in NSCLC patients with squamous histology 
and hence these patients are excluded from bevacizumab and most of anti-
angiogenesis inhibitors in clinical trials(Johnson et al., 2004; Sandler et al., 
2006). 
3) The discovery that an antifolate agent, pemetrexed, has poor response in 
NSCLC patients with squamous histology than other types of NSCLC thus the 



















2 Chemotherapy  
Chemotherapy for the treatment of cancer has been introduced more than 50 years 
ago. The aim of chemotherapy is to: 
 Kill cancer cells 
 Stop cancer cells from spreading 
 Slow the growth of cancer cells 
Chemotherapeutic drugs can be taken orally or intravenously, furthermore, a drug can 
be administered alone or in combinations with other drug treatments. In some cases, 
chemotherapy can be the only standard of care available for cancer patients, such as 
advanced NSCLC. While in other cases, chemotherapy can be used to enhance other 
treatments, such as surgery and radiotherapy, this is termed as adjuvant chemotherapy 
(Benson et al., 2004; Romond et al., 2005). Chemotherapy can be broadly classified 











Table 1: Examples of FDA-approved chemotherapeutic drugs used in the treatment of cancer. HDAC: 
Histone deacetylases ; mTOR: Mammalian target of rapamycin; VEGF: Vascular endothelial growth 
factor; VEGFR: Vascular endothelial growth factor receptor; EGFR: Epidermal growth factor receptor 
 
Conventional Chemotherapy Targeted Therapy 
Alkylating agents HDAC inhibitors 
Nitrogen mustards: Cyclophosphamide, Ifosfamide Romidepsin 
Nitrosoureas Vorinostat 
 Alkylsulfonates mTOR inhibitors 
Ethyleneimines Everolimus 
 Triazene Temsirolimus 
 Methyl Hydrazines VEGF/VEGFR inhibitors 
Platinum complexes: Cisplatin, Carboplatin,Oxaliplatin Bevacizumab (antibody) 
Antibiotics-derived DNA intercalating agents Sorafenib 
Doxorubicin Sunitinib  
Bleomycin Pazopanib 
 Epirubicin Ziv-aflibercept 
 Daunorubicin  EGFR/Her1 inhibitors 
Antimetabolites Cetuximab (antibody) 
 Folate Antagonists: Methotrexate Panitumumab  (antibody) 
Purine antagonists: Fludarabine, 6-Mercaptopurine Gefitinib 
Pyrimidine antagonists: 5-Fluorouracil,  Gemcitabine Erlotinib 
DNA enzyme topoisomerase inhibitor  EGFR/Her2/neu inhibitors 
Epipodophyllotoxins: Etoposide Pertuzumab (antibody) 
Camptothecins: Irinotecan,Topotecan Trastuzumab  (antibody) 
Mitotic inhibitors Lapatinib 
 Vinca Alkaloids: Vincristine, Vinblastine Proteasome inhibitor 
Taxanes: Paclitaxel, Docetaxel Bortezomib 
 Carfilzomib 






 Targets surface proteins markers  
 Brentuximab vedotin (antibody) 
 Ofatumumab (antibody) 
 Rituximab (antibody) 
 Ipilimumab (antibody) 
 B-RAF inhibitor 
   Vemurafenib 
 Hormones and Antagonists 
 Corticosteroids: Prednisone, Dexamethasone 
 Estrogens-based: Ethinyloestradiol  Tamoxifen 
 Progesteron derivative: Megestrol acetate 
 Androgen-based:Testosterone propionate 
 Flutamide, Bicalutamide, Enzalutamide 
 Aromatase inhibitor: Letrozole , Anastrazole 
 5-Alpha reductase inhibitor: Finasteride 
 GnRH analogue: Leuprolide, Buserelin 




Cancer cells are characterized by their uncontrolled growth rates and this shaped the 
fundamental basis of drug discovery and development in early cancer management. 
Over the last decades, a wide array of drugs has been primarily developed to target 
different mechanisms that interfere with DNA synthesis and cell division processes 
(Table 1). The different classes of drugs include DNA alkylating agents, DNA 
intercalating agents, antimetabolites, topoisomerase inhibitors and mitotic inhibitors. 
While these drugs target rapidly dividing cancer cells, the indiscriminate nature of 
these drugs also affects the normal cells. As a result, many patients suffer from the 
adverse effects of chemotherapy. Common toxicities associated with chemotherapy 
include alopecia, gastrointestinal symptoms, and myelosuppression (Ganz et al., 2002; 
Wong and Giandomenico, 1999). 
 
Targeted therapy (small molecules and antibody-based therapy) 
Cancer is a multistage process driven by the progressive accumulation of mutations 
and epigenetic abnormalities in expression of various genes with diverse biochemical 
functions (Hanahan and Weinberg, 2011). Recent advancement in the understanding 
of cancer etiology and pathology has allowed us to identify key altered signaling 
pathways and proteins driving tumorigenesis, tumor progression and maintenance. It 
has been shown that inhibiting these abnormalities can profoundly inhibit the growth 
of cancer cells, a phenomenon known as oncogene addiction (Weinstein and Joe, 
2006). This knowledge has greatly fuelled the development of molecular targeted 
drugs; drugs that target specific altered pathway or proteins which the cancer cells are 
highly dependent on for its malignant phenotype (Table 1). This therapeutic approach 
is deemed more superior than conventional chemotherapy as it specifically targets 
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cancer cells with altered pathways or proteins and spares the normal cells, resulting in 
greater efficacy and less toxicity (Aggarwal, 2010; Starakis, 2011). 
 
2.1 Conventional chemotherapy: Platinum-based therapy 
Despite the development of newer chemotherapeutic drugs, platinum-based 
chemotherapeutics remain one of the most commonly used and effective broad 
spectrum anticancer drugs available. It is widely used in the treatment of a variety of 
human malignancies such as lung, ovarian, testicular, bladder, head and neck and 
other sarcoma-derived cancers (Jamieson and Lippard, 1999). The first platinum-
based drug is discovered in 1965 by by Barnett Rosenberg, when he found that 
cisplatin caused filamentous growth of E. coli. Filamentous growth of E.coli is 
characterized by the continued growth of bacteria in the absence of DNA synthesis, 
therefore postulating that cisplatin essentially affects DNA synthesis (Rosenberg et 
al., 1967). This initiates the use of cisplatin as an anticancer agent. Despite its 
efficacy, the use of cisplatin has been limited by its high toxicity profile such as 
nephrotoxicity, gastrointestinal toxicity, neurotoxic, ototoxicity, myelosuppression 
and thrombocytopenia (Courjault et al., 1993; Miyajima et al., 1997; Portilla et al., 
2006; Von Hoff, 1987; Wong and Giandomenico, 1999). Subsequently, newer 
generation of cisplatin analogues have been developed (Figure 1). A second 
generation platinum-based drug, carboplatin, was developed and showed to cause less 
toxicity than cisplatin, however it has been shown to exhibit cross resistance to 
cisplatin (Johnson et al., 1997; Jones et al., 1993; Rixe et al., 1996). Third generation 
representative include oxaliplatin, a third generation platinum compound with a broad 
spectrum of anticancer activity approved for the use in colorectal cancer. It has a 
better safety profile than cisplatin and shows a lack of cross-resistance with cisplatin 
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or carboplatin (Kelland, 2007b; Rixe et al., 1996).  Newer analogues of platinum 
drugs such as picoplatin, satraplatin and lobaplatin, developed to overcome 
chemoresistance and toxicities issues, are currently undergoing clinical trials (Eckardt 




Figure 1: Structure of different of platinum-based anticancer drugs. Cisplatin, cis-
diamminedichloroplatinum(II); Transplatin, trans-diamminedichloroplatinum(II); Carboplatin, cis-
diammine(cyclobutane-1,1-dicarboxylato)- platinum(II); Oxaliplatin, 1,2-diaminocyclohexaneoxalato 
platinum (II). (Fabio Arnesano, 2009). 
 
2.2 Mechanism of Action 
2.2.1 DNA damage 
The best characterized mode of cytotoxicity of the platinum compounds is their 
interaction with DNA to form DNA adducts. Platinum compounds belong to the class 
of alkylating agents, capable of forming strong electrophiles usually via a carbonium 
ion or carbon radical. In the aqueous environment of the body, the platinum 
compounds are inherently unstable, leading to the replacement of the chlorine ligands 
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with hydroxyl group, thus forming aquated species. These aqua groups are good 
leaving group rendering the platinum compounds positively charged. Consequently, 
these reactive compounds electrostatically attract negatively-charged DNA helix 
resulting in the formation of intrastrand cross-links adducts between two neighboring 
deoxyguanosines (GG). The modification preferentially occur through the nitrogen (7) 
position on the purine ring of the DNA, which is particular susceptible to alkylation 
(Jamieson and Lippard, 1999; Roberts and Thomson, 1979; Takahara et al., 1995). 
The formation of platinum-DNA adducts distort the DNA helical structure and thus 
interfere with normal DNA replication and transcription. This induces genotoxic 
stress, triggering the activation of DNA repair mechanism by nucleotide excision 
repair (NER) pathway (Zamble et al., 1996). However, it has been well documented 
that platinum-DNA adducts are often poorly repaired  in cells, due to a class of 
abundant chromosome constituents known as the high-mobility-group (HMG) 
proteins, which bind to platinum-DNA adducts and shield them from repair (Huang et 
al., 1994). 
 
2.2.2 Induction of DNA-damage signals 
DNA damage caused by the platinum compounds triggers the multiple signaling 




Figure 2: A summary of cisplatin-induced signaling pathways following DNA damage. The 
pathways can lead to cell death by apoptosis or necrosis depending on the dose of cisplatin. While 
death pathways are initiated, survival pathways might also be activated to antagonize the death signals. 
Edited from (Wang and Lippard, 2005). 
 
2.2.2.1 Induction of cell death pathways  
Cell death is initiated when the DNA damage induced is irreparable. One of the most 
important regulators that signal cisplatin-induced cell death is the tumor suppressor 
protein p53. It is a potent activator of apoptosis, and p53 deficient cancer cells are less 
responsive to cisplatin therapy (Vogelstein et al., 2000). Furthermore studies have 
shown that  the sensitivity of cancer cells to cisplatin is positively correlated with the 
presence of wild-type (WT) p53 (Vekris et al., 2004). p53 has a crucial role in 
numerous cellular processes. Following DNA damage, p53 has been described to 
mediate DNA nucleotide excision repair (NER) by interacting with proteins of NER 
machinery. p53 is a transcriptional factor responsible for the upregulation of a group 
of genes encoding for proteins that facilitate cell death. These pro-apoptotic proteins 
include p21
WAF/CIP
, puma, noxa, bax (Gottlieb and Oren, 1998; Villunger et al., 2003). 
A p53 family protein, p73 has also shown to play a role in meditating cisplatin-
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induced cell death (Al-Bahlani et al., 2011; Shimodaira et al., 2003). In addition, 
upstream signals that mediates regulates p53, such ATM (positive regulator), and 
Mdm2 (negative regulator) proteins are also important for mediating cisplatin-induced 
cell death.  
Ciplatin has been shown to induce 2 modes of cell deaths: apoptosis and necrosis. 
Similar to other genotoxic drugs, the mode of cell death is dependent on the dose of 
cisplatin exposure (Gonzalez et al., 2001). It has been shown that high dose of 
cisplatin induce necrosis after a few hours of cisplatin treatment while low dose of 
cisplatin induces apoptosis only after several days of exposure to cisplatin (Lieberthal 
et al., 1996). The mechanism of cell death is further elaborated in section 3. 
2.2.2.2 Cell cycle perturbations 
It is well understood that the binding of cisplatin to DNA by itself is not sufficient to 
cause cell death. It usually takes several days for the cells to die following cisplatin 
treatment and it is during this time that decisions are made that impact on the survival 
or death of the cell (Lieberthal et al., 1996). The cell fate decision of the cells often 
depends on the dose of cisplatin treatment. At low concentrations of cisplatin, cells 
accumulated in the G2-phase for a few days and then recovered, indicating that these 
cells have the capacity to replicate on damaged DNA and arrest in G2-phase to repair 
DNA damage before resuming the cell cycle progress. At higher drug concentrations, 
the cells still progressed to G2-phase but often preceded by a slow passage through the 
S-phase. The progress of the cell through the different cell cycle phases is tightly 
governed by the cell cycle checkpoints and if DNA damage is irreparable, the cells 
eventually undergo an abortive attempt at mitosis that results in cell death and it has 
been previously described that G2 phase cell arrest is a key event in mediating 
cisplatin-induced cell death (Dasika et al., 1999). The proteins shown to play a role in 
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mediating cell cycle arrest include Aurora A, p53 and p73. Overexpression of Aurora 
A has been shown to down-regulate checkpoint response pathways and hence promote 
dysregulation in cell cycle (Katayama et al., 2004). 
2.2.2.3 Induction of cell survival signals  
In response to cisplatin trigger, besides activation of DNA repair mechanisms, the 
MAPK (ERK and p38) and stress activated protein kinases (JNK) signaling pathways 
are also activated (Cui et al., 2000; Persons et al., 2000). These proteins are 
commonly associated with cell survival and protection from cell death however their 
roles in mediating cisplatin-induced survival are still poorly understood.  But in 
refractory cancer cells resistant to platinum-based drugs, they often have molecular 
characteristics that suggest the role of MAPK/ JNK in mediating the resistance 
phenotype. 
 
2.2.3 Other non-genome associated damage  
DNA damage and cell cycle arrests cannot explain all the toxicities associated with 
platinum-based drugs. Clinically, ototoxicity, neurotoxicity and nephrotoxicity are 
examples of the toxicities described with the use of platinum compounds. Studies 
have shown other non-genomic target of cisplatin such as phospholipids, reactive 
oxygen species production, enzymes and other cellular organelles such as 
mitochondria and ER (Cullen et al., 2007; Gemba and Sugihara, 1986; Hannemann 
and Baumann, 1988; Hirama et al., 2006; Nakano and Gemba, 1989; Vermeulen and 
Baldew, 1992). The underlying molecular mechanisms responsible for the pleiotropic 
effects of platinum compounds remain poorly understood.  
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3 Cell death 
In cancer therapeutics, death of the malignant cells is the ultimate aim for 
chemotherapy. To this end, understanding modulators of cell death programmes and 
characterization of the death mechanism allow us to improve therapeutic approaches 
for treatment of these diseases. Over the years, extensive work in the field of cell 
death has identified various types of cell death and refined them by their distinct 
molecular characteristics rather than the morphological criteria. They are apoptosis, 
anoikis autophagic cell death, cornification, entosis, necrosis, necroptosis, mitotic 
catastrophe, netosis, parthanatos, pyroptosis (Galluzzi et al., 2012). Here, we highlight 
a few of the best characterized mechanisms of cell death namely autophagy, necrosis, 
necroptosis and apoptosis.  
 
3.1 Autophagy 
Autophagy (which means “self eating” in Greek), is a general term that describe a 
homeostatic process in which cells degrade their own cytoplasmic components, such 
as soluble macromolecules and organelles, within the lysosomes (Levine and 
Klionsky, 2004; Mizushima and Klionsky, 2007). There are three types of autophagy, 
namely, macroautophagy, microautophagy, and chaperone-mediated autophagy, 
which are defined by the process by which the intracellular proteins to be degraded 
access the lysosomes (Blommaart et al., 1997). Amongst these processes, 
macroautophagy is the most extensively studied and often referred as “autophagy”. In 
this process, the cytoplasmic contents of the cells are engulfed to form a double-
membrane structure known as the autophagosome. This is followed by the fusion of 
the autophagosome with the lysosome to become an autolysosome, leading to the 
degradation of autophagosomal contents by lysosomal enzymes (Klionsky and 
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Ohsumi, 1999). The mechanism of autophagy is highly complex mediated by a group 
of proteins encoded by autophagy-related genes (Atg). Autophagy plays an important 
role in both cell survival and cell death. In response to cellular stress, such as nutrient 
starvation, the ability of autophagy to recycle nutrients, maintain cellular energy 
homeostasis and degrade toxic cytoplasmic constituents helps cells to survive(Lum et 
al., 2005; Rodriguez-Enriquez et al., 2004). Although it serves as a protective 
adaptation response to hinder cell death, autophagy has also been extensively studied 
in cell death. Autophagic cell death is a term used to describe cell death accompanied 
with autophagy, and in rare cases cell death by autophagy. This type of cell death 
occurs in the absence of chromatin condensation but is accompanied by massive 
autophagic vacuolization of the cytoplasm (Kroemer and Levine, 2008). Biochemical 
features of autophagic pathway activation in cell death includes exhibition of 
lipidation of microtubule-associated protein1 light chain 3 (LC3/Atg8) or increased 
degradation of autophagic substrates like sequestosome 1 (p62/ SQSTM1) (Komatsu 
et al., 2007; Pankiv et al., 2007). 
Due to the recent explosion associating autophagy and cell survival, the role of 
autophagy in cell death has been less defined. It is believed that that concomitant 
occurrence of cell death and autophagy is not sufficient to qualify as “cell death is 
executed by autophagy”, but rather “cell death with autophagy”. Hence to validate the 
role of autophagy in effecting cell death, several investigators have proposed an 
operational definition for autophagic cell death, in which specific inhibition of 
autophagy (by inhibiting VPS34 AMBRA1, ATG5, ATG7, ATG12 and Beclin 1)  
should prevent irreversible loss of cellular functions and confer cells with survival 
(Galluzzi et al., 2012; Kroemer and Levine, 2008). Finally, autophagy has been 
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shown to play an important role in cancer as defects in autophagy have been described 
to drive tumorigenesis (Degenhardt et al., 2006).  
 
3.2 Necrosis and Necroptosis 
Conventionally, necrosis is conceptualized as a nonregulated and accidental type of 
cell death. Following acute injury, cells show distinct morphological features of 
necrosis which includes cell swelling, swelling of intracellular organelles, resulting in 
rupture of plasma membrane and the discharge of intracellular organelles into 
extracellular milieu (Majno and Joris, 1995). These events can be replicated 
experimentally by impairing a cell’s ability to produce ATP and hence necrosis is 
considered as a form of passive cell death (Zong and Thompson, 2006). A study by 
Reed (2002) has defined the possible molecular events that ensue following a necrotic 
stimulus. It described that necrosis stimuli can damage the mitochondria electron 
transport chain therefore disrupting ATP production, leading to mitochondrial 
depolarization. The leakage of electrons from the damaged electron transport chain 
can lead to reactive oxygen species (ROS) formation ROS-induced cellular damage 
results in the disruption of the integrity of cellular membrane components and thus 
causes rupture of the organelles and plasma membranes. This type of cell death 
potentially engages damaging inflammatory response that inflicts damage on 
neighboring cells and promotes tumorigenesis (Vakkila and Lotze, 2004). 
Recent developments in the realm of cell death have overturned the notion that 
necrosis represents a merely accidental cell death mechanism (Degterev et al., 2005; 
He et al., 2009). It is well established that necrotic cell death can be induced by the 
same stimuli that normally activates apoptosis in the form of death domain receptor 
engagement by their respective ligands under conditions where apoptotic execution is 
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prevented (Holler et al., 2000; Matsumura et al., 2000). This form of cell death is 
clearly distinct from apoptosis as it does not involve key regulators of apoptosis such 
as caspases, Bcl-2 family proteins and cytochrome c release from mitochondria 
(Degterev et al., 2005). In addition to apoptotic features, it exhibit similar 
morphological features observed in  necrosis cell death, such as rapid loss of plasma 
membrane integrity, lack of nuclear fragmentation, mitochondrial dysfunction and 
oxidative stress. It is now clear that necroptosis has a prominent role in numerous 
physiological and pathological processes. The mechanism of necroptosis is regulated 
by a group of proteins receptor-interacting proteins (RIP1 and RIP3) with 
serine/threonine kinase activity (Declercq et al., 2009). These proteins are the key 
players in initiating necroptosis when caspsase-8 activity is block. In TNFR1-
mediated necroptosis, a necrosome signaling complex is form; where RIP1-RIP3 
recuits FADD and caspase-8 and mediate downstream caspase independent pathways, 
characterized by alterations in mitochondrial bioenergetics, massive ROS/ RNS 
generation and DNA damage. Besides TNFR1, Fas/ TRAIL can also mediate 
necroptosis. In the death receptor pathway, a similar signaling complex is formed, 
known as the ripoptosome, which comprise of mainly RIP1, FADD and capase 8 
however the formation of this ripoptosome complex is tightly regulated by 
ubiquitylation of the IAP proteins, cFLIP isoforms (Bianchi and Meier, 2009; Tenev 
et al., 2011) and NFkB (Lin et al., 2004). The formation of these necrosome or 
ripoptosome complexes have been shown to be efficiently suppressed by a potent 
small molecule, necrostatin-1 (Degterev et al., 2005). Several triggers have been 
shown to induce necroptosis, such as DNA alkylating DNA damage, death receptors 
ligations, pathogen infection, ROS and ATP depletion (by nutrient starvation or low 
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oxygen conditions) under controlled conditions (Vandenabeele et al., 2010; Zong and 
Thompson, 2006).  
 
3.3 Apoptosis 
Apoptosis is the best characterized form of programmed cell death mechanism thus 
far. It is essential for normal embryonic development, immune system function and 
maintenance of homeostasis in multicellular organism (Fuchs and Steller, 2011; 
Jacobson et al., 1997). And therefore, deregulation of apoptosis has been linked to 
various disease pathologies, including neurodegenerative diseases, autoimmunity and 
cancer.  
Apoptosis was first described by Kerr et al. (1972) as a regulated form of cell death 
characterized by cell shrinkage, blebbing of plasma membrane, maintenance of 
organelles integrity, condensation and fragmentation of DNA, and subsequently 
removed by phagocytes. Further studies on Caenorhabditis elegans (C. elegans) 
model defined the molecular genetic pathways involved in the process of apoptosis 
and thus provide a basis for understanding the mechanism of programmed cell death 
(Ellis and Horvitz, 1986; Horvitz, 1999). These findings demonstrated that a family of 
cysteine proteases known as CED-3 (in C. elegans) or caspases (in mammals) is 
essential for mediating the highly ordered apoptotic process (Alnemri, 1997; 





4 Molecular mechanisms of apoptosis 
4.1 Caspases  
Caspases are the main effectors that drive apoptosis. They belong to the mammalian 
interleukin-1β-converting enzyme (ICE) family cysteine proteases which are highly 
homologous to C. elegans cell death gene CED-3 (Nicholson and Thornberry, 1997). 
The function of caspases is denoted by their names; Cysteine-dependent ASPartyl-
specific proteASE, in other words, aspartate-specific cysteine proteases. Their 
catalytical activity depends on a critical cysteine-residue within a highly conserved 
active site penta-peptide, QACXG (Denault and Salvesen, 2002). Activated caspases 
are highly selective in their substrate, exhibiting an absolute requirement for cleavage 
after an aspartate residue. Substrate specificity is further defined by at least three other 
amino acid residues at the N-terminal of the aspartate residue; (XXXD) (Denault and 
Salvesen, 2002; Earnshaw et al., 1999). 
It has been shown that loss of ced-3 and ced-4 functions inhibit developmentally 
programmed cell death in C.elegans (Ellis and Horvitz, 1986). In mammals, caspase-3 
or caspase-9 knockout mice have defective apoptosis in the brain, and their 
lymphocytes are partially resistant to some apoptotic stimuli (Hakem et al., 1998; 
Kuida et al., 1996). These findings demonstrate that roles of caspases are highly 
conserved and critical regulators of cell death initiation. In addition to apoptosis, 
caspases have been known to play a role in inflammation, immune response and 
epithelial cell differentiation. 
There are at least 14 isoforms of caspases identified so far (Alnemri, 1997). Caspases 
are synthesized as zymogens, with a pro-domain at the N-terminal followed by 
sequences encoding first a large and then a small subunit (Nicholson, 1999). Under 
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the pro-apoptotic stimuli, procaspases become proteolytically cleaved between these 
domains. This is followed by association of the large and small subunits to form a 
heterodimer. Subsequently, two heterodimers come together to form a tetramer, the 
functional unit of caspases (Earnshaw et al., 1999). The conversion of the zymogens 
to active mature enzymes is highly regulated. It requires a minimum of 2 cleavages in 
an ordered fashion to generate fully active enzymes that are heterotetramers 
comprised of two identical subunits of large subunit and two identical subunits of 
small subunits. These subunits can be produced by caspase-mediated cleavage and in 
some cases, aggregation of caspase zymogens is sufficient to promote self-processing. 
Based on their functions, the capases are classified into initiator caspases (caspase-2, -
8, -9, -10), executioner or effector caspases (caspase-3, -6 and -7) and inflammatory 
caspases (caspase-1, -4, -5, -11 and -12) (Alnemri, 1997; Alnemri et al., 1996). Figure 





Figure 3: The mammalian caspase family and C.elegans caspase, ced-3. Based on substrate 
specificity, the caspase family can be subdivided into 3 groups: initiators, which are able to auto-
activate and initiate the proteolytic processing of other caspases, effectors, which are activated by other 
caspase molecules and subsequently cleave a vast majority of substrates during apoptosis and lastly, 
cytokine activators, which are involved in inflammatory functions. Edited from (Chang and Yang, 
2000). 
 
Upon apoptotic trigger, initiator caspases start an inundation of increasing caspase 
activity by processing and activating the effector caspases (Nicholson and Thornberry, 
1997). Once the effector caspases are activated, they results in the cleavage of 
numerous vital cellular substrates that result in the apoptotic phenotype. The 
substrates include DNA repair enzymes, poly(ADP-ribose) polymerase (PARP) and 
inhibitor of caspase-activated DNAse (ICAD), (Fesik, 2000; Rosen and Casciola-
Rosen, 1997). Caspase cleavage of ICAD permits the release and translocation of 
caspase-activated DNAse (CAD) to the nucleus where it is responsible for 
internucleosomal DNA cleavage, generating oligonucleosomal DNA fragments (Enari 
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et al., 1998). Caspases also mediate nuclear shrinkage by cleaving la and membrane 
blebbing by targeting proteins such as Rho-associated kinase 1 (ROCK1), p21 
activated kinase (PAK) and gelsolin (Levkau et al., 1998; Orth et al., 1996; Rudel and 
Bokoch, 1997; Wen et al., 1997). 
 
4.2 Bcl-2 family proteins 
The Bcl-2 (B-cell lymphoma 2) protein family of proteins plays a central role in the 
regulation of apoptosis facilitating the release of pro-apoptotic factors from the 
mitochondria (Chipuk and Green, 2008; Letai et al., 2002; Youle and Strasser, 2008). 
Bcl-2 is first discovered as a proto-oncogene in B lymphocytes (Bakhshi et al., 1985; 
Tsujimoto et al., 1985). Subsequently, a number of proteins with structural similarity 
to Bcl-2 have been discovered during recent years. The Bcl-2 family of proteins 
includes both pro-apoptotic and anti-apoptotic molecules, all of which contain at least 
one conserved Bcl-2 homology (BH) domain (BH1 to 4) (Figure 4; Gross et al. 
(1999)). The ratio between these two subgroups helps determine, to some extent, the 




Figure 4: A summary of Bcl-2-family proteins. (BH domains: 1-4) denote the BCL-2 homology 
regions and (TM) denote the carboxy-terminal hydrophobic domain. These proteins have are broadly 
characterized into three groups depending on their role in the regulation of apoptosis. Edited from 
(Gross et al., 1999). 
 
Anti-apoptotic Bcl-2 family members includes Bcl-2, Bcl-xl, Bcl-w, Mcl-1 and A1. 
They all share 4 BH domains and contain a hydrophobic binding pocket that binds the 
BH3 domain of other family members. These proteins are generally integrated within 
the OMM, but may also be in the cytosol or ER membrane. Their main function 
within the apoptotic pathway is to maintain the OMM integrity by directly inhibiting 
the pro-apoptotic Bcl-2 proteins. In addition to their role in apoptosis, they are also 
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important for other cellular processes including mitochondrial dynamics, endoplasmic 
reticulum (ER), calcium stores, and autophagy (Chipuk and Green, 2008). 
The pro-apoptotic Bcl-2 family members can be subdivided into 2 groups, the pro-
apoptotic effectors proteins (Bax, Bak and Bok) and the BH3-only proteins (Bid, Bad, 
Bim, Puma, Noxa etc). The effectors proteins contain multiple domains, namely BH1-
3. In the presence of apoptotic stimuli, Bax and Bak translocate from the cytosol to 
the mitochondria, homo-oligomerize and incorporated into the outer mitochondria 
membrane to form a pore to promote mitochondria outer membrane permeabilization 
(MOMP) (Chipuk and Green, 2008; Kuwana et al., 2002). The activation of Bax/Bak 
is regulated by the BH-3 only pro-apoptotic proteins, which mainly resides in the 
cytosol (Puthalakath and Strasser, 2002; Wei et al., 2000). These BH-3 proteins 
function as sensors of death and undergo modifications following various cellular 
stresses to translocate to the mitochondria. At the mitochondria, they interact and 
neutralize the anti-apoptotic Bcl-2 proteins (Kim et al., 2009; Luo et al., 1998; Wei et 
al., 2000). These sequence of events allows the activation and oligomerization of 
Bax/Bak, resulting in MOMP that releases the pro-apoptotic proteins such as 
cytochrome c and second second mitochondria-derived activator of caspase 
(Smac/Diablo) from the mitochondrial intermembrane space(Adrain et al., 2001; 
Goldstein et al., 2000). These pro-apoptotic factors essentially functions to activate 
caspases to drive apoptosis. 
 
4.3 Role of IAP proteins  
The Inhibitor of APoptosis (IAP) proteins consist of a family of anti-apoptotic 
proteins that promote pro-survival signalling pathways and prevent the activation of 
apoptosis by interfering with the activation of caspases (Deveraux et al., 1997; Hay, 
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2000). The IAP gene was first discovered in baculovirus where it was shown to 
enhance virus replication by protecting infected cells from apoptosis. Subsequently, a 
number of IAP homologues have been identified (Wright and Duckett, 2005). To 
date, eight IAP proteins have been identified in humans: neuronal apoptosis inhibitory 
protein (NAIP), cellular inhibitor of apoptosis protein 1 (cIAP1), cellular inhibitor of 
apoptosis protein 2 (cIAP2), X-linked IAP (XIAP), survivin, BRUCE, melanoma IAP 
(ML-IAP)/Livin and IAP-like protein-2 (ILP2) (Vaux and Silke, 2005). 
All IAP proteins contain baculoviral IAP repeat (BIR) domain, which is allow them to 
bind and inhibit caspases, and hence inhibits apoptosis. In some IAPs, they also have 
a RING domain on the carboxy-terminal, which enables them to bind E2 ubiquitin-
conjugating enzymes and thus function as a E3 ubiquitin ligase. These IAP proteins 
can polyubiquitylate proteins that interact with them (e.g. caspases) enabling them to 
regulate the stability of many cell death modulators and effectors playing a critical 
role in survival and signaling pathways. In addition to the BIR and RING domains, 
IAP proteins have several other domains that are found to mediate protein–protein 
interactions. For example, mammalian cIAP1 and cIAP2 contain a caspase 
recruitment domain (CARD) that allows them to increase their binding affinity for 
caspases (Blankenship et al., 2009; Deveraux and Reed, 1999; Vaux and Silke, 2005). 
All IAP proteins were initially believed to block apoptosis by directly binding to and 
inhibiting caspases. However, it was demonstrated later that only XIAP is a potent 
direct inhibitor of caspase-3, caspase-7 and caspase-9 (Eckelman et al., 2006). Studies 
have shown that inhibition of caspase-9 by XIAP involves the interaction of BIR3 
domain of XIAP, thus preventing caspase-9 homodimerization and activation 
(Srinivasula et al., 2001). cIAP1 and cIAP2 bind and inhibit caspase-3 and -7, albeit 
less strongly than XIAP (Deveraux et al., 1998; Eckelman et al., 2006). The functions 
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of survivin are distinctly different from XIAP, cIAP1 and cIAP2 and remains poorly 
understood. It has been shown that survivin blocks mitochondria mediated apoptosis 
by preventing the release of apoptosis inducing factor (AIF) into the cytosol, 
independent of caspase inhibition (Liu et al., 2004). In addition, survivin seems to 
play a more important role in regulating cell division (Kallio et al., 2001; Li et al., 
1999). Interestingly, while IAP proteins are known for inhibiting caspases, caspases 
have also been shown to cleave, and inactivate, IAPs. So far, XIAP, c-IAP1 and Livin 
have been reported to undergo specific and functional cleavage by caspases (Denault 
et al., 2007; Nachmias et al., 2003). In addition to caspase-mediated inhibition, IAP 
proteins can also be inhibited by the IAP antagonists Smac/DIABLO and HtrA2/Omi 
which is released from the mitochondria following apoptotic stimuli (Du et al., 2000; 

























4.4 Apoptotic pathways  
Apoptosis have been broadly classified into two types of death pathways, namely the 
intrinsic (mitochondria-mediated) and extrinsic (death receptor-mediated) pathways 
(Green and Kroemer, 1998; Nagata, 1997; Susin et al., 1998). However, these two are  
pathways are not exclusive and evidence suggest that they crosstalk and eventually 
converge on the activation of caspases, which orchestrate the demise of the cells 
(Danial and Korsmeyer, 2004) (Figure 5).  
 
 
Figure 5: An illustration of the apoptotic pathways. Two major pathways leading to apoptosis: the 
intrinsic pathway, regulated by the Bcl-2 family proteins and the extrinsic pathway mediated by the 






4.4.1 Intrinsic or mitochondria-mediated pathway 
Mitochondria are double membrane organelles in the cell that wield both vital and 
lethal functions. On one hand, mitochondria are the source of energy production for 
the survival of a cell, but on the other hand, it is equipped with various pro-apoptotic 
factors that are able to induce apoptosis, known as the intrinsic mitochondria pathway. 
The mitochondria pathways of cell death can be activated by various stimuli; 
development signals or cytotoxic insults, such as viral infection, irradiation, DNA 
damaging agents, oxidative stress and growth-factor deprivation. This pathway is 
distinguished by its regulation through the Bcl-2 family proteins and the engagement 
of the mitochondria in the killing of the cell. A key event in this pathway is the 
process of mitochondrial outer membrane permeabilization (MOMP) (Green and 
Evan, 2002; Green and Kroemer, 2004). Following apoptotic trigger, MOMP is 
induced leading to the opening of the mitochondrial permeability transition pore 
(MPTP). This leads to the loss of mitochondria transmembrane potential (ΔΨm), and 
the subsequent release of pro-apoptotic proteins (cytochrome c, smac/DIABLO, 
HtrA2/Omi, AIF etc) from the mitochondrial intermembrane space into the cytosol. 
These proteins can be broadly classified into 2 groups. The first group compose of 
proteins that activate the caspase-dependent pathway. This includes cytochrome c and 
smac/DIABLO. Cytochrome c initiates the apoptotic protease activating factor-1 
(APAF-1) oligomerization with procaspase-9 via the caspase activation and 
recruitment domain (CARD), forming a platform known as the apoptosome,  this 
results in the auto-activation of caspase-9, which subsequently activates effector 
caspases (caspase-3 and -7). These effectors caspases proceed to cleave vital cellular 
substrates to elicit apoptotsis (Liu et al., 1996a; Riedl and Salvesen, 2007; Srinivasula 
et al., 1998). Besides the formation of apoptosome, the activation of caspases is 
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enhanced by Smac/DIABLO, an IAP antagonist, which binds to IAP proteins and thus 
inhibiting their anti-apoptotic function. The second group compose of pro-apoptotic 
proteins, such as apoptosis inducing factor (AIF) and endonuclease G. Upon their 
release into the cytosol, they translocate to the nucleus and induce DNA 
fragmentation, and hence initiate nuclear apoptosis in a caspase-independent manner 
(Joza et al., 2001; Marchetti et al., 1996; Susin et al., 1999). 
The key event in the intrinsic mitochondria pathway: mitochondrial outer 
membrane permeabilization (MOMP) 
Under physiological conditions, the mitochondria maintain a highly polarized 
mitochondrial transmembrane potential (ΔΨm), generated by the electrochemical 
gradient of the electron transport chains. The mitochondrial membrane possesses 
several protein complex channels that function as solute carriers exchanging 
metabolic solutes between the cytosol and the mitochondria. The permeability 
transition pore complex (PTPC) is an example of these complexes. It is composed of a 
voltage-dependent anion channel (VDAC), adenine nucleotide translocase (ANT) and 
cyclophilin D. In normal conditions, PTPC is tightly regulated with low conductance. 
Upon apoptotic stimuli, PTPC is dysregulated and assumes a high conductance state, 
allowing uncontrolled entry of small solutes into the mitochondria resulting in the 
disspation of mitochondrial membrane potential, known as the mitochondrial 
permeability transition (MPT). This results in the swelling of the mitochondrial matrix 
and leading to the expansion of inner mitochondrial membrane, leading to MOMP. 
When MOMP is initiated, the damage is irreparable and contents of the matrix and 




The sequence of events leading to MOMP is intricately regulated by the Bcl-2 family 
proteins. The decision to survive or die is a tight balance between the ratio of the anti-
apoptotic to pro-apoptotic Bcl-2 family proteins. Bcl-2 anti-apoptotic proteins 
maintain the OMM integrity, and studies have shown that Bcl-2 and Bcl-xl can 
protect the cells by interacting with ANT and VDAC, thus preventing the formation 
of PTPC and MOMP. The Bcl-2 anti-apoptotic proteins also act by directly inhibiting 
the Bcl-2 pro-apoptotic proteins Bax and Bak.  
As mentioned earlier, BH-3-only proteins function upstream of the Bcl-2 pro-
apoptotic proteins, Bax and Bak.  BH-3-only proteins neutralize the Bcl-2 anti-
apoptotic proteins by directly interacting with them and thus inhibiting the anti-
apoptotic proteins to bind Bax or Bak. This results in the activation of Bax and Bak, 
allowing them to homo-oligomerize into proteolipid pores within the OMM to 
promote MOMP.  
4.4.2 Extrinsic or receptor-mediated pathway 
The other mode of apoptotic signaling pathway is triggered by extracellular 
cytokines, which bind and signal through the specialized cell surface receptors, the 
TNF receptor superfamily. Here we describe the classical apoptotic pathway 
mediated by Fas and TRAIL. Binding of the ligand to its cognate receptor leads to 
receptor oligomerization and recruitment of adaptor proteins such as Fas-
associated death domain (FADD) through its death domain (DD). In addition to its 
DD, the adaptor proteins also contain a death effector domain (DED) that recruits 
the procaspase -8 and together these proteins form a supramolecular platform 
termed death inducing signaling complex (DISC), a signaling platform similar to 
apoptosome of the intrinsic pathway. DISC brings the procaspase-8 in close 
proximity and thus promotes its self-activation by proteolytic cleavage (Muzio et 
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al., 1998). Robust activation caspase-8 suffices to rapidly activate downstream 
effector caspases such as caspase 3, thereby leading to apoptosis in some cell 
types. These cells are classified as Type I cells, where DISC formation induces 
large amount of caspase 8 activation, sufficient to inititate apoptosis. On the other 
hand, when DISC formation weakly activates caspase 8, an amplification signal 
from the mitochondria mediated apoptotic pathway is required. The link between 
these two pathways lies in a BH-3 only protein, Bid. a member of the Bcl-2 family 
(Li et al., 1998a) The weak activation of caspase-8 cleaves Bid to truncated Bid 
(tbid) which undergoes post-translational modifications to translocate to the 
mitochondria and interacts with pro-apoptotic members of the Bcl-2 family. This 
interaction promotes mitochondrial outer membrane permeabilization (MOMP), 
causing a drop in the mitochondrial transmembrane potential (ΔΨm), leading to 
release of apoptogenic factors from the mitochondria, thereby enhancing apoptosis 
by death receptors in Type 2 cells death receptors (Wei, 2000). Of note, it has been 
shown that Type I cells can also engage the mitochondria mediated apoptotic 
pathway, but the commitment to apoptosis can occur without the amplification 
signal from the mitochondria. This property is confirmed by a critical experiment 
whereby overexpression of anti-apoptotic protein, Bcl-2, can block apoptosis in 
type II but not in type I cells (Barnhart et al., 2003; Fulda et al., 2002; Scaffidi et 
al., 1998).  
4.4.2.1 The death ligands and TNF receptor superfamily 
The death ligands belong to a group of cytokines known as the tumor necrosis factor 
(TNF) superfamily. The members of this unique superfamily of ligands include 
TNFα, TNFβ, Fas ligand (CD95L), OX40L, CD40L, CD27L, CD30L, 4-1BBL, and 
LTb, Apo3L/TWEAK, APO2L/TRAIL and RANKL (Ashkenazi and Dixit, 1998; 
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Baker and Reddy, 1998; Suda et al., 1993; Wiley et al., 1995). Many of these proteins 
are type II membrane protein containing a conserved 150 amino acid in the c-terminal 
region which binds to their cognate receptors. However, there are also a few 
members, such as TNF, which are functional in a soluble form (Cheng et al., 1994; 
Grell et al., 1995). 
The TNF ligands bind to their cognate receptors, known as the TNF receptor 
superfamily.  Members of the TNF receptor superfamily that signal for cell include 
TNF-R1 (DR1, CD120a); Fas (DR2, APO-1, CD95); DR3 (also known as APO-3, 
LARD, TRAMP); DR4 (TRAIL-R1, APO-2); DR5 (TRAIL-R2, KILLER and 
TRICK2); DR6; ectodysplasin A receptor (EDAR) and nerve growth factor receptor 
(NGFR), they all contain the characteristic death domain (DD) in their cytoplasmic 
region (Tartaglia et al., 1993; Wang and El-Deiry, 2003; Wiley et al., 1995). In 
addition, the other receptors studied in this superfamily are called decoy receptors 
(DcRs) and they include TRAILR3 (DcR1), TRAILR4 (DcR2), DcR3 and 
osteoprotegrin (OPG, RANK). These decoy receptors either contain a truncated 
version of the DD or do not contain the DD and hence cannot transduce apoptotic 
signals (Ashkenazi and Dixit, 1999).  
4.4.2.2 Tumor Necrosis Factor (TNF) and its cognate receptors 
The role of TNF-TNFR in cell signaling is complex and the exact mechanisms are 
still being explored. The ligands, TNFα and TNFβ, bind two receptors namely TNF-
R1 and TNF-R2 at the extracellular ligand binding N-terminal region with high 
affinity. Contrary to TNFR2 which does not contain a death domain, TNF-R1 is a 
death domain containing receptor and hence the latter mediates most biological 
activities of TNF. Since these receptors are widely expressed, it is not surprising that 
almost all cell types respond to TNF and thus have diverse roles in various 
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physiological processes such as inflammatory response, cell proliferation or cell death 
(Bankey et al., 1990; Camussi et al., 1987; Tartaglia et al., 1991). TNF has been 
shown to play a significant role in cancer biology due its potential to activate the anti-
apoptotic protein NF-κB. 
Activation of TNF-R1 by TNF-α leads to the recruitment of the adaptor protein, 
TNFR1-associated death domain protein (TRADD) via the DD of both proteins. 
Depending on the adapter protein recruited by TRADD, different signaling cascade is 
initiated resulting in apoptosis, survival signal or other inflammatory responses. Here, 
we highlight a few mechanistic models of TNF signaling. In the first pathway, 
TRADD can recruit TRAF-2 (TNF-α receptor associated factor-2) and a serine-
threonine kinase receptor interacting protein (RIP) to form a distinct complex 
initiating the activation of NF-ĸB , a protein that promotes cell survival, inhibiting 
TNF-induced cytotoxicity (Liu et al., 1996b; Rothe et al., 1994). In this model, the 
complex formed is known as complex I. In the event when NF-kB activation by 
complex I fail to initiate, for example, caspase-8 inhibitor, FLICE-like inhibitory 
protein(cFLIP) expression is not induced, an alternative pathway is initiated. In the 
alternative pathway, TRADD and RIP are associated with FADD and caspase 8  to 
form complex II in the cytosol, leading to caspase-8 activation and apoptosis via the 
extrinsic pathway(Hsu et al., 1996; Micheau and Tschopp, 2003).  Recently, it has 
also been shown that induction of NF-ĸB inhibits TNF-α mediated JNK activation 
and that blocking of NF-ĸB results in sustained activation of JNK, promoting TNF-α 
induced apoptosis. Deng et al. (2003) reported that activated JNK induces caspase-8-
independent cleavage of Bid at a distinct site to generate a cleavage product jBid, 
leading to the preferential release of Smac from mitochondria and subsequently 
35 
 
apoptosis. In addition, complex II has also been shown to induce necroptosis when the 
target cells lack caspase activity to trigger apoptosis(Vercammen et al., 1998). 
4.4.2.3 CD95 ligand and its receptor 
CD95, or Apo-1/Fas, was the first member of the TNF receptor superfamily to be 
associated with apoptosis (Itoh et al., 1991). It is a Type 1 transmembrane protein 
ubiquitously expressed in hepatocytes, thymocytes, epithelial cells and activated T 
lymphocytes(Nagata, 1994; Nagata and Golstein, 1995). On the other hand, its natural 
ligand is CD95L or FasL which is a Type 2 transmembrane protein and is present 
both in its membrane-bound and soluble form (Cheng et al., 1994; Suda et al., 1993). 
Loss of activity is observed in the soluble form obtained by proteolytic cleavage of 
the ligand by serine proteases such as matrix metalloproteinases (MMP-7) (Powell et 
al., 1999; Tanaka et al., 1998). 
Our understanding of the function of Fas receptor and its ligand has been mainly 
through genetic studies with mouse models. Lpr (lymphoproliferation) mice lacking a 
functional Fas receptor and gld (generalized lymphoproliferative disease) mice 
bearing mutant Fas ligand both exhibit various autoimmune phenomenon such as 
lymphadenopathy, splenomegaly, and similar symptoms resembling systemic lupus 
erythematosus in humans (Watanabe-Fukunaga et al., 1992). Recently, it has been 
identified that dysfunctional Fas in children results in autoimmune 
lymphoproliferative syndrome (ALPS). This loss-of-function phenotype in mouse and 
man indicates the key role of Fas in the regulation of immune response and 
maintenance of self-tolerance (Fisher et al., 1995; Rieux-Laucat et al., 1995). Fas has 
also been implicated in the progression of viral diseases such as HIV-1 or Hepatitis B 
virus infections where massive apoptosis occurs. It was shown that T-lymphocytes 
from HIV-1 infected patients exhibit an elevated expression of Fas and sensitivity 
36 
 
towards Fas-mediated apoptosis and this process may result in the continuous 
depletion of CD4
+
 T-cells during AIDS disease (Debatin et al., 1994; Katsikis et al., 
1995). 
It has been shown to play an important role in cancer biology as well. Studies have 
demonstrated increased expression FasL in leukemic, hepatocellular, NSCLC and 
neuroblastoma cells following chemotherapy. FasL neutralizing agents inhibited 
apoptosis induced by these drugs (Friesen et al., 1996; Fulda et al., 1997; Muller et 
al., 1997; Wu et al., 2010). On the other hand, Fas has been shown to promote cell 
proliferation and drives tumorigenesis. This is mediated by the Fas-induced 
recruitment of the caspase-8 inhibitor, FLICE-like inhibitory protein (cFLIP), which 
also contain the DD. Subsequently, cFLIP interacts with TRAF1 /TRAF2, RIP and 
Raf-1, resulting in the activation of the NF-κB and AP-1, leading to the activation of 
ERK signaling pathway (Kataoka et al., 2000). 
While Fas induce the classical extrinsic apoptotic pathway, recent studies have shown 
that Fas can induce a regulated form of necrosis, termed necroptosis, a caspase-
independent type of cell death mediated by a different set of signaling proteins when 
caspase-8 acitivity is compromised (See Necrosis and Necroptosis).  
4.4.2.4 TRAIL (Apo2L) and its cognate receptors 
Like most other ligands of the TNF superfamily, TRAIL is a type 2 transmembrane 
protein which can be cleaved at its C-terminal region to obtain the soluble form (Pitti 
et al., 1996; Wiley et al., 1995). ). As with most other members of the TNF 
superfamily, TRAIL forms a homotrimer that binds to three receptor molecules. Both 




TRAIL can bind to mainly four of its cognate receptors. The two death receptors 
namely DR4 (TRAIL-R1) and DR5 (TRAIL-R2) contain the DD in their cytoplasmic 
region which allows for binding to adaptor proteins such as FADD and subsequent 
activation of caspase 8 or 10 at the DISC (Pan et al., 1997). The other two receptors 
are decoy receptors, DcR1 (TRAI-R3) and DcR2 (TRAIL-R4) which are unable to 
transduce apoptotic signals as they either contain a truncated version of the DD or do 
not contain the DD. (Marsters et al., 1997; Sheridan et al., 1997). These decoy 
receptors are frequently upregulated in cancers as they compete with the death 
receptors for ligand binding and hence act as inhibitors of TRAIL-apoptotic signal. 
TRAIL can also bind to another soluble receptor called Osteoprotegerin (OPG, 
RANK) (Emery et al., 1998). OPG functions mainly as a regulator of the development 
and activation of osteoclasts in bone remodelling. This activity is, however, not due to 
its interaction with TRAIL as the binding affinity of TRAIL to OPG is weak and the 
function of this interaction is still poorly understood (Cheng et al., 2003). 
Similar to Fas, TRAIL has also been implicated in necroptosis. 
4.4.2.4.1 TRAIL as a “tumor suppressor”  
TRAIL has been shown to play a role in host immunosurveillance against primary 
tumor development. Knockout studies with mice have shown that loss of TRAIL 
promoted tumor development in mice treated with carcinogen methylcholanthrene 
(MCA) (Cretney et al., 2002).  In addition, more than 20% of TRAIL knockout mice 
have been reported to develop lymphoid malignancies. All these findings show that 
TRAIL is important in tumor development. Besides the genetic alterations of TRAIL, 
allelic losses of chromosomal segments encoding both DR4 and DR5 have been 
observed in several cancers, including non-Hodgkin’s lymphoma and lung, breast, 
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colon, prostate, hepatocellular and head and neck cancers, suggesting their tumor 
suppressive role (Shin et al., 2001). 
4.4.2.4.2 TRAIL as potential chemotherapeutic agent  
In recent years, TRAIL has received particular attention as a potential tumor specific 
cancer therapeutic because it selectively induces apoptosis in a wide variety of 
transformed cells and most importantly, with no toxicity to normal cells (Ashkenazi et 
al., 1999; Pitti et al., 1996; Wiley et al., 1995).A study by Song et al. (2006) showed 
that in mice transplanted with hematopoietic cells over-expressing mouse TRAIL, the 
syngeneic grafts of carcinoma cells had a decreased tumoural growth rate and it was 
also observed that those tumor cells were undergoing TRAIL-mediated apoptosis 
while normal cells were left intact. The potential of TRAIL therapy was further 
supported in immunodeficient mice bearing human tumor xenografts, where TRAIL 
treatment substantially inhibited tumor progression in a variety of human tumors 
including breast and colon carcinomas, gliomas and multiple myelomas (Ashkenazi et 
al., 2008; Wiley et al., 1995).  
Although TRAIL has been very promising as a chemotherapeutic agent, one major 
impediment for the use of this agent in cancer therapy is that many cancer cells are 
developing resistance to TRAIL and the potential of toxicity effects (Koschny et al., 
2007). Many efforts have been made to understand the TRAIL signaling pathways 
and solve the problem of resistance (Clayer et al., 2001; Horak et al., 2005a; Poh et 
al., 2007). To reduce the toxicity profile of TRAIL, development of alternative 
substitutes for TRAIL such as monoclonal antibodies against TRAIL and TRAIL 
receptors, regulation of other targets in the TRAIL signaling pathways and lower 
doses of combinatorial drugs have been proposed (Hotte et al., 2008). 
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4.4.2.4.3 Important regulators of the extrinsic pathway 
The extrinsic apoptotic pathway is has more levels of regulation as compared to the 
intrinsic apoptotic pathway, which is essentially regulated by the Bcl-2 family 
proteins. Interventions of the extrinsic pathway include; alterations of the receptor 
expressions and the distribution of the receptors, assembly of the DISC and caspase 
activation. 
4.4.2.4.3.1 Factors affecting ligand-receptor binding 
Activation of the extrinsic pathway relies on the binding of ligand to the receptors. 
Factors affecting this include cell surface receptor expression, the distribution of the 
receptor on the membrane and the presence of decoy receptors. 
It has been reported that reduced expression of the receptors due to epigenetic 
silencing correlates with resistance to apoptosis (Hopkins-Donaldson et al., 2003; 
Horak et al., 2005a). In addition, reports on defective transport of the receptors lead to 
reduced surface receptors increases resistance to receptor-mediated apoptosis (Jin et 
al., 2004). Mutations resulting in loss-of-function of these receptors have also been 
observed in various cancers (Chen et al., 2001; Fisher et al., 2001; Lee et al., 1999; 
Pai et al., 1998; Shin et al., 2001). Increased expression of the death receptors by 
chemotherapeutic drugs or small pharmacological molecules can significantly 
enhance the activation of the receptor-induced apoptosis (Evdokiou et al., 2002; Kang 
et al., 2005; Shenoy et al., 2009). 
Post-translational modifications of the death receptors have been postulated to play 
key roles in their abilities to transmit signals upon ligation.  A link between death-
receptor O-glycosylation and TRAIL-signaling that O-glycosylation promotes ligand-
stimulated clustering of DR4 and DR5, which mediates recruitment and activation of 
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the apoptosis-initiating caspase-8 (Wagner et al., 2007).  In addition, S-palmitoylation 
of DR4 has also been identified recently to be required for its raft localization as well 
as for its ability to oligomerize and provide efficient TRAIL-induced signal 
transduction. (Rossin et al., 2009). Studies have shown that redistribution and 
clustering of the receptors in the lipid rafts, in this case, serve as a platform for 
mediating death receptor signaling and thus greatly enhance cytotoxicity of the death 
ligands (Muppidi and Siegel, 2004; Muppidi et al., 2004; Rossin et al., 2009; Song et 
al., 2007). 
In TRAIL signaling, the sensitivity of the cells to TRAIL-induced apoptosis depends 
on the ratio of TRAIL decoy receptor (DcR1 and DcR2) to TRAIL receptors (DR4 
and DR5). The decoy receptors differentially inhibit TRAIL by either competing with 
DR4 and DR5 for binding to the ligand, thus abolishing death signal transduction, or 
they can be recruited with DR4 or DR5 within the DISC where it inhibits activation of 
initiator caspase-8 (Bernard et al., 2001; Merino et al., 2006). In addition, mutant DR5 
can similarly compete for ligand binding by acquiring a decoy property (Bin et al., 
2007). Such mutant retains their ability to bind TRAIL, yet lack the capacity to form 
functional apoptotic transmitting DISC upon TRAIL ligation.  
4.4.2.4.3.2 Factors affecting DISC formation 
The DISC is composed of death receptors, adaptor protein and procaspase-8. The 
formation of DISC is often hindered by an inhibitor of caspase-8, cellular FLICE 
inhibitory protein (cFLIP), which contains a death domain (DD) and two death 
effector domains (DED), and a caspase-like domain that lacks a cysteine residue 
critical for catalytic activity accounting for its lack of enzymatic activity and inability 
to transmit death signal induced by TRAIL. Its association with the DISC via 
homotypic interactions with the DED-containing FADD blocks the auto-proteolytic 
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cleavage of caspase-8 and blocks transduction of death signal at the DISC level. 
Hence, caspase-8 to cFLIP ratio is a major determinant of TRAIL resistance whereby 
high levels of cFLIP leads to lack of sensitivity to TRAIL that has been observed in 
various cancer cells including lung and breast cancer cells, colon carcinomas, 
melanomas, hepatocarcinomas, B-cell chronic lymphocytic leukemia as well as 
glioblastomas (Dolcet et al., 2005; Geserick et al., 2008; Guseva et al., 2008; Horak et 
al., 2005b; Panner et al., 2005; Wang et al., 2008). 
4.4.2.4.3.3 Factors affecting downstream signaling 
As mentioned earlier, IAP proteins (XIAP) are potent inhibitors of the effector 
caspase -3 and hence high levels of IAP proteins can hinder the apoptotic signal and 
hence resistant to apoptosis. 
In Type 2 cells, where the engagement of the intrinsic mitochondria pathway is 
necessary for mediating apoptosis, levels of anti-apoptotic Bcl-2 family members may 
determine its sensitivity to death receptor-induced apoptosis. 
Lastly, other possible determinants of cell fate, such as the phosphatidylinostol-3-
kinase (PI3K)/Akt signaling pathway, the transcription factor, NF-ĸB, the mitogen-
activated protein (MAP) kinases signaling pathways, been shown to play vital roles in 






5 Reactive oxygen species 
Although oxygen is essential for normal aerobic metabolism of cells, due to its radical 
nature, it inevitably forms reactive oxygen species (ROS), a by-product of cellular 
metabolism. ROS can be broadly divided into oxygen-derived radicals and non-
radicals.  A radical is defined as any species capable of independent existence that 
contains one or more unpaired electrons (Halliwell and Gutteridge, 1984). Oxygen-
derived radicals include the superoxide anion (O2
•





) and hydroxyl radical (OH
•
), while non-radicals include molecules like 
hydrogen peroide (H2O2), hypochlorous (HOCl) and peroxynitrite (ONOO
-
). To avoid 
misconception, ROS is just a collective term; all oxygen radicals are ROS but not all 
ROS are oxygen radicals. There are some oxides of nitrogen that are free radicals 
(NO
•
) and therefore, ROS can be further classified as reactive nitrogen species (RNS), 
reactive chlorine species (RCS) etc (Halliwell, 1991).  
RS can have varied effects on the cells depending on the type as well as the dose. 
While high doses of RS is usually lethal to the cell, inducing necrosis or apoptosis 
depending on the type of stress stimuli. At low concentration of RS, such as O2
•
- , NO 
and H2O2, they function to initiate cell survival and proliferation through the 
activation of growth factors and kinases (Denu and Tanner, 1998; Rhee et al., 2000) 
and redox-regulated pathways such as NF-kB and AP-1 (Bubici et al., 2006). 
Due to the diversity of RS, they are involved in many physiological processes 
associated with oxidative stress, such as inflammation, carcinogeneis, cell death and 




5.1 Types of Reactive Species and their sources 
Although there are many different types of RS, not every species are well understood 
in terms of their biochemistry and its biological relevance. Here, we highlight a few 
biologically important RS (Halliwell, 1991, 2006; Murphy et al., 2011).  





- is a relatively reactive reducing agent with a E°’value of -0.33V. It does not react 
with most biological molecules in aqueous solution however, it does react rapidly 
with NO , iron-sulpher clusters in enzymes or phenoxyl radicals. It can also react with 
H2O2 to form the highly reactive hydroxyl radical, OH, which can attack and destroy 
almost all known biomolecules (Fridovich, 1978a, b). It is a charged radical and hence 
does not diffuse readily across membranes, however, it can pass through anion 
exchange proteins. The main sources of superoxide are the xanthine oxidase, auto-
oxidation by O2, Haem proteins, mitochondria electron transport chain, endoplasmic 
reticulum (ER), uncoupling proteins and NADH/NADPH oxidase (NOX).  
5.1.2 Hydrogen peroxide (H2O2) 
H2O2 is a weakly oxidizing or reducing agent and poorly reactive with a E°’value of 
0.32V and has a significant role in signaling transduction (Neill et al., 2002; Rhee et 
al., 2000) Despite its low reactivity, it can be lethal at high concentration. Since it is a 
neutral non-radical, it diffuses readily across membranes. H2O2 is continuously 
produced in the cells by enzymes including xanthine oxidase, urate oxidase, 
superoxide dismutases as well as mitochondria electron transport chain. 
5.1.3 Nitric oxide (NO) 
NO is an uncharged radical and therefore highly diffusible.  It can react with other 
free radicals to form a more reactive intermediate, and subsequently react with thiols 
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to form S-nitrothiols through a reaction known as S-nitrosylation, a reversible process 
(Stamler et al., 1992). This reaction is characterized by the attachment of an NO group 
to a thiol or metal group. These complexes can function as long distance NO-carrier 
which can release NO spontaneously or by enzymatic cleavge. 
The study of NO has largely focused on its reaction with O2
•
- to form peroxynitrite 
(ONOO−), a much more reactive species than its parent compounds. NO is 
synthesized in vivo by the nitric oxide synthase (NOS). There are 3 types of NOS 
neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). These 
enzymes convert L-arginine to NO and L-citrulline (Marletta, 1994).  The role of NO 
was first identified as a product of macrophages activated by cytokines or/and 
microbial compounds but it well recognized that it has important physiological roles 
in the nervous system, vascular system and wound healing(Balligand et al., 1994; 
Bogdan, 2001; Calabrese et al., 2007; Xia and Zweier, 1997). 
5.1.4 Peroxynitrite (OONO-) 
OONO- is a powerful and short-lived oxidant with a E°’value of 2.10. It is produced 
by the reaction of O2
•






 . The sites of OONO- 
production are assumed to be spatially associated with the sources of of O2
•
- , as it has 
a much shorter half live and poor diffusibility, while NO is a highly diffusible free 
radical. Regardless of its non-radical nature, OONO- is more reactive than its parent 
molecules. It initiates lipid peroxidation, causes DNA breakage, reacts with thiols and 
causes protein modifications (Radi et al., 1991a, b; Salgo et al., 1995). Protein 
modifications include protein oxidation (on methionine, cysteine, tryptophane or 
tyrosine residues) and nitration (of tyrosine or tryptophane residues). It also targets 
enzymes containing a redox active transition metal center, for example, MnSOD. Due 
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to its unique nitration ability, the detection of conversion of tyrosine to 3-nitrotyrosine 
is used as a biomarker for OONO- formation (van der Vliet et al., 1996).  
When peroxynitrite-induced cellular damage reaches a threshold where the cell cannot 
handle the oxidative stress, cell death is initiated. Cell death can be apoptotic, where 
by oxidative stress activates the intrinsic mitochondria pathway. This is supported by 
findings showing that the anti-apoptotic Bcl-2is able to inhibit peroxynitrite-induced 
apoptosis (Spear et al., 1998). When the concentration of OONO- is too high, necrosis 
is induced. In the necrosis model, A sequence of events mediated by poly(ADP-
ribose) polymerase-1 (PARP) drives the ATP depletion and this deterioration  the 
cellular energetic status trigger necrosis (Virag et al., 2003). 
5.2 Intracellular antioxidant defences  
Since the generation of ROS is an inevitable in the cells, by evolution, cells have 
developed sophisticated antioxidant strategies to combat the oxidative insults so as to 
protect them from the undesirable consequence of oxidative stress.   
In vivo, various systems are in place to ensure that defense mechanisms are being 
activated when harmful situation arises for the cells. These antioxidant mechanisms 
are broadly divided into enzymatic and non-enzymatic antioxidant defences 
(Halliwell, 1999). The enzymatic antioxidants include superoxide dismutatases 
(SOD), catalase, gluthathione peroxidase (GPx) peroxiredoxins and thioredoxins. 
Non-enzymatic Antioxidants consist of gluthathione, carotenoids, flavonoids, 




5.2.1 Superoxide dismutases (SOD) 
The superoxide theory of oxygen toxicity states that O2•ˉ is the main contributor of 
oxygen toxicity and thus, highlighting the importance of SOD in cellular defences 
(Fridovich, 1995). SOD catalyses the dismutation of O2•ˉ to H2O2. There are 3 forms 
of SODs in human cells. SOD 1, a copper- and zinc- containing SOD (Cu/ZnSOD) ,is 
mainly located in the cytosol. SOD2, a manganese containing SOD (MnSOD) is 
largely found in the mitochondria. Lastly, SOD3, also a copper- and zinc- containing 
SOD but it is an extracellular SOD (Fridovich, 1978b; Liochev and Fridovich, 1999). 
The different spatial distribution of the different SOD ensures that O2•ˉ is effectively 
removed from the subcellular compartments as O2•ˉ is cannot diffuse readily across 
the membrane due to its charged nature. In normal cells, increased expression of 
SODs is favoured in protecting the cells from oxidative stress while the levels are 
often reduced in cancer cells. 
5.2.2 Catalase 
The spontaneous dismutation of O2 •ˉ results in the formation of H2O2. In addition, 
H2O2 is also generated by a wide variety of sources such as urate oxidases and D 
amino oxidas . Catalase functions to catalyze the decomposition of H2O2 to H2O and 
O2. The catalase comprises 4 units, containing a ferric haem group at each active site. 
Catalase has been shown to localize in the mitochondria, cytosol and peroxisomes 
(Chance et al., 1979). 
5.2.3 Glutathione system 
The glutathione system is one of the most important antioxidant systems in the cells. 
Glutathione (GSH) is a thiol tripeptide that contains a γ-peptide bond between 
glutamate and cysteine. It mediates detoxification of ROS mainly via three 
mechanisms. In the first mechanism, it reacts enzymatically with toxic compounds, to 
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form conjugates, catalysed by the GSH S-transferase family of proteins. Next, it can 
participate in a non-enzymatic chemical reaction with reactive metabolites to form 
conjugates and detoxify them. Lastly, the thiol group of the cysteine residue provides 
the reducing power to interact with free radical and as a result in the oxidation of GSH 
to gluthathione disulphide (GSSG). The accumulation of GSSG can occur as a result 
of oxidative stress (Meister, 1988). The ratio of GSH /GSSG must be maintained to 
keep a highly reducing intracellular environment. Hence GSH levels is maintained by 
various enzymes. GSH can be synthesized by γ-glutamylcysteine synthase and GSH 
synthetase (Huang et al., 1993). Another enzyme, glutathione reductase (GR) 
mediates the conversion of GSSG to GSH (Pai and Schulz, 1983). Lastly, Gluthation 
peroxidase (GPx) enzymes function to catalyze the reaction of peroxides; it catalyzes 
the reaction of hydroperoxides with reduced gluthatione (GSH) to form oxidized 
glutathione disulphide (GSSG)(Chance et al., 1979). In addition, GSH could also 
directly scavenge OH• and singlet oxygen (Halliwell, 2007). 
5.2.4 Peroxiredoxins (Prx) 
A family of thioredoxin dependent peroxidase enzymes involved in the degradation of 
H2O2, organic hydroperoxides and peroxynitrite. The members are Prx I, II, III, IV, V 
and VI. I II IV, VI, are located in the cytosol and Prx III in the mitochondria. Prx V in 
both cytosol and mitochondria. Prx I and II found in abundance in the cytosol and 
thus most likely the major regulators of H2O2 levels (Rhee et al., 2001). 
5.2.5 Thioredoxins (Trx) 
The Trx system consists of Trx and Trx reductase (TrxR). Trx protein members all 
contain a conserved Cys-Gly-Pro-Cys- active site. They use their active sites to reduce 
disulfides present in protesin and peptides including Prx and GSSG. TrxR then 
reduces oxidized cysteine group in Trx and other proteins via a NADPH dependent 
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reaction. The two main Trx are Trx1 and Trx 2. Trx1 is found in the cytosol and 
nucleus while Trx2 is found in the mitochondria (Holmgren, 1995; Holmgren and 
Bjornstedt, 1995). 
5.3 Role of ROS and cell death 
ROS has been widely regarded as an effector mechanism of cell death. Numerous 
studies have reported a concomitant increase in intracellular ROS accumulation with 
various death stimuli (Berndtsson et al., 2007; Pierce et al., 1991) as well as different 
pathological conditions(Buttke and Sandstrom, 1994; Haddad, 2004) In support of 
these findings, when antioxidant is used to scavenge the ROS induced by the death 
stimuli, cell death is attenuated. To validate that ROS is an effector of cell death, 
exogenous addition of oxidants results in oxidative stress leading to cell death 
(Garban and Bonavida, 1999; Lee et al., 2001). All these experiments confirm the 
concept of ROS as a death effector.  
UV irradiation and chemotherapeutic drug induced genotoxic stress often leads to 
ROS production which enhance the initiation of apoptosis via the intrinsic  
mitochondria pathway(Wiseman and Halliwell, 1996). However, there is 
accumulating evidence showing ROS mediated apoptosis independent of DNA 
damage (Berndtsson et al., 2007).  
Mitochondria are the major sites of ROS production in the cell (Jezek and Hlavata, 
2005), and thus, it is logical to presume that ROS generated within mitochondria 
could represent an important regulatory axis in mitochondrial dependent cell death. 
Indeed, ROS generation can target the mitochondrial membrane permeabilization, 
thereby initiating the intrinsic apoptotic pathway. In addition, H2O2 has been shown to 
be an important signaling molecule in triggering Bax translocation to the 
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mitochondria, through enhancing cytosolic acidification of tumor cells. Interestingly, 
H2O2-mediated Bax translocation results in an increased H2O2 amount in the 
mitochondria, further amplifying the death signals. Acidification of the intracellular 
milleu provides a more conducive environment for efficient caspase activation 
(Ahmad et al., 2004; Ahmad et al., 2006). 
Numerous findings have demonstrated a direct association between ROS and the 
receptor-mediated apoptotic pathways. Exogenous addition of ROS or the utilization 
of ROS-generating compounds has been shown to sensitize cells to receptor-mediated 
apoptosis by upregulating CD95 and TRAIL death receptors expression (Shenoy et 
al., 2009). Another probable explanation is that the catalytic domain of the death 
executors, caspases, contains an oxidation-sensitive cysteine residue, whose thiol 
group gets oxidized under oxidative conditions (Sen, 2000), rendering them inactive 











Despite the plethora of chemotherapeutic drugs available for cancer therapy, the 
efficacy of the drugs is often limited by acquisition of resistance to these drugs. Most 
chemotherapeutic drugs achieve good initial response, but after a while, the cancer 
relapses and stops responding to the same chemotherapy drug regimen. The 
development of chemoresistance can be inherent due to germ-line genetic variation, 
explained by the heterogeneous nature of cancer and the cancer stem cell theory or 
due to acquired molecular mechanisms that render the cancer cells resistant to these 
drugs. While chemoresistance is prevalent, a more worrying problem is the shortage 
of chemotherapy options to treat these refractory tumors as they express mechanisms 
that confer cross-resistance to a broad range of functionally and structurally unrelated 
drugs, a phenomenon known as multidrug resistance. For the past deacades, 
researchers have attempted to understand the underlying mechanisms that could 
confer drug resistance and in this study, the mechanism of cisplatin resistance is 
discussed.  
 
6.1 Decrease in drug accumulation in the cells 
One of the classical mechanisms that explain the multidrug resistance phenotype is 
the ability of the cancer cells to limit the accumulation of the drugs in the cell. This is 
achieved by decreasing the drug intake and increasing the drug efflux in and out of the 
cells, hence reducing the bioavailability of these drugs to induce toxicity in the 
neoplastic cells. The drug uptake and efflux is largely mediated by a family of energy-
dependent transporters, known as ATP-binding cassette (ABC) transporters (Szakacs 
et al., 2006). The human genome carries 49 ABC genes, divided into seven 
subfamilies, named A-G. Members of this conserved superfamily of transporters 
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essentially function to translocate solutes across cellular membrane, crucial for normal 
cellular processes and multidrug resistance of cancer cells. These transporters have 
broad substrate specificity ranging from biological substrates to chemotherapy drugs. 
Members that are often associate with drug resistance includes, Pgp, ABCB4 
(MDR3), ABCC1(MRP1), ABCC2 (MRP2), ABCC3 (MRP3), ABCC6 (MRP6), 
ABCC10 (MRP7)and ABCG2 (MXR/BCRP) (Chen et al., 1986; Cole et al., 1992; 
Szakacs et al., 2004). Overexpression and genetic alterations of these ABC members 
have been previously described in chemoresistant cells and they often show 
characteristic cross-resistance to structurally unrelated drugs, thus conferring 
resistance to a broad range of chemotherapeutic drugs. Despite the clear rationale for 
the use of inhibitors of ABC transporters, especially of Pgp, the clinical response to 
the candidate inhibitors has been disappointing and associated with severe toxicities.  
In addition to ABC transporters, the copper transporter CTR1, has also been 
previously described to play a role in mediating the uptake of chemotherapeutic drugs. 
This protein has been shown to be down-regulated in ovarian cancer cell lines 
following cisplatin treatment. The CTR1 expression level has been closely correlated 
to influx of cisplatin and genetic knockout of CTR1 results in cellular resistance to 
cisplatin and carboplatin in vivo (Ishida et al., 2002). 
Reduced endocytosis is another way for cells to decrease uptake of chemotherapeutic 
drugs, which is normally achieved via cellular fluid-phase endocytosis. When 
chemosensitive cells were treated with a vacuolar pump inhibitor, bafilomycin A1, the 
cells acquired chemoresistance phenotype, suggesting that chemoresistance may be an 
effect of defective endocytic uptake of the drugs. This mechanism is further supported 
by the discovery of altered distribution of endocytic recycling compartment (ERC) in 
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chemoresistant cells, validating that reduced uptake of drug is a result of endocytic 
defect. (Liang et al., 2006). 
 
6.2 Detoxification through glutathione conjugation 
When the platinum drugs entered the cell, they form a more reactive species that alter 
biologically important molecules, such as DNA and proteins. One important 
consequence of the reaction of the reactive nucleophilic drugs with biological 
molecules is the detoxification of the drug, rendering the drugs less reactive and toxic.  
Drug detoxification is a described in two phases phase II and phase III detoxification 
pathways (Ishikawa, 1992).In phase II detoxification, drugs are detoxified via 
conjugation with reduced glutathione (GSH), carbohydrate, glucuronide or sulphate. 
Conjugation of the reactive drugs to GSH can be mediated with or without the 
enzyme, glutathione S tranferase (GST) (Hayes and Pulford, 1995).  The role of GST 
in mediating drug resistance has been well documented. Genetic ablation of GST can 
often revert the drug resistant phenotype of the cells.  Phase III detoxification involves 
the energy-dependent, transporter-mediated efflux of drugs or drug-conjugates from 
the cell (Loe et al., 1998). The ABC transporters, MRP1 and MRP2 has been shown 
to transport these drug conjugates out of the cells (Jedlitschky et al., 1994). 
 
6.3 DNA repair capacity 
As mentioned earlier, platinum drugs cause DNA damage by the formation of 
platinum-DNA adducts. This induces genotoxic stress that triggers the DNA repair 
mechanisms to remove the adducts through a DNA repair pathway, NER. NER is a 
multi-step process which first involves recognition of the Platinum-DNA adduct by 
the RAD23B/XPC complex, which then recruits the TFIIH complex to the site. This 
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transcription factor complex includes the two helicases, XPB and XPD. These 
helicases unwind the DNA around the site, which then allows for the binding of XPA 
and RPA to stabilize the complex. XPG, a 3’endonuclease and XPF a 5’endonuclease, 
are responsible for the DNA incisions at the damage site. The missing nucleotides are 
then replaced by re-synthesis and ligation(de Laat et al., 1999) . Since the formation 
and persistence of DNA adducts of cisplatin leads to the development of apoptosis, 
the ability of the cell to successfully undergo repair process and remove the platinum-
DNA lesions will result in either resistance or sensitivity to platinum-based 
chemotherapy. Reports on the increased expression of XPA, ERCC1, ERCC1-XPF 
complexes, and BRACA1 has been linked to cisplatin resistance (Dabholkar et al., 
1994; Gowen et al., 1998).In NSCLC cell lines, elevated DNA repair capacity was 
associated with chemoresistance (Zeng-Rong et al., 1995). 
Recently, a new DNA repair mechanism in cisplatin resistance has been described; in 
which the oncoprotein c-Myc suppresses BIN1, thereby releasing the DNA repair 
protein poly(ADP-ribose)polymerase (PARP) 1, facilitating DNA repair and thus 
enabling cancer cells to acquire cisplatin resistance (Sakamuro et al., 1996) . 
 
6.4 Cell cycle control 
When the cells detect DNA damage, DNA repair mechanism is triggered and the cell 
cycle checkpoints are activated to arrest the cell allowing time for repair mechanisms 
to correct genetic lesions before progressing through the cell cycle. This ensures that 
intact copies of genomes are inherited by the daughter cells. It has been shown that 
cisplatin is able to induce S- and G2/M phase arrests. The G2/M arrest allows for 
repair of damaged DNA in the late S- or G2 phase of the cell cycle before mitosis. G2 
phase arrest has been found to be essential for initiation of cell death to occur 
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(Sorenson and Eastman, 1988). A number of agents that abrogate the G2 cell cycle 
checkpoint and induce premature mitosis have demonstrated enhancement of 
cisplatin-induced cytotoxicity (Demarcq et al., 1994; Shi et al., 1995). Hence genetic 
alterations in proteins involved in cell cycle regulation, such as p53, cdc25, ATR, 
Chk1 and Chk2 is important in mediating cisplatin resistance.  
6.5 Heat shock and ribosomal proteins 
Heat shock proteins and others have been linked to stress response in protein folding 
and unfolding in drug resistance (Mandic et al., 2003; Shen et al., 2006).  
Heat shock proteins are stress-inducible molecular chaperones that are abundantly and 
ubiquitously expressed in the cell, modulating protein homeostasis to protect against 
DNA damage and apoptosis. Several studies have observed up-regulation of HSP27, 
HSP70, HSP72, GRP78, and HSP90 in cisplatin-resistant ovarian cancer (Arts et al., 
1999; Vargas-Roig et al., 1998). 
While the ribosome plays an essential role in the structural assembly of proteins 
during protein synthesis, it has also been described to coodinate the expression of 
stress-response genes during stressed conditions, such as drug-induced DNA damage 
and apoptosis trigger (Holcik and Sonenberg, 2005).  
6.6 Epithelial to mesenchymal transition (EMT) 
EMT is characterized as a process through which an epithelial cell undergoes 
transformation into a mesenchymal phenotype (Mani et al., 2008). The role of EMT in 
embryogenesis and metastasis is well-characterized, recently, there has been 
increasing evidence suggesting that elements of the transition may be important in 
drug resistance in various different cancers. In a study by Arumugam et al. (2009), the 
authors found an inverse correlation between levels of E-cadherin and Zeb-1 and 
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resistance to cisplatin, gemcitabine, and fluorouracil, suggesting that the EMT 
pathway may contribute to cisplatin resistance in pancreatic cancer cells. EMT 
transcription factors, snail and slug, has been also been found to directly contribute to 
cisplatin resistance in ovarian cancer; reducing expression of snail and slug, can revert 
the mesenchymal to epithelial phenotype and cells were resensitized to cisplatin 
(Haslehurst et al., 2012). These data suggest that resistant cancer cells utilize the EMT 
program to become
 
motile, stem cell–like, to resist cancer therapeutics. 
6.7 Inhibition of Apoptosis 
Tumorigenesis is a multistep process in which mutations in key cellular genes 
equipped the cancer cell to grow unchecked in the absence of growth-stimulating 
signals, meanwhile overcoming growth-inhibitory signals and host immune responses. 
They also allow the tumor to replicate indefinitely, maintain an oxygen and nutrient 
supply, and adjacent and distant tissues. Importantly, the ability of cells to evade 
apoptosis is also an essential “hallmark of cancer” (Hanahan and Weinberg, 2000). 
Since the aim of chemotherapy is to kill the cancer cells, in order to acquire resistance 
to the chemotherapy, the cancer cells try to evade apoptosis by altering expression or 
mutation of genes encoding key apoptotic proteins can provide cancer cells with both 
an intrinsic survival advantage and inherent resistance to chemotherapeutic drugs. 
There are several lines of evidence to support that apoptotic pathways contribute to 
the cytotoxic action of most chemotherapeutic drugs (Lowe and Lin, 2000). To begin, 
mutations in p53 or in the p53 pathway can produce multi drug resistance and 
reintroducing the wild-type p53 into p53 null tumor cells can re-establish 
chemosensitivity (Vogelstein et al., 2000; Wallace-Brodeur and Lowe, 1999). 
Alterations in other pro-apoptotic proteins, PTEN, BAX and p19ARF are also often 
observed in drug resistant cancer cells (Siddik, 2003). Besides pro-apoptotic proteins, 
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mutations or altered expression of Bcl-2-related anti-apoptotic proteins can drastically 
alter drug sensitivity in experimental models and are associated with multidrug 
resistance (Beale et al., 2000; Reed, 1995). Other anti-apoptotic proteins that have 
been reported in cisplatin-resistant cells include inhibitors of apoptosis (IAP), NFkB, 
cFLIP and Ras (Asselin et al., 2001; Guinea Viniegra et al., 2002; Mansouri et al., 
2003; Siddik, 2003). While alterations in the effector apoptotic proteins, caspase 8 
and Apaf1, results in resistance to drug-induced apoptosis. 
The understanding of the mechanism of resistance to chemotherapeutic drugs 
(platinum-based compounds) allows us to identify specific targets that confer the 
resistance and thus design the best chemotherapeutic action with specific targets in 
cellular pathways offer powerful new approach to cancer therapeutics that might 













As outlined in the introduction, chemoresistance remains one of the most pressing 
problems in the treatment of NSCLC in patients. Since platinum-based therapies are 
widely used for treatment of various cancer types, we used cisplatin as a tool in this 
study to explore the molecular mechanisms underlying platinum-based resistance. 
Understanding the mechanism of cisplatin resistance will enable us to design better 
therapeutic strategies against cancers with acquired resistance to cisplatin and 
perhaps, other anticancer drugs. Hence our specific aims are: 
Aim 1: To determine the molecular mechanisms underlying cisplatin resistance 
in our NSCLC model 
Although the study on drug resistance has been extensive, the findings are classically 
attributed to the upregulation of drug transporters, which are able to expel a broad 
range of anticancer drugs out of the cells. However, the inhibitors for these drug 
transporters have been somewhat disappointing. Hence, this study aims to identify 
other possible molecular determinants of cisplatin resistance. 
Aim 2: To find a potential drug therapy for NSCLC with acquired resistance to 
cisplatin resistance.  
With our findings that clearly showed mitochondrial dysfunction in cisplatin-resistant 
cells, we next proposed the use of TRAIL to eradicate these cisplatin-resistant cells. In 
addition, we sought to understand the mechanisms that could render these cells 
sensitive to TRAIL. 
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Aim 3: To assess if TRAIL sensitivity in cisplatin-resistant cells is a common 
characteristics for other cancer models. 
Having shown that TRAIL is a potential therapeutic agent for NSCLC A549 cells, we 
wanted to determine if the findings can be extrapolated to another NSCLC model, 






MATERIAL AND METHODS  
1 Antibodies  
1.1 For Western Bot analysis: 
Rabbit polyclonal Anti-ANT was generously provided by Dr Catherine Brenner. 
Mouse monoclonal Anti-Bid, Mouse monoclonal Anti-CuZnSOD, Mouse monoclonal 
Anti-p53, Mouse monoclonal Anti-Caspase-3, Mouse monoclonal Anti-Caspase-8, 
Rabbit monoclonal Anti-Bax, Rabbit polyclonal Anti-Caspase-9, Rabbit polyclonal 
Anti-XIAP, Rabbit polyclonal Anti-PARP, Rabbit polyclonal Anti-VDAC, Rabbit 
polyclonal Anti-Cytochrome C,  Rabbit polyclonal Anti-RIP, Rabbit polyclonal Anti-
phospho Akt, Rabbit polyclonal Anti-total Akt, Rabbit polyclonal Anti-phosphoERK 
1/2, Rabbit polyclonal Anti-total ERK 1/2, Rabbit polyclonal Anti-phosphoJNK  
Rabbit polyclonal Anti-total JNK, Rabbit polyclonal Anti-VDAC and Rabbit 
polyclonal Anti-DR5 were all purchased from Cell Signalling Technology, Inc 
(Danvers, MA, USA). Mouse monoclonal Anti-Mcl-1, Mouse monoclonal Anti-Bcl2, 
Mouse Monoclonal Anti-beta-actin, Rabbit polyclonal Anti-GAPDH, Goat polyclonal 
anti-AIF and Rabbit polyclonal anti-Bcl-xL were all purchased from Santa Cruz 
Biotechnologies, Inc (Santa Cruz, CA, USA). Mouse monoclonal anti-cIAP1, Mouse 
monoclonal anti-cIAP2, Mouse monoclonal anti-FADD and Mouse monoclonal anti-
iNOS were purchased from BD Biosciences, (San Jose, CA, USA). Mouse monoclonal 
Anti-nitrotyrosine, Rabbit polyclonal Anti-MnSOD and Rabbit polyclonal Anti-DR4 
were purchased from Upstate, EMD Millipore Corporation, (Billerica, MA, USA). 
Rabbit polyclonal Anti-Caveolin, Goat polyclonal Anti-Flotillin were purchased from 
Abcam, (Cambridge, UK). Mouse monoclonal Anti-cFLIP was purchased from 
Alexis, Enzo Life Science, (Farmingdale, NY, USA). Rabbit polyclonal anti-catalase 
was purchased from Epitomics, Inc (Burlingame, CA, USA). Goat Anti-mouse IgG 
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HRP conjugated secondary antibody, Goat Anti-Rabbit IgG HRP conjugated 
secondary antibody and Rabbit Anti-Goat IgG HRP conjugated secondary antibody 
were purchased from Pierce, Thermo Fisher Scientific, Inc (Rockford, IL, USA). 
1.2 For flow and confocal analysis:  
Anti-AnnexinV-FITC was purchased from BD Biosciences, (San Jose, CA, USA). 
Anti-human TRAIL-R1 (DR4)-Phycoerythrin and Anti-human TRAIL-R2 (DR5)-
Phycoerythrin were purchased from R&D Systems, (Minneapolis, MN, USA). Mouse 
monoclonal Anti-DR4 was purchased from Abcam, (Cambridge, UK). Alexa Fluor-
568 Goat Anti-rabbit IgG and Alexa Fluor-488 Rabbit Anti-mouse IgG were 
purchased from Molecular Probes, Life technologies, (Carlsbad, CA, USA). 
1.3 For death receptors activation and inhibition experiments 
Mouse monoclonal Anti-DR4 (neutralizing), Mouse monoclonal Anti-DR5 
(neutralizing) were purchased from Alexis, Enzo Life Sciences (Farmingdale, NY, 
USA). Mouse monoclonal Anti-Fas Antibody (activating) was purchased from 
Upstate, EMD Millipore Corporation, (Billerica , MA, USA). 
2 Reagents and Chemicals  
TRAIL, pan-caspase inhibitor ZVAD-FMK and fluorogenic substrates of caspase-3, -
6, -8 and -9 were all purchased from Biomol, Enzo Life Sciences (Farmingdale, NY, 
USA). Catalase, JNK inhibitor SP600125, MEK inhibitor PD98059, Cisplatin, 
Carboplatin, 5-Fluorourail, Etoposide, Gemcitabine, Lucigenin, 2-Deoxyglucose, 
Sucrose, MTT, Crystal violet, PMA, ADP, ATP, rotenone, succinate, digitonin, β-
Mercaptoethanol, Bromophenol Blue, DMSO, HEPES, Pepstatin A, PMSF, 
Aproptinin, sodium orthovanadate, sodium fluoride, Tween 20, EDTA, DTT, TRIS, 
BSA and glycine were all purchased from Sigma Aldrich (St. Louis, MO. USA) 
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Dharmafect transfection reagent, Coomassie Blue reagent from Thermo Fisher 
Scientific, Inc (Rockford, IL, USA) Superfect transfection reagent from Qiagen, 
(Hilden, Germany). CM-H2-DCFDA, MitoSOX, DAF-FM, Propidium iodide (PI) and 
Dioc6 from Molecular Probes, Life technologies, (Carlsbad, CA, USA) FeTPPS from 
Merck, Darmstadt, Germany and Peroxynitrite from Cayman Chemical (Ann Arbor, 
MI, USA). 10x PBS and 10x SDS were obtained from NUMI Media Preparation 
Facility , (NUS, Singapore). 
3 Cell lines  
The human NSCLC A549 WT and its cisplatin- resistant derived cell lines (R1 and 
R2) as well as ovarian A2780 (WT) and its cisplatin -resistant derived cell line, 
A2780CR, were generously provided by Dr. Catherine Brenner (INSERM U769-
LabEx LERMIT, Université Paris-Sud). The human NSCLC A549 (WT and cisplatin-
resistant) cells were cultured in Dulbecco's Modified Eagle Medium: Nutrient Mixture 
F-12 (DMEM/F12; Gibco,Life technologies, Carlsbad, CA, USA) supplemented with 
10% fetal bovine serum (FBS, Hyclone, ThermoScientific, Waltham, MA), 1% L-
glutamine (Hyclone, ThermoScientific, Waltham, MA) and 1% penicillin/streptomycin 
(Hyclone, ThermoScientific, Waltham, MA). The ovarian A2780 WT and A2780CR 
cells were cultured in in Roswell Park Memorial Institute 1640 medium (RPMI, 
Hyclone, ThermoScientific, Waltham, MA) supplemented with 10% FBS, 1% L-
glutamine and 1% penicillin/streptomycin. The NSCLC H2030 cells were purchased 
from American Type Cell Culture (ATCC; Rockville MD) and cultured in Roswell 
Park Memorial Institute 1640 medium (RPMI, Hyclone, ThermoScientific, Waltham, 
MA) supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin. 
All cell lines used were grown and passaged in a humidified incubator at 37°C with 
5% CO2.  
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4 Generation and maintenance of cisplatin-resistant clones 
For the NSCLC A549 cells, Dr Catherine Brenner’s lab generated the A549 cisplatin-
resistant derived cell lines R1 and R2, by first subjecting the parental A549 cells to 
low sublethal dose of cisplatin (5μM) consistently for a period of 6 months. Following 
which, individual clones isolated from a mix of heterogeneous cisplatin-resistant cells 
using cloning cylinders and thus establishing R1 and R2 cells. Cells were then 
subsequently growth in complete DMEM/F12 supplemented with  5μM of cisplatin to 
maintain the cisplatin-resistant phenotype. We generated the NSCLC H2030 cisplatin-
resistant H2030CR cells using a method similar to Dr Brenner’s lab; where H2030 
cells were treated to low dose of cisplatin, starting with 2.5μM and when the cells 
recovered from the cytostatic effect of cisplatin, we increased the dose of cisplatin to 
5μM. And subsequently, the cells were maintained as a heterogeneous culture in 
complete RPMI supplemented with 5μM of cisplatin. Lastly, the ovarian A2780 
cisplatin-resistant cells, also a gift from Dr Brenner, were also maintained in in 
complete RPMI supplemented with 5μM of cisplatin. All cell lines used were grown 
in a humidified incubator at 37°C, supplemented with 5% CO2.  
5 Transient knockdown of protein expression  
A549 R1 cells (at 0.08 x10
6
 cells/well) were plated in six-well plates for 24 h before 
transfection to obtain about 40% confluence the next day and the medium was 
replaced with antibiotic-free DMEM about 2 h before commencing transfection. 
Transient transfections were performed
 
using Dharmafect transfection reagent and 
50nM of DR4 siRNA or 50nM of DR5 siRNA smartpool siRNA (Dharmacon 
technologies,
 
Lafayette, CO, USA) dissolved in opti-MEM (Life 
Technologies, Oregon. USA). The control cells were transfected with scrambled non-
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targeting siRNA 24 h after transfection, the media was replaced with
 
complete 
DMEM and cells were incubated
 
further for 48 h before any subsequent experiments. 
6 Transient overexpression of Bcl-2 protein  
A549 R1 and R2 cells were seeded (at 0.1 x10
6
 cells/well) in six-well plates for 24 h 
before transfection to obtain about 40% confluence the next day and the cells were 
replaced with fresh complete about 2 h before commencing transfection. Cells were 
transfected with 1μg of pcDNA/Bcl-2 plasmids using Superfect transfection reagent. 
and the control cells were transfected with 1μg of pcDNA plasmid. 24 h after 
transfection, the media was replaced with
 
complete DMEM and cells were incubated
 
further for 24 h before any subsequent experiments. 
7 Determination of proliferation rates 
For every cell line, (0.05x10
6
) were plated in duplicates onto 6-well plate in complete 
medium and cells were left to grow over a period of 3-4 days in a humidified 
incubator at 37
o
C with 5% CO2, supplemented with complete medium every other 
day. Cells were harvested, stained with trypan blue and counted with haemocytometer 
every subsequent 24h (at 24h, 48, 72, 96h)  Cell numbers were obtained were 
tabulated. 
8 MTT proliferation assay  
The effects of various treatments on cell viability was determined by the 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay modified from 
(Mosmann, 1983). WT (0.15 x 10
6
), R1 (0.3 x 10
6
) and R2 (0.3 x 10
6
) cells per well 
were seeded in duplicates on a 12-well plate and cultured for 24h before drug 
treatment. At the end of drug treatment, floating cells were collected and cells still 
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attached to the culture dish were trypsinized and re-plated onto a 96-well plate (100μl 
of medium per well) and incubated with 100μl of (5mg/ml MTT) per well at 37oC for 
2 h. After this, formazan crystals formed were spun down with centrifugation at 
3,000rpm for 15 min, following which the supernatant was aspirated and the formazan 
crystals were dissolved with DMSO. Absorbance was measured with a TECAN 
sprectrophotometer (Tecan Trading AG, Switzerland) at 570nm. The optical density 
(OD) measured is proportional to the number of viable cells. Percentage of cell 
survival is calculated relative to the untreated control cells as (mean triplicate OD of 
treated cells/mean triplicate OD of vehicle control cells) x 100%. 
 
Number of cells seeded for A2780 cells: WT (0.2 x10
6
 ), CR  (0.4 x10
6
) 
Number of cells seeded for H2030 cells: WT (0.1 x 10
6
 ), CR (0.1 x 10
6
) 
9 Colony forming assay 
At the end of drug treatment, cells were washed with 1 x PBS, trypisinized, and 
counted. For every treatment, 5,000 cells were re-plated onto a 100mm dish in 
complete tissue culture medium. Re-plated cells were left to form colonies over a 
period of 10 to 14 days in a humidified incubator at 37
o
C with 5% CO2, supplemented 
with complete medium every 3-5 days. Colonies formed were assessed by staining 
cells with crystal violet. 
10 DNA fragmentation assay by propidium iodide staining 
DNA content of cells was analysed using propidium iodide (PI) staining. Cells were 
harvested, collected and pelleted down by centrifugation at 2,000 rpm. After washing 
twice withice-cold 1x PBS, cells were fixed with ice cold 70% (v/v) ethanol by 
vortexing while adding ethanol to prevent clumping. The cells in ethanol were 
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incubated for at least 1 h at -20°C. The fixed cells were then pelleted by centrifugation 
at 2,500rpm for 5 min at 4
o
C, washed twice with ice-cold 1xPBS before being stained 
with 500μl of PI/RNase (10μg/ml PI , 250μg/ml RNaseA in 1x PBS) solution for 30 
min at 37°C. Stained cells were filtered through a 40 μm pore size filter. At least 
10,000 events were analysed for DNA content with flow cytometry (CyAn ADP, 
Beckman Coulter, USA) with the excitation set at 550nm and emission at 610nm. Data 
collected were analysed with the Summit 4.3 software. In a typical DNA analysis, the 
apoptotic population of cells are represented in the histograms as having hypodiploid 
DNA content, marked as the sub-G1 population. 
11 Dectection of phosphatidylserine externalization by Annexin V staining 
Following treatment, cells were harvested and pelleted down by centrifugation at 
2,000 rpm. Cells were washed in 1X PBS, then once in 1X Binding Buffer. Cells were 
then resuspended in 1X Binding Buffer (diluted from 10X buffer: 0.1M Hepes, 1.4M 
NaCl, and 25 mM CaCl2 with dH2O at pH 7.4) and stained with FITC-conjugated 
Annexin V for 15 min at roon temperature. Subsequently, cells were washed twice in 
1X Binding Buffer and resuspended in 200ul of 1x binding buffer for flow cytometry 
(Beckman Coulter Inc., Sunnyvale, CA) using an excitation wavelength of 488 and 
emission at 525nm. Data for 10,000 events were collected and analysed by Summit 
4.3 software. 
12 Caspase activity assay  
Activation of caspases was determined using fluorogenic substrates, which are 
synthetic oligopeptides of the caspase cleavage site where the C-terminal aspartic acid 
has been modified with 7-amino-4 trifluoromethyl coumarin (AFC). Cells were 
harvested on ice at the end of different time points and lysed with chilled 1x Cell 
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Lysis Buffer (BD Pharmingen, San Diego, CA). Protein concentration was quantified 
using the Coomassie Blue reagent. 5-10ug of cell lysates were added to equal volumes 
of 2x Reaction Buffer (20mM HEPES, 4mM EDTA, 10mM DTT and 3mM MgCl2 
pH 7.4) and 1μM of respective caspase substrates on a 96-well plate. Substrate for 
caspase-3 is AcDEVD-AFC, caspase-6 is Ac-VEID-AFC, caspase-8 is Ac-IETD-AFC 
and caspase-9 is Ac-LEHD-AFC. Samples were incubated at 37°C for 1 hour, after 
which caspase activity is determined by measuring the relative AFC fluorescence with 
TECAN spectrophotometer (Tecan Trading AG, Switzerland) with excitation at 
400nm and emission at 505nm. Protein concentration of each sample was determined 
using the Coomassie Blue reagent and caspase activity was normalized with protein 
amount and expressed as relative fluorescence unit (RFU)/μg protein. 
13 Isolation of mitochondrial of cytoplasmic fractions 
A549 WT (2 x 10
6
)and R1 (4.0 x 10
6
) cells were seeded on 100mm dish for two days 
before drug treatment. At least 2 dishes were required per treatment. Cells were 
harvested and washed once with ice-cold 1xPBS, cells were then resuspended 
homogenously with extraction buffer A (50mM PIPES-KOH pH 7.4, 200mM 
mannitol, 68mM sucrose, 50mM KCl, 5mM EGTA, 2mM MgCl2, 1mM DTT, 
pH7.4), supplemented with the protease inhibitors (1 mM PMSF, 10 μg/ml Aprotinin, 
20 μg/ml Pepstatin A) and phosphatase inhibitors (1 mM NaF, 1 mM Na3VO4) and 
incubated on ice for 10 min. After incubation, cells were homogenized using a dounce 
homogenizer for 20 strokes before being centrifuged at 100g for 10 min at 4
o
C. The 
supernatant was transferred out and centrifuged again at 10,000g for 15 min at 4
o
C. 
The pellet containing intact mitochondrial fraction was lysed with standard 1 x RIPA 
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lysis buffer supplemented with protease inhibitors. The supernatant was collected as 
the cytosolic fraction. 




 cells) and R1 (4x10
6 
cells) cells were seeded in 100mm petri dishes 
2 days before experiment. Cells were harvested and washed with ice-cold 1xPBS 
before incubating in 500ml of HEPES buffer (25 mM HEPES, 150 mM NaCl, pH7.4 
containing 1% Triton X-100) and supplemented with the protease inhibitors (1mM 
PMSF, 10 μg/ml Aprotinin, 20 μg/ml Pepstatin A) and phosphatase inhibitors (1mM 
NaF, 1 mM Na3VO4) on ice for 10 min. Lysates were then subjected to 1 round of 
freeze thaw action before homogenising it with a dounce homogeniser for 20 strokes. 
The homogenised lysates were centrifuged at 500g for 10 min at 4°C to remove 
debris. Following which, the supernatant were subjected to 10 passes through a 27G 
syringe. This is followed by sonication (3 sets of 10 sec pulses at 40V) and protein 
quantification to standardize the amount of protein used for subsequent 
ultracentrifugation. The samples were then mixed with an equal volume of 80% 
sucrose (w/v) in HEPES buffer, transferred to a centrifuge tube and carefully overlaid 
with 2 ml of 30% sucrose and 2 ml of 5% sucrose solutions. The sucrose gradient was 
centrifuged for 21 h at 4ºC in a Beckman rotor at 32,000rpm and nine 0.5 ml fractions 
were collected from top to bottom (named 1-9). The fractions are subjected to SDS-




15 Western blot analysis  
Following drug treatment, whole cell protein extracts were isolated using 1XRIPA 
lysis buffer. In other instances, subcellular (mitochondrial, cytosolic or sucrose 
density gradient) fractions were obtained as described in other sections. Protein 
concentration was quantified using the Coomassie Blue reagent. Briefly, 1μl of the 
supernatant was added to 200μl of Coomassie Blue reagent into a 96-well plate and 
read for absorbance at 595nm using TECAN spectrophotometer. Equal amounts of 
proteins from the lysates were mixed with 5X Laemelli loading dye and boiled at 
100°c for 5min. The samples were then subjected to different concentrations (8%, 
10% or 12%) of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) depending on the molecular weight of the target proteins. The resolved 
proteins were subsequently transferred onto PVDF membranes (BioRad Laboratories, 
CA, USA). The membranes were then blocked with 5% (w/v) fat-free milk in TRIS 
buffered saline (TBS) containing 0.1% (v/v) Tween 20 (TBST) for 1 h and washed 
thrice with TBST for 10 min each time (applied for all washes) to remove excess 
milk. The membrane was probed for the target protein with the relevant primary 
antibodies (refer to antibodies list above) overnight at 4ºC. The membrane was 
washed thrice with TBST to remove unbound primary antibody and probed again 
using appropriate HRP-conjugated secondary antibody in TBST containing 1% (w/v) 
fat-free milk at room temperature for 1 h. After three washes with TBST to remove 
any excess unbound secondary antibody, the proteins of interest were detected with 
Kodak Biomax MR X-ray film (Eastman Kodak Co., Rochestor NY) by enhanced 
chemiluminescence using the SuperSignal Chemiluminescent Substrate (Pierce, 




Buffers used in western blot analysis: 
RIPA lysis buffer: 50 mM Tris base, 150 mM NaCl, 1% v/v NP-40, 0.5% v/v 
deoxycholic acid, 0.1% v/v SDS, 1 mM EDTA at pH 7.5. Before use, the buffer was 
supplemented with protease inhibitors (1 mM PMSF, 10 μg/ml Aprotinin, 20 μg/ml 
Pepstatin A) and phosphatase inhibitors (1 mM NaF, 1 mM Na3VO4).  
Running Buffer for SDS-Page gel, 10X (1L): 25mM Tris base, 190mM glycine, 0.1% 
SDS with dH2O at pH 8.3, diluted to 1x before use. 
Wet Transfer Buffer for western blot, 1X (1L): 25mM Tris base, 190mM glycine, 
20% methanol with dH2O 
Lammeli Loading Buffer, 5X (10 ml): 100 mM Tris base, 3.1 ml (1M), SDS 1g 
(10%), glycerol 2 ml (20%), β-Mercaptoethanol 2.5 ml (25%), Bromophenol Blue 
0.01g (0.1%), top to 10 ml with 2.4 ml distilled H2O at pH 6.8.  
TBS : 60.5g Tris base and 87.8 g of NaCl in 10L of dH2O at pH 7.4 and stored at 
room temperature.  
TBST: 1L TBS with 1ml of Tween-20 and stored at room temperature. 
16 Analysis of DR4 and DR5 surface expression 
A549 WT (0.25 x 10
6
), R1 (0.5 x 10
6
), R2 (0.5 x 10
6
) cells were seeded in 6-well 
plates for 24 h and harvested and washed with FACS buffer (1X PBS + 0.5% FBS) 
after detachment of adherent cells with EDTA. Cells were then stained with the 
phycoerythrin (PE)-conjugated mouse monoclonal anti-human  DR4 or DR5 for 45 
min at 4
oC according to manufacturer’s instructions before washing and resuspension 
in FACS buffer for flow cytometry (CyAn ADP, Beckman Coulter, USA) using an 
excitation wavelength of 488. PE-conjugated mouse IgG2b was used as an isotype 
control and the obtained events were analysed by Summit 4.3 software. 
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17 Confocal analysis of DR4 and caspase-8 localization 
A549 WT (2x10
6
 cells) and R1 (4x10
6 
cells) R1 cells were plated in a 12-well plate on 
polylysine-coated coverslips. Cells were washed twice with 1x PBS and fixed with 
2% paraformaldehyde in 1xPBS for 15 min at room temperature. After which, cells 
were washed three times with ice cold 1xPBS and subjected to permeabilization with 
50uM of digitonin in 1xPBS for 15 min at room temperature. Cells were then washed 
three times with ice cold 1xPBS followed by an hour blocking with 5% BSA in 
1xPBS. Subsequently, cells were incubated with either mouse anti-DR4 or mouse 
anti-caspase-8 and rabbit anti-caveolin in 1xPBS with 5% BSA (1:250 dilution for 
anti-caspase-3 and anti-DDK; 1:500 dilution for anti-caveolin) for 2 h. After that, they 
were washed three times with 1xPBS in 5% BSA followed by 1 h incubation with 
1:500 dilution for Alexafluor-488 anti-mouse secondary antibody (Invitrogen) and 
1:500 dilution for Alexafluor-568 anti-rabbit secondary antibody in 1xPBS with 5% 
BSA. Cells were similarly washed three times with 1xPBS before the coverslips were 
mounted on glass slides and imaged with Olympus Fluoview FV1000 confocal 
microscope and images analysed using Olympus Fluoview 1.7 viewer. 
18 Measurement of mitochondria membrane potential 
3,3'-Dihexyloxacarbocyanine Iodide (DiOC6(3)) is a cell permeant, lipohilic dye that 
is selective for mitochondria membrane at low concentrations. This cationic dye is 
depolarized by the negatively charged mitochondrial membrane to yield green 
fluorescence and thus used to measure mitochondrial transmembrane potential 
(ΔΨm). Following treatment, the cells were harvested and loaded with 20nM of 
DiOC6(3), and incubated at 37°C for 15 min. Stained cells were washed again with 1x 
PBS and analysed by flow cytometry (CyAn ADP, Beckman Coulter, USA) using their 
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respective excitation and emission wavelengths. At least 10,000 events were analysed. 
Data collected were analysed with Summit 4.3 software. 
19 Oxygen Consumption 
Mitochondrial respiration of the A549 WT and R1 cells was measured using the 
Oxytherm Electrode (Hansatech Instruments, Norfolk, UK). (30x 10
6
) WT and (50x 
10
6
) R1 cells at exponential growth were harvested and permeabilized with digitonin. 
Samples were normalized by protein quantification at the start of the experiment. For 
the initiation of each measurement, the chamber was added with 1.25 ml of 
mitochondrial buffer III (200 mM mannitol, 75 mM sucrose, 0.1 mM EDTA, 10 mM 
K2HPO4, 10 mM KCl, and 10 mM Tris-HCl adjusted to pH7.4) containing 10 mM 
succinate, 5 mM rotenone, 80 mM ATP, and 50 mg of digitonin permeabilized cells. 
Oxygen consumption measurement was then initiated and monitored for 20 min at 
30°C. To measure state 3 respiration, 0.2mM ADP was added 5 min after initiation. 
Each measurement was initiated with 5 min of state 4 respiration, followed by another 
15 min of state 3 respiration. Data acquisition and analysis were carried out using 
Oxygraph Plus software developed for high-resolution respirometry (Hansatech 
Instruments Norfolk, UK). 
20 Enzymatic activities of mitochondrial respiratory complex I, II and IV  
Quantitative analysis of the mitochondrial complex I, II and IV activities was 
performed using the Human Complex I, II and IV activity Microplate Assay Kit 
provided by MitoSciences (Eugene, OR). Experiments were carried out according to 
the protocol provided by the manufacturer. Briefly, for all enzymatic assays, whole 
cells lysates were extracted with detergent and buffers supplied in the kit. Samples 
were incubated on ice for 30 min and centrifugated for 20 min at 4°C. The supernatant 
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were collected and protein quantification was performed and diluted to the 
recommended concentration for the optimal assay conditions. Diluted samples were 
then added to the wells, which are coated with antibodies targeting the mitochondrial 
complex enzymes, and the plates were left to incubate for the recommended time. 
Following which, the contents in the wells were emptied and washed twice with the 
buffers supplied in the kit. After washing, substrates for the complexes; NADH and 
CoQ1 (dye), succinate, ubiquinone and DCPIP (dye) for complex II and cytochrome c 
for complex IV, were added to the wells and their enzymatic reactions are assayed by 
measuring the change in absorbance with TECAN spectrophotometer (Tecan Trading 
AG, Switzerland). 
21 Determination of intracellular ATP 
The total intracellular ATP levels were assayed using the highly sensitive ATP 
Bioluminescence Assay Kit HSII (Roche, Basel, Switzerland) following the 
manufacturer’s instructions. Briefly, cells were counted in triplicate and washed in 
PBS. Cells (0.5 x 10
6
/ml) were resuspended in lysis buffer and incubated for 5 min at 
room temperature. To ensure complete lysis, the samples were further boiled for 2 
min at 100°C. Cell lysates (50 μl) were diluted in 50 μl of dilution buffer, and 100μl 
of luciferase reagent was added. The luciferase enzyme catalyzes the oxidation of 
luciferin to oxyluciferin and light (luminescence) in the presence of ATP and the 
emitted luminescence was measured using TECAN spectrophotometer (Tecan 
Trading AG, Switzerland) and ATP concentration was determined by comparing 
values to a standard curve. 
73 
 
22 Measurement of intracellular ROS levels by flow cytometry 
The different species of intracellular ROS are detected using different redox sensitive, 
cell- permeant dye specific for different species. The probes are: 
I. 5-(and-6)-chloromethyl-2,7-dichlorofluorescin diacetate (CM-H2-DCFDA) 
for the detection of general ROS/RNS (including H2O2 and ONOO-) Ex/Em 
wavelength: ~495/520nm 
II. MitoSOX ™Red for the detection of mitochondrial superoxide O2•
-
 Ex ⁄Em 
wavelength: ~510⁄580 nm 
III. 4-Amino-5-Methylamino-2',7'-Difluorofluorescein Diacetate (DAF-FM 
Diacetate) for the detection of nitric oxide Ex/Em wavelength: ~495/515 nm 
After treatment, cells were trypsinized, centrifuged at 2,000 rpm and washed in 1X 
PBS. Cells were then resuspended in 200ul FBS-free media and loaded with the 
specific redox probe and incubated at 37°C for 15 min. Stained cells were washed 
again with 1x PBS and analysed by flow cytometry (CyAn ADP, Beckman Coulter, 
USA) using their respective excitation and emission wavelengths. At least 10,000 
events were analysed. Data collected were analysed with Summit 4.3 software. 
23 O2•
-
 measurement by lucigenin 
A lucigenin-based chemiluminescence assay was used for measuring intracellular O2•
-
 
as described previously.ref A549 WT (0.3x10
6
) and R1 (0.6x10
6
) cells were seeded 
onto 6-well plates and incubated for 24 h before the experiment was performed. 
Following treatment, cells were washed once with 1xPBS, trypsinized, collected and 
centrifuged at 2000 rpm at room temperature for 3 min. Supernatant was removed and 
cells were resuspended and permeabilized in 400 μl of 1x ATP releasing agent (Sigma 
St Louis ). 100 μl of 10 mM lucigenin was injected automatically before the reading 
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and chemiluminescence was monitored for 30 s using a Berthold Sirius Luminometer 
(Titertek-Berthold, Huntsville, USA and Pforzheim, Germany). Data are shown in 
relative light units per second (RLU/s) and the values are normalized by the protein 
concentration of the samples.   
24 NADPH oxidase activity assay 
NADPH oxidase (NOX) is a plasma membrane-bound protein that, when activated, 
produces O2•- and thus its acitivity can be assayed by measuring the O2•- production 
by a lucigenin based assay previously described previously in (Griendling et al., 
1994). Following TRAIL treatment for the indicated time, A549 WT (2 x 10
7
) and R1 
(2 x10
7
) cells were harvested and washed 3 times with 5 ml of ice cold 1x PBS. Cells 
were then centrifuged at 750g at 4°C for 10 min. The supernatant was discarded, and 
the pellet was resuspended in 1ml of lysis buffer supplemented with protease 
inhibitors (20 mM monobasic potassium phosphate (pH7.4), 1 mM EGTA, 10 ug/ml 
aprotinin, 0.5 g/ml leupeptin, 0.7 ug/ml pepstatin, and 0.5 mM PMSF). The cell 
suspension was then dounced 25 times on ice, and the homogenate was stored on ice 
until use. Protein content of the homogenate was quantified using the Coomassie Blue 
reagent. NOX oxidase activity was subsequently measured by a luminescence assay in 
a 50 mM phosphate buffer, (pH 7.0), containing 1 mM EGTA, 150 mM sucrose, 500 
μM lucigenin as the electron acceptor, and 100 μM NADH as the substrate (final 
volume, 0.9 ml). The reaction was started by the addition of 100 μl of homogenate 
(500 μg protein). Chemiluminescence emitted from the reaction was monitored for 5 
min using a Berthold Sirius Luminometer (Titertek-Berthold, Huntsville, USA and 
Pforzheim, Germany). Data are shown in relative light units per second (RLU/s) and 
the values are normalized by the protein concentration of the samples.   
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25 Superoxide dismutase activity 
Quantitative analysis of the SOD activities was performed using the SOD IV activity 
Microplate Assay Kit provided by Cayman Chemical (Ann Arbor, MI, USA).  
Experiments were carried out according to the protocol provided by the manufacturer. 
Briefly, following TRAIL treatment, 10 x10
6
 cells were washed 3 times with ice cold 
1x PBS, and harvested. Cells were centrifugated at 500g for 5 min. Next, cells were 
homogenized in the ice cold HEPES buffer (20 mM HEPES (pH7.2), 1 mM EGTA, 
210 mM mannitol and 70 mM sucrose) using 20 strokes with a dounce homogenizer. 
Mitochondria can cytosolic fractions were isolated using the method described above 
(see section 13). And the fractions were assayed for SOD activity by adding radical 
detection and xanthine oxidase (provided by kit) to the samples. The samples were 
then incubated on a shaker for 20 min at room temperature. The activity of SOD is 
assayed by its indirect driving xanthine oxidase meditated conversion of tetrazolium 
salt to formazan dye resulting in a change in the absorbance. Absorbance is measured 
by TECAN sprectrophotometer (Tecan Trading AG, Switzerland) at 440-460nm. The 
SOD activity was determined by comparing values to a standard curve and 
normalizing to protein concentration. 
26 Cholesterol assay 
The total cholesterol content of cell was quantified using a Cholesterol/Cholesteryl 
Ester Quantitation Kit provided by Abcam, (Cambridge, UK). The fluorometric-based 
assay detects total cholesterol (cholesterol and cholesteryl esters) in the presence of 
cholesterol esterase or free cholesterol in the absence of cholesterol esterase. 
Experiments were carried out according to the protocol provided by the manufacturer. 
Briefly,  A549 WT and R1 cells (1x 10
6) were harvested and extracted with 200 μl of 
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chloroform: Isopropanol : NP-40 (7:11:0.1) by vortexing. Extracts were centrifugated 
at 15,000g in a centrifuge for 15min and the liquid phase is collected and air dried at 
50°C. Following which the dried lipids were dissolved with 200 μl of Cholesterol 
Assay Buffer (provided by kit) by sonicating or vortexing until homogeneous. The 
assay is then initiated by adding a cholesterol Probe, Cholesterol Enzyme Mix and 
Cholesterol Esterase (all provided by the kit) to the samples. The reaction mix is then 
incubated for 1h at 37°C and measure the fluorescence at Ex/EM 535/590 by TECAN 
sprectrophotometer (Tecan Trading AG, Switzerland). The SOD activity was 
determined by comparing values to a standard curve and normalizing to protein 
concentration. 
27 Statistical analysis 
All experiments were carried out 3 times or more, unless otherwise stated. Results 
were expressed as mean ± s.d. Statistical differences for experiments involving more 
than two groups were evaluated using the one-way analysis of variance (ANOVA) 
followed by the Post-hoc Dunnett test, while the unpaired Student’s t-test was used 
when comparisons between two groups were performed with confidence intervals set 




1 Validation of the cisplatin-resistant phenotype and their cross-resistance to a 
broad range of anticancer drugs 
1.1 Cisplatin-resistant clones displayed distinct morphological characteristics 
compared to their parent A549 WT cells. 
Since platinum-based chemotherapies remain as the standard first-line treatment for 
patients with advanced non-small cell lung cancer (NSCLC), we chose a NSCLC cell 
line, A549, as the main model of study. To study the mechanism of cisplatin 
resistance, two new cisplatin-resistant cell lines, R1 and R2, were established from 
single clone selection following repeated exposures of the parental A549 cells to low 
dose of cisplatin (5 μM) over a period of six months. First, we examined the 
morphological characteristics of the cell lines during exponential growth. The parental 
WT cells appeared more cohesive and clustered (Figure 6A). In contrast, the resistant 
clones were relatively smaller and grew in a more sparse and disorderly fashion (R1; 
Figure 6B and R2; Figure 6C). 
 
Figure 6: Representative photomicrographs showing the general cellular morphology of the WT 
and cisplatin-resistant cells. NSCLC A549 A, WT B, R1 and C, R2 cells with phase-contrast 





1.2  Cisplatin-resistant clones are more insensitive to platinum-based 
chemotherapeutic drugs as compared to the WT cells. 
To verify the resistance of R1 and R2 cells to cisplatin, the WT and cisplatin-resistant 
clones (R1 and R2) were treated with increasing doses of cisplatin (0-100 μM) for 
24h. Resultant loss of cell viability was estimated by a metabolic activity assay, MTT 
assay, where the MTT dye is reduced by actively respiring cells to formazan crystals, 
which is subsequently dissolved and quantified by measuring at a wavelength 570 nm 
by a spectrometer. The absorbance value allows for the quantitation the number of 
viable cells. Results from the MTT assay confirmed that the R1 and R2 cells were 
significantly more resistant to cisplatin treatment as compared to the WT cells. 
Following cisplatin treatment, a dose-dependent decrease in cell viability was 
observed in WT cells (IC50 values at ~50 μM cisplatin) and in comparison, only a 
slight decrease in cell viability was observed at higher doses of cisplatin (~25% and 
~30% in R1 and R2 respectively at 100 μM cisplatin) in the cisplatin-resistant clones 
(Figure 7A).  
One of the most common features in cisplatin-resistant cells is their cross-resistance to 
other platinum-based drugs. To investigate this, the cells were treated with carboplatin 
(0-1.5 mM), a second generation platinum drug, for 24 h. Results showed that the 
resistance was more pronounced with carboplatin in the cisplatin-resistant clones. As 
can be seen in Figure 7B, carboplatin had minimal effect on cell viability in the 
resistant clones, on the other hand, the cisplatin-sensitive WT cells exhibited a dose-
dependent decrease in cell viability with carboplatin treatment (IC50 values at ~1.5mM 
carboplatin). Our findings were consistent with reports by other groups that showed 
acquired resistance to platinum drugs can lead to cross resistance to other platinum 
analogues (Jones et al., 1993; Rixe et al., 1996; Rose and Basler, 1990). And notably, 
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mechanistic studies on DNA adduct formation had shown higher doses (~30-fold) of 
carboplatin are required to obtain equivalent cytotoxic effects elicited by cisplatin 
(Chaney et al., 2005; Cruet-Hennequart et al., 2009), in agreement with our data. 
 
 
Figure 7: Effects of platinum drugs on the cell viability of parental WT and cisplatin-resistant 
cell. A549 WT and the cisplatin-resistant cells were treated with A, cisplatin (μM) and B, carboplatin 
(mM) with the indicated doses for 24 h. Cell viability was measured by MTT assay detected at an 
abosrbance of 570 nm and expressed as % of untreated control. In all panels, the bars represent mean 
±SD of at least 3 independent experiments.  Statistical significance of control and treated samples were 
determined by unpaired t-test.  **, p < 0.01, and ***, p < 0.005 compared with WT control; #, 
p<0.05compared to R2 control  
 
1.3 Cisplatin-resistant cells have enhanced survival capacity following cisplatin 
treatment in a dose- and time-dependent manner, as compared to WT cells.  
To further substantiate the cisplatin-resistant phenotype of the clones (R1 and R2), the 
WT cells and the resistant clones were treated with increasing doses of cisplatin (0-50 
μM) for 24, 48, and 72 h and cell viability was assessed by MTT assay. Consistent 
with the MTT results obtained with the 24 h assay earlier, WT cells were more 
susceptible to cisplatin treatment in a dose- and time-dependent manner as compared 
to the resistant clones. Treatment with 50 μM cisplatin resulted in a significant 
reduction (~50%) in cell viability in WT cells by 24h, which was further enhanced 
with 48h treatment, and by 72 h, only  ~15% of cells were viable (Figure 8A). On the 
contrary, the cisplatin-resistant R1 and R2 cells clearly showed significant survival 




cisplatin, ~55% and ~50% of the R1 and R2 cells were still viable, respectively (R1; 
Figure 8B and R2; Figure 8C). 
. 
 
Figure 8: Time-dependent effects of cisplatin on the cell viabilty of parental WT and cisplatin-
resistant cell. A549 A, WT and the cisplatin-resistant cells B, R1, C, R2, were treated with various 
concentrations of cisplatin for 24, 48 and 72 h. Cell viability was measured by MTT assay detected at 
an abosrbance of 570 nm and expressed as % of untreated control. The data are expressed as means 
±SD of 3 independent experiments. Statistical significance of control and treated samples were 
determined by unpaired t-test.  . *, p < 0.05, **, p < 0.01, ***p<0.005 compared with WT control. Δ, p 





1.4 Cispatin inhibits long-term colony formation of the WT cells but the 
inhibitory effect is minimal on the resistant cells. 
Thus far, our preliminary results from the short term viability assay showed that the 
resistant clones have a greater survival advantage with cisplatin treatment as 
compared to the WT cells. We proceeded to assess if the results from the short term 
viability can be translated to long term proliferative capacity of the cells following a 
cytotoxic hit from cisplatin. To investigate clonogenic abilities of these cells, WT, R1 
and R2 were treated with increasing doses of cisplatin for 24 h. Following treatment, 
the cells were counted and reseeded at low density to form colonies for 10-14 days. In 
the WT plates, the same potent inhibitory effect elicited by cisplatin observed in the 
MTT assay, was reproduced in the clonogenic assay with almost complete inhibition 
of colony formation at a much lower dose of 5 μM (Figure 9A). On the other hand, 
the cisplatin-resistant cells showed significantly improved ability to form colonies 




Figure 9: Cisplatin abolishes clonogenic abilities of parental WT but not the cisplatin-resistant 
cells.A549 A, WT , B, R1 and C, R2 cells were treated with the indicated doses of cisplatin for 24h 
before being re-seeded onto 100mm Petri dishes and allowed to form colonies for over 10 days. 
Following which, colonies formed were stained with crystal violet for assessment. Data shown are 
representative of at least 3 independent experiments. 
 
1.5 Cisplatin-induced apoptosis is inhibited in cisplatin-resistant cells 
1.5.1  Cisplatin induced cell cycle arrest and apoptosis only in WT cells 
Loss of cell viability can be a consequence of cell cycle arrest or cell death and hence, 
to further characterize the loss of cell viability, cell cycle analysis was carried out. 
Cells were stained with propidium iodide (PI), a most commonly used nucleic acid 
stain to quantitatively assess DNA content as it binds to DNA by intercalating 
between the bases with little or no sequence preference, and subsequently analyzed by 
flow cytometry to obtain a distribution of cells in various stages of cell cycle, namely, 
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sub-G1, G1, S and G2/M phase. The population of dead cells containing DNA 
fragmentation, a hallmark of apoptosis, is represented by the sub-G1 population. 
Following cisplatin treatment for 24 h, there was a clear dose-dependent effect of 
cisplatin on the cell cycle status in WT cells. At a lower dose of cisplatin (25 μM), 
most of the WT cells were arrested in the S-phase (32% of S-phase population with 
cisplatin as compared to 12.3% in the untreated control cells). And at 50 μM of 
cisplatin, there was a significant accumulation of WT cells in the sub-G1 phase 
(31.6% of sub-G1 population with 50 μM cisplatin compared to 0.6% in the untreated 
control cells), suggesting cisplatin induced apoptosis in WT cells at higher 
concentrations (Figure 10A). Unlike the WT cells, only a slight increase in S-phase 
population following cisplatin treatment (25 and 50 μM) was observed in R1 (Figure 
10B) but not in R2 (Figure 10C). Furthermore, cisplatin has minimal cytotoxic effects 
on both the resistant clones. This is clearly indicated by the negligible increase in 
percentages of sub-G1 population with the indicated doses of cisplatin treatment. 
These findings are in agreement with previous studies showing that cisplatin can 
induce growth arrest in cancer cells in an attempt to repair the DNA damage, 
however, apoptosis is eventually initiated when DNA damage overwhelms the 





Figure 10: Cell cycle analysis shows that cisplatin induces cell cycle arrest and DNA 
fragmentation in parental WT cells but not the cisplatin-resistant cells.A549 A, WT, B R1 and C, 
R2 cells were treated with 25 and 50 μM of cisplatin for 24h. DNA content was analyzed by flow 
cytometry after staining with propidium iodide (PI) as described in Materials and Methods. Cell cycle 
profiles obtained from one set of experiment are shown here; they are representative of 3 independent 
experiments. y-axis: events and x-axis: PI lin fluorescence.   
 
1.5.2 Cisplatin-induced activation of caspase cascade in the WT cells, but not in 
the cisplatin-resistant cells 
Although DNA fragmentation is a key feature in apoptosis, it is not a cause but rather 
a consequence of initial apoptotic signaling events that involves the sequential 
activation of caspases (Collins et al., 1997). Caspases act as the main “executioners” 
of apoptosis by cleaving cellular substrates to bring about the apoptotic process 
(Nicholson and Thornberry, 1997). To investigate the involvement of caspases in 
cisplatin mediated cell death, Western blot analysis was carried out to detect caspase 
activation by their proteolytic processing. Here, we assessed the activities of 3 key 
caspases; caspase-8, -9 and -3, which are broadly classified as initiators (caspase-8 
and -9) and effectors (caspase-3). Figure 11 clearly demonstrates that there was robust 
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proteolytic cleavage of procaspase-3, -8 and -9 to their active subunits with 50uM 
cisplatin treatment in the WT cells. However, the same treatment did not activate 
these caspases in the resistant clones. In addition to caspase processing, Poly (ADP-
ribose) polymerase (PARP), a primary substrate of the effector caspase-3, was also 
evaluated. PARP cleavage, from its 116kDa to an 86kDa fragment, was observed in 
the WT cells but not in resistant clones. 
 
 
Figure 11: Cisplatin mediates processing and activation of procaspases in the WT but not 
cisplatin-resistant cells. A549 WT and cisplatin-resistant cells were treated with the indicated doses of 
cisplatin for 24 h. Whole cell lysates were then collected to assay for caspase-3, caspase-8 and caspase-
9 processing as well as PARP cleavage by Western blot analysis. GAPDH was used as loading control. 
 
1.5.3 Cisplatin engages the mitochondrial-mediated apoptotic pathway in WT 
cells 
Cumulatively, the data from cell cycle analysis and caspase activation has clearly 
shown induction of apoptosis by cisplatin in WT cells. Cisplatin is a well-
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characterized DNA damaging agent (Jamieson and Lippard, 1999) and this group of 
cytotoxic drugs typically induce apoptosis through the mitochondria-dependent 
apoptotic pathway (Roos and Kaina, 2006). A key event in the mitochondria-
dependent apoptotic pathway involves mitochondrial outer membrane 
permeabilization (MOMP), and the subsequent release of apoptogenic factors such as 
cytochrome c, which normally reside in the intermembrane space of the mitochondria, 
into the cytosol (Kuwana et al., 2002; Tait and Green, 2010). Cytochrome c, together 
with Apaf-1 and procaspase-9 form the apoptosome which initiate a cascade of 
caspase activation. 
Here, we studied the subcellular distribution of cytochrome c after cisplatin treatment 
by preparing cytosolic and mitochondrial fractions of the WT and cisplatin-resistant 
(R1 and R2) cells. Following cisplatin treatment (50 μM), an increase in the 
cytochrome c level was observed in the cytosolic fraction of the WT cells but not in 
the resistant clones (Figure 12).  
 
 
Figure 12 Cisplatin induces release of cytochrome C into the cytosol in parental WT cells but not 
the cisplatin-resistant cells. Cells were treated with 50 μM of cisplatin for 12 h following which, cells 
were fractionated to obtain the mitochondrial (HM) and cytosolic (C) fractions. Cytochrome c levels 
were analyzed by Western blot analysis.VDAC and Cu/ZnSOD was used as mitochondrial and 




1.6 High levels of intracellular ROS are generated by cisplatin treatment in 
WT cells 
As with most DNA damaging agents, intracellular ROS production plays an important 
role in cisplatin-mediated apoptosis (Miyajima et al., 1997; Schweyer et al., 2004). 
Hence this prompted us to investigate the involvement of ROS in cisplatin-induced 
cytotoxicity in our model. Cells were treated with cisplatin and following which, their 
intracellular ROS levels were assayed by staining the cells with specific redox 
sensitive probes, which react and oxidize with ROS, to yield fluorescence signals 
detectable by flow cytometry. To begin, we measured the intracellular ROS levels 
with CM-H2-DCFDA (DCFDA), a fluorophore commonly used to measure 
intracellular ROS and RNS, which include hydrogen peroxide (H2O2), peroxynitrite 
(ONOO-) and hydroxyl radical (HO·) in the cells (Myhre et al., 2003). The results 
showed that cisplatin induced high levels of intracellular ROS/RNS production in WT 
cells, demonstrated by the rightward shift in DCFDA fluorescence. (~51% in cisplatin 
treatment compared to ~11% in control; Figure 13A) On the other hand, there was no 
significant change in intracellular ROS/RNS levels with cisplatin treatment in R1 and 
R2. Figure 13b shows a bar graph representative of the average fold difference in 
ROS/RNS levels between control and cisplatin-treated samples, calculated from the 
G-mean values of DCFDA fluorescence obtained from three independent 
experiments. It clearly illustrates that cisplatin induced a significantly larger increase 
of intracellular ROS/RNS in WT cells as compared to the cisplatin-resistant cells.  
Besides using the DCFDA dye, we also assayed for the production of mitochondrial 
O2•- using another fluorogenic dye, MitoSOX Red. MitoSOX Red is highly selective 
for the detection of mitochondrial O2•-, and once oxidized, it produces an increase in 
red fluorescence detectable by flow cytometry (Mukhopadhyay et al., 2007). An 
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elevated mitochondrial O2•- level was detected with cisplatin treatment in WT cells 
(~44% in cisplatin-treated compared to ~9% in control Figure 13C). In contrast, no 
detectable increase in mitochondrial O2•- levels was observed in R1 and R2 cells. 
Figure 13D shows the bar graph representative of an average fold difference of 










Figure 13: Cisplatin induces increase in intracellular ROS levels in WT cells. A549 WT, R1 and 
R2 cells were treated with 50 μM cisplatin for 12 h. Cells were subsequently harvested and analyzed by 
flow cytometry for general intracellular ROS/RNS production using redox sensitive probe DCFDA. A, 
A density plot, y-axis: forward scatter, x-axis: DCFDA fluorescence B, A bar graph was plotted with 
the G-mean values and expressed as % of untreated control. Mitochondrial O2•
-
 level was measured in 
WT, R1 and R2 cells following 12 h of cisplatin treatment by loading with MitoSOX RED and 
analyzed by flow cytometry. C, A density plot, y-axis: forward scatter, x-axis: MitoSOX fluorescence 
D, A bar graph was plotted with the G-mean values and expressed as % of untreated control. In all 
panels, the bars represent means ± SD of at 3 independent experiments. Statistical significance of 




1.7 Cisplatin resistance confers resistance to other chemotherapeutic drugs 
Numerous studies have reported that mechanisms that confer platinum resistance 
often lead to resistance to other structurally and mechanistically unrelated drugs, a 
phenomenon known as multidrug-resistance (Gottesman, 2002). Hence to further 
define the drug resistant properties, we examined the cell viability of these cells with 
other widely used chemotherapeutic drugs. Here, we treated WT, R1 and R2 cells 
with increasing doses of each cytotoxic drug for 24 h and then cell viability was 
assessed using MTT assay. 
The first drug we used was 5-Fluorouracil (5-FU), an analogue of uracil with a 
fluorine atom at the C-5 position in place of hydrogen. Its active metabolites interfere 
with nucleoside metabolism and can be incorporated into RNA and DNA, leading to 
DNA damage and cytotoxicity in cells (Diasio and Harris, 1989; Kanzawa et al., 
1980). Figure 14A showed that the cisplatin-resistant clones were less sensitive to 5-
FU treatment as compared to WT cells. 
Next, we tested with another nucleoside analogue; gemcitabine, a second generation 
deoxycytidine analogue, which functions primarily to inhibit DNA synthesis. Its 
active metabolites act on several intracellular targets, such as DNA polymerase, 
thymidylate synthase, ribonucleotide reductase and its incorporation into DNA and 
RNA, together, these actions mediate the cyotoxic effects of gemcitabine (Hertel et 
al., 1990; Huang et al., 1991; Mini et al., 2006). Following treatment with 
gemcitabine, we found that the cisplatin-resistant clones were sparingly affected in 
comparison to the WT cells (Figure 14B). 
Finally, we treated the cells with etoposide, a topoisomerase II inhibitor, which 
disrupts the DNA re-ligation mechanism by stabilizing the covalently bound 
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complexes formed between the topoisomerase and the 5’ cleaved ends of the DNA 
molecule during DNA replication, which causes double strand break lesions and 
eventually mitotic catastrophe cell death (Hande, 1998; van Maanen et al., 1988). 
Similar to the results observed for 5-FU and gemcitabine, the cisplatin-resistant clones 
were less susceptible to etoposide as compared to the WT cells (Figure 14C). 
Taken together, our data have established the cisplatin-resistant properties of R1 and 
R2 cells, which also seem to inherently possess multidrug resistance properties. These 
findings corroborate earlier reports where multi-drug resistance is often a 
phenomenon observed in refractory cancer cells. Consequently, these cisplatin-
resistant cells represent a good model for studying the molecular determinants 
underlying cisplatin resistance, a pressing problem in the treatment of cancer. 
Figure 14: Cisplatin resistance renders R1 and R2 cells resistant to other chemotherapy drugs. 
A549 WT and the cisplatin-resistant cells were treated with A, 5-fluorouracil (μM), B, gemcitabine 
(mM) and C, etoposide (μM) at the indicated doses for 24 h. Cell viability was measured by MTT 
assay detected at an abosrbance of 570 nm and expressed as % of untreated control. In all panels, the 
bars represent mean ±SD of at least 3 independent experiments. Statistical significance of control and 
treated samples were determined by unpaired t-test. **, p<0.005, ***, p<0.001  compared with WT 




2 Characterizing the differences between WT and cisplatin-resistant cells.  
Next, we sought to determine the molecular mechanism which could confer resistance 
in these clones. Many studies have endeavoured to answer the same questions and 
have identified many mechanisms contributing to drug resistance; such as limiting the 
drug accumulation in the cells by expressing drug efflux pumps, inhibiting cell death 
by apoptosis, modifications in cell cycle and checkpoints and ways to evade DNA 
repair (Gottesman, 2002; Gottesman and Pastan, 1988; Lowe et al., 1993). Hence, in 
this study, we focus on a few areas in our expertise and identify the possible 
molecular determinants that are relevant in our model.  
2.1 Cisplatin-resistant cells exhibit a decreased cell proliferation rate as 
compared to the WT cells. 
One of the most distinct differences observed between the cisplatin-resistant cells and 
the WT cells is the rate of proliferation. To determine their proliferation rate, the cells 
were seeded at the same density and their cell number was monitored every 24h up to 
a total of four days. As can be seen in Figure 15, when cultured under normal 
conditions, both the resistant clones grew at markedly lower rates as compared with 
WT cells. This observation is consistent with reports by other groups that had 
generated cisplatin-resistant clones in vitro (Eckstein et al., 2009; Frenzel et al., 
1995).  
Conventional anticancer therapies typically target actively dividing cancer cells by 
interfering with DNA synthesis and/or the cell division process hence these resistant 
cells with reduced proliferation rates are more resistant to this category of drugs. 
Since the genotoxic mechanisms of action for cisplatin have been extensively studied 
and well characterized, it was of interest to explore other determinants of cell growth, 




Figure 15 : Cisplatin-resistant cells have decreased growth rates. A549 WT, R1 and R2 cells were 
seeded at the same confluency (0.05x10
6
) and the cell number is monitored every 24 h up to 96 h. The 
growth curve of each cell line is plotted and compared between the 3 cell lines. The data are expressed 
as means ±SD of at least 3 independent experiments. Statistical significance between WT versus 
cisplatin-resistant cells at different timepoints were determined by unpaired t-test. **, p<0.005 
compared with R1 and R2 cells. 
  
2.2 Impaired mitochondrial function in cisplatin-resistant cells 
Mitochondria are the major sites of energy production in the cells and therefore, are 
essential for all cellular functions, which include cell growth and cell viability. To 
address if the mitochondrial function is impaired in the cisplatin-resistant cells, we 
evaluated their mitochondrial respiratory function and integrity.  
2.2.1 Loss of mitochondrial membrane integrity in R1 cells 
An important parameter of mitochondrial function is the integrity of the mitochondrial 
membrane. The mitochondrial membrane potential (ΔΨm) in normal cells is highly 
polarized at ~ -150-180mV relative to cytosol. Thus, to measure the ΔΨm of the cells, 
we stained the cells with a lipophilic, cationic fluorescent dye, DiOC6(3), that 
selectively binds to the highly polarized mitochondrial membrane, and subsequently 
analyzed by flow cytometry. The difference in ΔΨm is indicated by the intensity of 
the fluorescence. R1 cells appeared to exhibit a reduced DiOC6(3) fluorescence as 





than the WT cells (Figure 16). Thus far, these findings provide strong evidence 
suggesting that the mitochondrial function is compromised in the R1 cells. 
 
 
Figure 16: The cisplatin-resistant R1 cells exhibits a lower mitochondrial membrane potential 
(ΔΨm). A549 WT and R1 cells were stained with a cationic fluorescent dye, DiOC6, and analysed by 
flow cytometry. Data shown in histogram is representative of at least 3 independent experiments. 
Histogram showing y-axis: number of events, x-axis DiOC6 fluorescence. 
 
2.2.2 R1 cells exhibit lower oxygen consumption rate as compared to WT cells 
Next, oxygen consumption rate, an indicator of mitochondrial respiration of the cells, 
was measured with a Clark electrode system using cells permeabilized with digitonin. 
The addition of succinate, rotenone and ATP is to maximally stimulate respiration 
through complex II of the electron transport chain, thus measuring the State 4 
respiration of the cells in vitro, following which exogenous ADP was added to initiate 
State 3 respiration. The results showed that the succinate-driven mitochondrial 
oxygen consumption was higher in the WT cells than the R1 cells, clearly 
demonstrated by the steeper gradient of curve in the WT cells as compared to R1 cells 




Figure 17: The cisplatin-resistant R1 cells exhibits a lower oxygen consumption rate. Oxygen 
consumption rate was assessed using a Clark electrode on WT and R1 cells permeabilized with 
digitionin, respiring on succinate in the presence of ATP to simulate state 4 respiration. Reverse 
electron flow was inhibited by rotenone and state 3 respiration was initiated with addition of exogenous 
0.2mM ADP (Arrow). Samples were normalized prior to initiation of experiment. The slope of the 
curve is a measure of the rate of oxygen consumption for a period of 20min.  Data shown are 
representative of 3 independent experiments.  
 
2.2.3 The respiratory enzyme complex I, II and IV of the election transport 
chain showed lower activities in R1 cells as compared to WT cells 
To further support the findings from the oxygen consumption data, we took a closer 
look at the electron transport chain that drives oxidative phosphorylation (OXPHOS) 
process in the cells. The electron transport chain consists of up of four major 
respiratory enzyme complexes that couple the energy released from electron transfer 
to generate an electrochemical proton gradient across the inner mitochondria 
membrane and the flow of proton back into the matrix of the mitochondrion via ATP 
synthase generates ATP from ADP (Hatefi, 1985). The enzyme activity of these 
complexes were evaluated in vitro and we found that the activity of complex I (Figure 







Figure 18: Enzymatic activities of the respiratory complexes are lower in R1 cells. Respiratory 
ETC complex A I , B II, C IV activity was measured in WT and R1 cells using the 96-well enzymatic-
based microplate assay kit (Mitosciences) as described in Materials and Methods. Samples were 
normalized prior to initiation of the experiment. Statistical significance of WT cells versus R1 cells was 
determined by unpaired t-test. The bars represent means ± SD of at least 3 independent experiments. *, 
p<0.05, **, p<0.01 compared with WT cells. 
 
2.3 R1 cells are more dependent on glycolysis for its energy requirements 
Having established that R1 has lower rates of OXPHOS, this raises the question of 
whether R1 has lower energy requirements or is there another alternative energy 
source. To answer the question, we proceeded to investigate the glycolytic pathway. 
The main substrate for the glycolytic process is glucose and hence we incubated the 
cells with increasing doses of 2-Deoxyglucose, a competitive inhibitor of D-glucose. 
Clearly demonstrated in Figure 19, the R1 cells were more susceptible to 2-
Deoxyglucose than the WT cells, suggesting that the R1 cells are more dependent on 








Figure 19: Glucose deprivation reduces cell viability in cisplatin-resistant R1 cells.WT and the 
cisplatin-resistant R1 cells were treated with 2-deoxyglucose (mM) with the indicated doses for 24h. 
Cell viability was measured by MTT assay detected at an abosrbance of 570 nm and expressed as % of 
untreated control. The bars represent means ±SD of at least 3 independent experiments. Statistical 
significance of control and treated samples were determined by unpaired t-test.  *, p < 0.05, compared 
with WT control; #, p<0.05, ##, p<0.01 compared to R1 control 
 
2.4 ATP produced by glycolysis in R1 cells is still significantly lower than that 
in WT cells. 
Since R1 cells have a surrogate energy source, i.e.,  by producing ATP through 
glycolysis, it was of interest to determine if glycolysis in R1 cells was efficiently 
capable of producing ATP levels comparable to that in WT cells to sustain all cellular 
processes.  To this end, we measured the total intracellular ATP levels with a highly 
sensitive bioluminescence-based assay. In this assay, a luciferase reagent was used to 
catalyse luciferin to emit luminescence in the presence of ATP. The results showed 
that R1 cells have a much lower total intracellular ATP level as compared to that of 




Figure 20: The cisplatin-resistant R1 cells have lower levels of total intracellular ATP. WT and R1 
total intracellular ATP levels were measured with an ATP luminescence assay kit (Roche) as described 
in Material and Methods and normalized to total cellular protein. The bars represent mean ±SD of at 
least 3 independent experiments. Statistical significance between WT versus R1cells was determined 
by unpaired t-test. **, p < 0.005, compared with WT cells. 
 
2.5 Dysregulated expressions of proteins involve in the mitochondrial-related 
function 
To further reinforce the role of mitochondria in promoting acquired resistance in the 
refractory cells, we analyzed the expression of some proteins associated with 
mitochondrial function and their apoptotic signaling processes.  
To validate the function of the mitochondria, we assessed the levels of ANT, a 
mitochondrial carrier and a component of the mitochondrial permeability transition 
pore (MPTP), which plays a major role in apoptosis. The levels of ANT were much 
lower in cisplatin-resistant cells, suggesting the function of MPTP might be 
compromised. On the other, AIF, an apoptosis inducing factor, appeared unchanged.  
Next, Bcl-2, Bcl-XL and Mcl-1, are anti-apoptotic proteins, essentially function to 
maintain the mitochondrial membrane integrity, by nullifying the effects of 
proapoptotic proteins in the cells. As can be seen in Figure 21, Bcl-XL levels 
remained unchanged between the cell lines but Bcl-2 was down-regulated in the 




Mcl-1 levels as compared to WT cells, which might be a compensatory mechanism 
for the decrease in Bcl-2 levels. In addition to these, Bax, a proapoptotic regulator of 
the mitochondrial-mediated apoptosis appeared significantly lower in the cisplatin-
resistant cells. Lastly, p53, a tumor suppressor, appeared unchanged across the cell 
lines. 
Cumulatively, the protein expression profile corroborates with the mitochondrial 
function data, confirming that mitochondria play a critical role in the acquiring of the 
cisplatin-resistant phenotype.  
 
Figure 21: Expression levels of proteins important for mitochondrial apoptotic signaling. Whole 
cell lysates of WT, R1 and R2 were subjected to Western blot analysis for various proteins important in 
regulating mitochondria-mediated apoptotic signaling. Beta actin was used as loading control. 
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2.6 Redox status of the WT and cisplatin-resistant cells 
Since mitochondria are major sites of intracellular ROS production, it was of interest 
to characterize the redox status of the cells. We measured the basal intracellular ROS/ 
RNS levels in the cells with the DCFDA probe and the results showed that the 
cisplatin-resistant cells have a higher level of intracellular ROS/RNS as compared to 
WT cells (Figure 22A). Furthermore, we also measured the mitochondrial O2•- levels 
with the MitoSOX Red probe, and interestingly, the results showed that the cisplatin-
resistant cells have a significantly reduced level of mitochondrial O2•- levels as 
compared to WT cells (Figure 22B). As such, we proceeded to examine the major 
antioxidant proteins in the cells. Overall, catalase and Cu/Zn superoxide dismutase 
(Cu/ZnSOD) remained unchanged between the cell lines. However, Manganese 
superoxide dismutase (MnSOD) was significantly higher in the cisplatin-resistant 
cells as compared to the WT cells (Figure 22C). Here suggesting that mitochondria 






Figure 22: Redox milieu of the WT and cisplatin-resistant cells. Cells were harvested and stained 
with redox sensitive probe A, DCFDA (y-axis: number of events and x-axis: DCFDA fluorescence) B, 
MitoSOX Red (y-axis: number of events and x-axis: MitoSOX fluorescence) and analyzed by flow 
cytometry for general intracellular ROS/RNS and mitochondrial O2•- production respectively. C, 
Expression levels of the antioxidant enzymes, catalase, Cu/ZnSOD and MnSOD were examined by 
Western blots using whole cell lysates obtained from WT and cisplatin-resistant cells. Beta actin was 















3 Cisplatin-resistant cells are more sensitive to death receptor-mediated cell 
death as compared to WT cells. 
3.1 TRAIL induces cell death only in cells with acquired resistance to cisplatin 
Since the intrinsic mitochondria-dependent apoptotic pathway is compromised, it 
prompted us to study a different death signaling pathway in the apoptotic network, 
that is, the death receptor pathway, and explore its potential therapeutic use in 
eradicating these cisplatin-resistant refractory cancer cells. To investigate this idea, 
we treated the cisplatin-resistant cells with increasing concentrations of TRAIL and 
Fas ligand. Surprisingly, despite being resistant to cisplatin and other conventional 
anticancer drugs, the cisplatin-resistant cells were more vulnerable to TRAIL than the 
WT cells. As can be seen in Figure 23A, stimulation of the cisplatin-resistant clones 
with TRAIL resulted in a marked decrease in cell viability (~40% and ~50% decrease 
in cell viability in R1 and R2, respectively, at TRAIL 100ng/ml), whereas WT cells 
were unaffected by TRAIL. A similar trend was observed with the activation of 
another death receptor, Fas, using an activating antibody against Fas receptor (Figure 







Figure 23: Cisplatin-resistant cells are sensitive to receptor-mediated cell death. A549 WT and 
cisplatin-resistant cells were treated with different doses of A, TRAIL (0-200 ng/ml) B, Anti-Fas 
activating antibody (0-1 μg/ml) for 24h. Cell viability was measured by MTT assay detected at an 
abosrbance of 570 nm and expressed as % of untreated control.  In all panels, the bars represent means 
± SD of at least 3 independent experiments. Statistical significance between control and treated cells 
were determined by unpaired t-test *, p< 0.05, and **, p < 0.01, compared with R1 control; #, p<0.05, 
##, p< 0.01 compared to R2 control 
 
To determine the effect of TRAIL on the long term proliferative capacity of the 
cisplatin cells, we performed clonogenic cell survival assays on these cells following 
treatment with TRAIL and Figure 24 clearly shows that the R1 and R2 cells have 
reduced clonogenic abilities in response to TRAIL as compared to WT cells even after 
exposure to lower doses of TRAIL (25 and 50 ng/ml). Henceforth, for the subsequent 






Figure 24: TRAIL abolishes clonogenic abilities of cisplatin-resistant clones but not the WT cells. 
Cells were treated with the indicated doses of TRAIL for 4 h before being re-seeded onto 100 mm Petri 
dishes and allowed to form colonies for over 10 days. Following which, colonies formed were stained 
with crystal violet for assessment. Data shown are representative of at least 3 independent experiments. 
 
3.2 TRAIL induces classical apoptosis in the cisplatin-resistant cells 
3.2.1 Apoptotic feature 1: DNA fragmentation  
Although TRAIL is a classical apoptosis-inducing agent, recent experimental 
evidence has established its involvement in a newly characterized alternative form of 
cell death known as necroptosis or programmed necrosis, which is clearly distinct 
from apoptosis and necrosis (Holler et al., 2000; Matsumura et al., 2000). Briefly, 
necroptosis is a form of necrotic cell death triggered by the same stimuli that normally 
activate apoptosis, through the ligation of the death receptors, but does not involve 
key apoptosis regulators such as caspases and the Bcl-2 family proteins (Degterev et 
al., 2005). Thus, to confirm the apoptotic mechanism of TRAIL in this model, we 
performed a systematic analysis of the key events in the apoptotic signaling pathway. 
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Firstly, we performed a cell cycle profile analysis to confirm the accumulation of cells 
with DNA fragmentation. Indeed, as can be seen from Figure 25, R1 and R2 cells 
showed dose dependent accumulation of cells in the sub G1 phase with TRAIL 
treatment as early as 4 h. On the other hand, WT cells have no significant difference 
in the sub G1 population. 
 
Figure 25: Cell cycle analysis shows that TRAIL induces DNA fragmentation in cisplatin-
resistant cells. A549 WT, R1 and R2 cells were treated with the indicated doses of TRAIL (ng/ml) for 
4h. DNA content was analyzed by flow cytometry after staining with propidium iodide (PI) as 
described in Materials and Methods. Cell cycle profiles obtained from one set of experiment are shown 
here; they are representative of 3 independent experiments. y-axis: number of events, x-axis: PI lin 
fluorescence.   
 
3.2.2 Apoptotic feature 2: Phosphatidylserine externalization 
In addition to DNA fragmentation, another characteristic feature of apoptosis is the 
externalization of phosphatidylserine (PS) which is normally restricted in the inner 
leaflet of the membrane in living cells (Koopman et al., 1994). When apoptosis is 
initiated, PS is translocated from the inner leaflet of the plasma membrane to the outer 
leaflet. This physiological change can be detected with annexin V, a protein that has a 
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strong and specific affinity for PS. Following TRAIL treatment, cells were stained 
with fluorescent probe-labelled annexin V and analysed with the flow cytometry for 
positively labelled apoptotic cells. Figure 26 clearly showed that the population of 
cells with positive Annexin V stain is much higher in the cisplatin-resistant clones 
(~35% and ~25% in R1 and R2 cells, respectively, at 100 ng/ml of TRAIL) than the 
WT cells.  
 
Figure 26: TRAIL induces PS externalization in cisplatin-resistant cells. A549 WT, R1 and R2 
cells were treated with the indicated doses of TRAIL (ng/ml) for 4h, following which, the cells were 
stained with FITC-labeled  annexin V and analyzed by flow cytometry as described in Materials and 
Methods. Annexin V profiles obtained from one set of experiment are shown here but they are 
representative of 3 independent experiments. y-axis: forward scatter, x-axis: FITC fluorescence. 
 
3.2.3 Apoptotic feature 3: Caspase cascade activation and a caspase-dependent 
cell death 
Next, to confirm that TRAIL mediates a caspase-dependent apoptotic event in the 
cisplatin-resistant cells, we examined the effect of TRAIL on the activation of 
caspase-8 (initiator caspase) and -3 (effector caspase), which are the main caspases 
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involved in the extrinsic apoptotic pathway. Our western blot analyses showed robust 
activation of caspase-8 and -3 in the cisplatin-resistant cells with TRAIL treatment for 
24h, in contrast, WT cells displayed little or no caspase activation (Figure 27A). Since 
DNA fragmentation and PS externalization were detected at 4h, we performed a 
kinetic study of caspase processing upon TRAIL stimulation. We observed efficient 
processing of caspase-8 and -3 to their active subunits in R1 cells, as early as 2h post-
TRAIL induction. In stark comparison, the caspase processing in WT cells were fairly 
weak even up to 8h TRAIL treatment. In addition to caspase processing, we also 
observed pronounced PARP cleavage in the R1 cells with TRAIL treatment, an 
indication of caspase-3 activation (Figure 27B). 
To corroborate the western blot data, we also assessed the activity of various caspases. 
In addition to caspases involved in the extrinsic pathway (caspase-3 and-8), the 
activities of caspases involved in the intrinsic pathways, (caspase-6 and -9) were also 
examined using their respective fluorescence-conjugated caspase substrates, following 
TRAIL treatment. Similar results were observed with activity assay, the kinetic 
analysis detected robust activation of these caspases in the R1 cells as early as 2h after 
treatment and maximal amplification observed at 4h (Figure 27C). While in the WT 
cells, TRAIL-induced caspase activation, if any at all, were insignificant for all 







Figure 27: TRAIL mediates processing and activation of procaspases in the cisplatin-resistant 
cells. A, WT and cisplatin-resistant cells were treated with the indicated doses of TRAIL for 24h. 
Whole cell lysates were then collected to assay for caspase-3 and caspase-8 processing as well as 
PARP cleavage by Western blot analysis. B, Kinetics (2,4 and 8h) of caspase-3 and caspase-8 
processing as well as PARP cleavage following TRAIL treatment by Western blot analysis, in WT and 
R1 cells. GAPDH was used as loading control. C, WT and R1 cells were exposed to 50 ng/ml of 
TRAIL for varying durations as indicated. Total cell lysates were used to assess caspase-3, -6, -8, and -
9 activation levels using fluorescence-conjugated substrates. Caspase activity was normalized to total 
protein and expressed as fold increase over untreated cells from each time-point. The bars represent 
means ± SD of 3 independent experiments. Statistical significance between control and untreated 





To further establish the role of caspases as the main executors of TRAIL-mediated 
cell death, cisplatin-resistant cells (R1 and R2) were preincubated with the pan-
caspase inhibitor, Z-VAD-FMK, for 1h and then triggered the cells with TRAIL for 
24h. The cytotoxic effect (Figure 28A) and caspase activation (Figure 28B) mediated 
by TRAIL in the cisplatin-resistant cells was completely abrogated in the presence of 
Z-VAD-FMK. Thus far, these findings confirmed that TRAIL induces a caspase-





Figure 28: TRAIL mediates apoptosis in cisplatin-resistant cells in a caspase-dependent manner. 
A, Cisplatin-resistant R1 and R2 cells were pre-incubated with ZVAD-fmk 50 μM for 1h followed with 
50 and 100 ng/ml of TRAIL treatment for 24h. Cell viability was measured by MTT assay detected at 
absrobance 570 nm and expressed as % of untreated control. In all panels, the bars represent means 
±SD of at least 3 independent experiments. B, R1 cells were harvested and whole cell lysates were 
subjected to Western blot analysis for the assessment of caspase-3 and caspase-8 processing as well as 
PARP cleavage. GAPDH was used as loading control. Statistical significance between dmso +TRAIL 
versus ZVAD+ TRAIL samples were determined by unpaired t-test. *, p<0.05, **, p< 0.01  
 
3.3 Cisplatin-resistant cells exhibit a type I cell death receptor signaling 
pathway 
In the light of death receptor-mediated cell death, two distinct mechanisms have been 
characterized based on the cell types; Type I and Type II cells. Death receptor-
mediated apoptosis in type I cells is initiated by substantial activation of caspase-8 at 
the DISC followed by direct activation of caspase-3 in a linear manner without the 
need to engage the intrinsic mitochondria pathway. Whereas in Type II cells, DISC 
formation is fairly weak, thus activating only small amount of caspase-8 sufficient to 
induce the apoptogenic activity of mitochondria, which act as an amplification loop 
for caspase-8 and -3 activation (Scaffidi et al., 1998; Scaffidi et al., 1999). Hence, to 
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further our understanding of the mechanism of TRAIL-mediated cell death in the 
cisplatin-resistant cells, we proceeded to characterize the cell type as well as 
investigate the involvement of the intrinsic mitochondria pathway.  
 
3.3.1 TRAIL-induced cell death engages the mitochondrial apoptotic pathway 
in the cisplatin-resistant cells 
As mentioned earlier, a key event in the intrinsic pathway involves MOMP, which is 
often represented by a drop in mitochondria membrane potential (ΔΨm) and the 
release of apoptogenic factors, e.g. cytochrome c. To check whether the mitochondria 
pathway is involved, we assessed the effect of TRAIL on ΔΨm and cytochrome c 
release. Upon TRAIL stimulation, no significant change in ΔΨm was detected in the 
WT cells, whereas, we observed a decrease in ΔΨm in R1 cells as early as 1h as 
indicated by the backward shift of DIOC6 fluoresence to the left (Figure 29). Next, we 
compared the effects of cisplatin and TRAIL on cytochrome c release in both WT and 
R1. Again, cisplatin-induced cytochrome c release into the cytosol was detected in 
WT cells and not in R1. On the other hand, with TRAIL treatment, the reverse was 
observed (Figure 30). Concomitantly, Bid, a pro-apoptotic member of the Bcl-2 
family and a key mediator between the death receptor pathway and the mitochondria 
pathway, was cleaved and recruited to the mitochondrial fraction in the TRAIL-





Figure 29 : TRAIL induces a drop in mitochondrial membrane potential (ΔΨm) in cisplatin-
resistant R1 cells. A549 WT and R1 cells were treated with TRAIL 50 ng/ml for 1 and 2h. Cells were 
stained with DiOC6 and analysed by flow cytometry and plotted in density plots (upper panel: WT 
cells, lower panel: R1 cells). CiCCP is used as a positive control. y-axis: forward scatter, x-axis: DiOC6 
fluorescence. Data shown are representative of at least 3 independent experiments. 
 
 
Figure 30: TRAIL induces release of cytochrome c into the cytosol in cisplatin-resistant R1 cells 
but not in WT cells. Cells were treated with 50 ng/ml of TRAIL(tr) or 50 μM of cisplatin (cis) for 4h 
following which, cells were fractionated to obtain the mitochondrial (HM) and cytosolic (C) fractions. 
Cytochrome c and BID levels were analyzed by Western blot analysis. VDAC and Cu/ZnSOD were 





3.3.2 Transient overexpression of Bcl-2 does not confer any protection against 
TRAIL-induced apoptosis 
Although these findings demonstrated that the mitochondria are activated by TRAIL 
in R1, they are insufficient to conclude that the cisplatin-resistant cells are dependent 
on the mitochondria for TRAIL-mediated apoptotic pathway. To this end, we 
overexpressed the anti-apoptotic Bcl-2 protein, which functions as a guardian of 
mitochondria integrity and a key regulator of MOMP (Chipuk and Green, 2008), in 
the cisplatin-resistant cells prior to TRAIL treatment. Figure 31 clearly demonstrates 
that the enforced expression of the Bcl-2 protein does not render the cisplatin cells 
any survival advantage against TRAIL-induced apoptosis. Thus, our data suggest that 
TRAIL induced a mitochondria-independent apoptotic pathway in these cells, a 







Figure 31: Overexpression of Bcl-2 does not confer protection against TRAIL-induced apoptosis 
in cisplatin-resistant R1 and R2 cells. A, R1 and B, R2 was transiently transfected with 1 μg of 
pcDNA or pcDNA/Bcl-2 plasmid for 24h. Cells were then treated with 50 ng/ml of TRAIL for 24h. 
Cell viability was measured by MTT assay detected at an abosrbance of 570 nm and expressed as % of 
untreated control. All data represent means ± SD of at least 3 independent experiments. C, Western 
blot analysis showing overexpression of Bcl-2 in R1 and R2 cells 24h post-transfection. Beta actin was 












4 Unravelling the mechanisms of TRAIL sensitivity in cisplatin-resistant cells. 
4.1 Analysis of the DISC components  
4.1.1  Death receptors protein levels were elevated in the cisplatin-resistant 
cells 
Given that TRAIL-triggered apoptosis in cisplatin-resistant cells is essentially 
mediated through the death receptor pathway, we scrutinized in more detail the 
molecular mechanism of the death receptor signaling pathway that could contribute to 
TRAIL sensitivity in the cisplatin-resistant cells. 
Briefly, TRAIL induces apoptosis by binding to the death receptors, which triggers 
the oligomerization of the death receptors and recruitment of caspase-8 via FADD, an 
adaptor protein, to form the DISC (Bodmer et al., 2000), which subsequently activates 
the caspase cascade. Hence, the first rational step was to study the death receptors and 
the components of DISC. To begin, we first compared the protein expression of the 
DISC components in the TRAIL-resistant (WT) and TRAIL-sensitive (R1 and R2) 
cells. Western blots from the whole cell lysates showed that the protein expression of 
the death receptors, DR4 and DR5, were both slightly higher in R1 and R2 as 
compared to the WT cells (Figure 32), suggesting that the sensitivity of the cisplatin-
resistant cells to TRAIL could be a consequence of higher death receptor expression. 
The other two components of DISC, Caspase-8 precursor and FADD, were expressed 
at similar levels in the three cell lines (Figure 32). In addition to the DISC 
components, we also characterized the expression of the key regulatory proteins of 
DISC formation. RIP, a receptor interacting protein (Stanger et al., 1995), and cFLIP, 
a DED containing protein that interacts with FADD to block caspase-8 recruitment 
(Irmler et al., 1997). RIP was expressed in similar levels across the three cell lines. As 
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for cFLIP, the expression was comparable between WT and R2, however, R1 has a 
much lower expression compared to the other two. Besides RIP and cFLIP, we also 
examined the protein expression profile of two IAPs, cIAP2 and XIAP, which are 
known to inhibit caspases (Deveraux and Reed, 1999). We found that the trend of 
cIAP2 expression is opposite from that of XIAP in the three cell lines. Protein 
expression of cIAP2 is higher in the TRAIL sensitive cells, R1 and R2, as compared 
to WT cells and the reverse was observed for XIAP (Figure 32).  
 
Figure 32: Expression levels of proteins regulating DISC formation. Whole cell lysates of WT, R1 
and R2 were subjected to Western blot analysis for various proteins important in regulating DISC 
formation. GAPDH was used as loading control. 
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4.1.2 Surface expressions of the death receptors DR4 and DR5 did not correlate 
with total protein expression 
Although increased DR4 and DR5 protein expressions were detected in the cisplatin-
resistant cells, their functional relevance is yet to be determined. In order for the 
TRAIL receptors to elicit their physiological function, they have to be presented on 
the cell surface to enable their interaction with the ligands. For this reason, we 
assessed the surface expression level of the TRAIL receptors, DR4 and DR5, by using 
PE-conjugated antibodies against the respective receptors on live WT and cisplatin-
resistant cells and analyzed by flow cytometry to obtain quantitative representations 
of surface receptors expression. The results showed that under basal cell culture 
conditions, DR4 and DR5 are both expressed on the cell surface of the WT and 
cisplatin-resistant cells (Figure 33A). However, DR5 surface expression was much 
higher than that of DR4 in all the three cell lines (Figure 33A). Interestingly, the 
surface expression of the TRAIL receptors did not correlate with their protein 
expression as shown in the Western Blots. These findings indicate that the up-
regulation of the death receptor proteins might not be the key explanation to TRAIL 
sensitivity in R1 and R2 cells. Hence, the question remains: what is the underlying 




Figure 33: Decreased expression of surface TRAIL receptors DR4 and DR5 in cisplatin-resistant 
cells. A549 WT, R1 and R2 cells were analyzed for surface expression of DR4 and DR5 by staining 
with PE-conjugated mouse monoclonal anti-human DR4 or DR5 and sorted through flow cytometry. 
Non-specific IgG2B was used as an isotype control. Density plot; y-axis: forward scatter, x-axis: PE 
fluorescence. Data shown are representative of 3 independent experiments. 
 
4.2 Lipid rafts serve as a platform for mediating TRAIL-induced apoptotic 
signals in cisplatin-resistant cells 
4.2.1 Differential distribution of death receptors, DR4 and DR5, on the plasma 
membrane between the WT and R1 cells in basal conditions 
Published works have experimentally shown many mechanisms that sensitize cells to 
TRAIL, one of which is the redistribution of death receptors into lipid rafts thereby 
promoting their oligomerization for DISC formation (Muppidi and Siegel, 2004; Song 




TRAIL-mediated signals in the cisplatin-resistant clones. To achieve this, the lipid 
rafts were extracted from WT and R1 cells by a discontinuous sucrose density 
gradient. Since lipid rafts are rich in cholesterol and sphingolipids, they are resistant 
to non-ionic detergent disruption (Brown and Rose, 1992; Simons and van Meer, 
1988). So, we first lysed the cells with Triton X-100 containing buffer and 
subsequently removed the nuclear fractions. The postnuclear supernatants were 
obtained and applied to a 5-30% discontinuous sucrose density gradient. Following 
which, nine fractions of equal volume were collected from top to bottom of the 
gradient and analyzed by western blots for the distribution of the death receptors on 
the plasma membrane. Caveolin, a structural protein of caveolae (a subclass of lipid 
rafts) and flotillin, a transmembrane protein, were used as markers for lipid rafts (Fra 
et al., 1995; Harder and Simons, 1997). As illustrated in Figure 34, Fraction 4 to 6 
were identified as lipid rafts, shown by the higher levels of caveolin and flotillin, 
albeit flotillin was present in more fractions. Surprisingly, DR4 and DR5 were both 
detected in the lipid raft and non-raft fractions in R1 cells, on the other hand, only 
DR4 was detected in the lipid raft fraction in WT cells, but at a much lower level than 
that in R1 cells. These results indicate that redistribution of DR4 and DR5 could 
contribute to the sensitivity of the cisplatin-resistant cells to TRAIL. Of note, the 
levels of DR4 was markedly higher that DR5 in the lipid raft in R1, suggesting that 





Figure 34: Redistribution of the TRAIL receptors DR4 and DR5 in the lipid rafts in the cisplatin-
resistant R1 cells. Untreated WT (left panel) and R1 (right panel) Triton X-100 cell lysates were 
subjected to discontinuous sucrose density gradients for separation of lipid raft and nonraft fractions. 9 
fractions were collected and examined by Western blots for the presence of DR4 and DR5 (first two 
rows). Lipid raft fractions 5 and 6 were identified by Western blots by using lipid raft marker flotillin 
and caveolin-1 (last 2 rows).  
 
4.2.2 Redistribution of FADD and capase-8 to the lipid rafts with TRAIL 
treatment in R1 cells 
To further examine the role of lipid rafts in TRAIL-induced apoptosis, the WT and R1 
cells were next treated with TRAIL. Here, the lipid rafts fractions were collected and 
analyzed for the recruitment of DISC proteins to the lipid raft. In the WT cells, 
following TRAIL treatment, none of the DISC proteins were detected in the lipid 
rafts, fractions 4 to 6, as indicated by the lipid raft markers (Figure 35A). In striking 
contrast to WT cells, TRAIL induced a redistribution of caspase-8 and FADD from 




Figure 35: TRAIL-induced redistribution of FADD and caspase-8 to lipid rafts in the cisplatin-
resistant R1 cells. A, WT and B, R1 cells were treated with 50 ng/ml TRAIL for 15 min and Triton X-
100 cell lysates were subjected to discontinuous sucrose density gradients for separation of lipid raft 
and nonraft fractions. 9 fractions were collected and examined by Western blots for the presence of 
DR4 and DR5 (first two rows). Lipid raft fractions 5 and 6 were identified by Western blots. Flotillin 
and caveolin-1 (last 2 rows) were used as lipid raft markers. 
 
To further substantiate the results observed in lipid rafts isolation, we performed 
immunofluorescence confocal microscopy to visualize the distribution of death 
receptors on the plasma membrane. Since DR4 is much more abundant in the lipid 
rafts, we investigated the co-localization of DR4 and caveolin in WT and R1 cells 
under control and TRAIL-treated conditions. Cells were first treated, if applicable, 
followed by fixation and permeabilization. Subsequently, DR4 and caveolin were 
stained with their specific primary antibodies and fluorescent-labelled secondary 
antibodies by indirect immunofluorescence staining technique. The samples were then 
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analyzed using confocal microscopy. Clearly illustrated in Figure 36, there was 
minimal co-localization of DR4 (green) and caveolin (red) in the WT cells in both 
conditions. On the other hand, the overlapping staining patterns of DR4 and caveolin 
appeared more intense in the R1, even in the absence of TRAIL, suggesting that DR4 
is constitutively present in the lipid rafts (Figure 36B). Next, to verify that lipid rafts 
may serve as platforms for DISC assembly, we also examined the recruitment of 
casapase-8 to the lipid rafts by confocal microscopy. Similar to the lipid rafts results, 
caspase-8 (green) was shown to co-localize with caveolin (red) after TRAIL 
stimulation in the cisplatin-resistant R1 cells (Figure 36D). On the contrary, no 
caspase-8 recruitment to lipid rafts was observed in the WT cells (Figure 36C). 
Interestingly, we also noticed that the distribution of caveolin is starkly different 
between the WT and the R1 cells; in the WT cells, the staining for caveolin was 
predominantly perinuclear, whereas for R1 cells, the staining was generally localized 










Figure 36: Co-localization of DISC components with lipid rafts in the cisplatin-resistant R1 cells. 
A, WT and B, R1 cells were treated with 50 ng/ml of TRAIL, following which, the cells were fixed, 
permeabilized and stained for DR4 (green) localization with caveolin (red) and analyzed with confocal 
microscopy. C, WT and D, R1 cells were treated with 50 ng/ml of TRAIL, following which, the cells 
were fixed, permeabilized and stained for capase-8 (green) localization with caveolin (red) and 






Thus far, these preliminary findings only provide evidence showing that in R1 cells, 
the DISC components were recruited to the lipid rafts upon TRAIL stimulation, 
except for DR4 and DR5 receptors, which are already present in the lipid rafts in basal 
conditions. The question remains if lipid rafts were indeed critical for TRAIL-
mediated signaling in R1 cells. To this end, we performed a loss-of-function 
experiment, using a cholesterol-binding oligosaccharide, methylcyclodextrinβ 
(MCD), which depletes the cholesterols levels and hence disrupts lipid rafts in the 
plasma membrane (Kilsdonk et al., 1995). R1 cells were preincubated with increasing 
doses of MCD for 2h followed by TRAIL treatment and the MCD-mediated effects 
on TRAIL-induced cytotoxicity were assessed. As illustrated in Figure 37A, 
disruption of lipid rafts with MCD, appeared to have negligible effects on loss of cell 
viability induced by TRAIL. However, MCD treatment alone seems to elicit toxicity 
to the cells (~15 % and ~30% loss in cell viability for 2 and 4mM, respectively). Of 
note, at a higher dose of MCD (4mM), the loss of cell viability induced by a 
combination of TRAIL and MCD treatment, was almost comparable to that of MCD 
treatment alone (~60% versus ~70% respectively Figure 37A). Next, to further 
demonstrate the possible dependence of TRAIL signaling on lipid rafts in R1 cells, we 
examined the effects of MCD on the downstream signaling of TRAIL. Clearly 
demonstrated by Figure 37B, pretreatment with a higher dose of MCD (4mM) 
abolished TRAIL mediated caspase-8 and-3 processing as well as PARP cleavage, 
indicating successful inhibition of TRAIL-initiated signals by MCD. 
Taken together, these data suggest that that lipid rafts play a crucial role in mediating 
the initiation and efficiency of TRAIL-mediated signals and hence the eventual cell 




Figure 37: MCD abolishes TRAIL-induced caspase processing in cisplatin-resistant R1 cells. 
Cisplatin-resistant R1 cells were pre-incubated with the indicated doses of MCD for 1h followed with 
24h treatment of 50 ng/ml of TRAIL. A, Cell viability was measured by MTT assay detected at an 
abosrbance of 570 nm and expressed as % of untreated control. The bars represent means ±SD of 3 
independent experiments. Statistical significance between control and TRAIL treated samples were 
determined by unpaired t-test.  *, p< 0.05 B, R1 cells were harvested and whole cell lysates were 
subjected to Western blot analysis for the assessment of caspase-3 and caspase-8 processing as well as 
PARP cleavage. GAPDH was used as loading control.  
 
4.2.3 Presence of higher levels of DR4 in the lipid raft accounts for its 
sensitivity to TRAIL in R1 cells  
4.2.3.1 Specific blocking of the individual TRAIL receptors indicates that DR4 is 
more essential for TRAIL-induced apoptosis in cisplatin-resistant cells  
From our earlier findings, we have shown that the death receptors, DR4 and DR5, are 
both present in the lipid rafts, however, DR4 appeared to be more abundant than DR5 
in the lipid rafts hence to ascertain that DR4 plays a more important role in TRAIL-
induced apoptosis in R1, we assessed the ability of receptor blocking antibodies 
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against the DR4 and DR5 to neutralize the TRAIL-induced death signals. To achieve 
this, the cisplatin-resistant cells were preincubated with soluble monoclonal 
antibodies against DR4 or DR5 for 1h, followed with TRAIL stimulation for 24h, and 
the resultant loss of cell viability was assessed by MTT assay. Figure 38A clearly 
demonstrates that nullifying the function of DR4 alone was able to achieve almost 
complete rescue of the cell death in both R1 and R2. In contrast, blocking DR5 did 
not have any neutralizing effect on the TRAIL-induced death signals, suggesting that 
DR5 might play a less significant role in TRAIL-induced apoptosis in this model 
(Figure 38B).  
To confirm that DR4 play a more important role in TRAIL-mediated cytotoxicity, we 
investigated the downstream events of TRAIL-induced apoptotic signaling with 
specific blocking of DR4 and DR5 in R1 cells. Indeed, blocking DR4 inhibited 
TRAIL-induced caspase-8 and -3 activation in a dose dependent manner (Figure 
38C). In stark comparison to DR4, blocking DR5 had no effect on caspase-8 and-3 
activation in the R1 cells (Figure 38C). Similarly, PARP cleavage was inhibited by 





Figure 38: DR4 blocking antibodies abolish TRAIL-induced apoptosis in cisplatin-resistant cells. 
Cisplatin-resistant R1 and R2 cells were pre-incubated with soluble monoclonal antibodies against A, 
DR4 B, DR5 for 1h followed with 24h treatment of 50 ng/ml of TRAIL. Cell viability was measured by 
MTT assay detected at an abosrbance of 570 nm and expressed as % of untreated control. All data 
represent means ±SD of at least 3 independent experiments. Statistical significance between TRAIL 
versus DR4 mAb+TRAIL samples were determined by unpaired t-test. *, p<0.05, **, p< 0.01  C, 
Whole cell lysates prepared from R1 cells, which were pre-incubated with blocking antibodies against 
DR4 (left) and DR5 (right) for 1h followed with 24h treatment of 50ng/ml of TRAIL, were subjected to 
Western blot analysis for the assessment of caspase-3 and caspase-8 processing as well as PARP 




4.2.3.2 TRAIL induced cytotoxicity is abrogated by knockdown of DR4 but not 
DR5. 
To further support the findings observed with the blocking antibodies, we transiently 
knockdown the individual death receptors in R1 prior to TRAIL treatment. Following 
TRAIL treatment for 24h, the cell viability is assessed. Again, the results evidently 
showed that knockdown of DR4 is able to protect R1 cells from TRAIL-mediated cell 
death (Figure 39A) on the other hand, DR5 knockdown has negligible effect on cell 
viability upon TRAIL simulation (Figure 39B). Taken together, these findings suggest 
that TRAIL induced apoptosis in cisplatin-resistant cells preferentially through death 
receptor DR4. 
 
Figure 39: Transient knockout of DR4 abolish TRAIL-induced apoptosis in cisplatin-resistant R1 
cells. Cisplatin-resistant R1 cells were transiently transfected with either scrambled siRNA or siRNA 
against A, DR4 or B, DR5 and allowed to recover for 48hr post transfection. The cells were then 
subjected to 50ng/ml of TRAIL for 24hr and cell viability was measured by MTT assay detected at an 
abosrbance of 570 nm and expressed as % of untreated control. Data are expressed as means ± S.D of 
at least three independent experiments.  Statistical significance between siNEG +TRAIL versus 





4.2.4 The total cholesterol content is higher in R1 cells as compared to WT cells 
From the confocal images, caveolin staining patterns between the two cell types were 
distinctively different, suggesting the nature of the lipid rafts between the WT and R1 
cells might be different. To address this question, we evaluated and compared the 
cholesterol content between the WT and R1 cells. Using a sensitive fluorometric-
based assay, we quantitated the total amount of cholesterol in the presence of 
cholesterol esterase. R1 cells have a ~36% higher total cholesterol content as 
compared to WT cells (Figure 40). 
 
 
Figure 40: Cisplatin-resistant R1 cells have higher total cholesterol levels than WT cells.Whole 
cell lysates were prepared from A549 WT and R1 cells and total cholesterol levels was quantitated 
using a fluorometric-based cholesterol quantitation kit (Calbiochem) described in Material and 
Methods. Samples were normalized prior to initiation of experiment. Data are expressed as means ± SD 
of at least three independent experiments. Statistical significance between WT versus R1 cells were 
determined by unpaired t-test.  *, p< 0.05 
 
Cumulatively, the data presents strong evidence to suggest that TRAIL sensitivity in 
the cisplatin-resistant cells is highly dependent on death receptor, DR4, and its 
distribution in the plasma membrane. However, this poses the next question: Is the 
TRAIL sensitivity in the cisplatin-resistant cells confined to the receptor level or is 





4.3 Analysis of the signaling events downstream of the DISC formation 
4.3.1 TRAIL-induced cell death in the cisplatin- resistant cells is dependent on 
the down-regulation of inhibitory proteins of apoptosis. 
Numerous studies have reported to increase susceptibility of cells to TRAIL-mediated 
cell death by down-regulating the anti-apoptotic proteins downstream of the DISC, 
such as cFLIP and IAPs. To investigate the effect of TRAIL on these proteins, we 
analyzed the protein levels of FLIP, XIAP, cIAP2 following 24h of TRAIL treatment. 
The results showed that TRAIL successfully down-regulated all three proteins in the 
cisplatin-resistant cells (Figure 41A). In contrast, for the WT cells, XIAP and cIAP2 
levels remained unchanged upon TRAIL induction, whereas only FLIP was slight 
decreased after TRAIL treatment, however, the decrease was not as significant as the 
cisplatin-resistant cells (Figure 41A).  Further kinetic studies revealed that TRAIL-
induced down-regulation of FLIP and cIAP2 proteins in the R1 cells were evident as 
early as 2h (Figure 41B). As for XIAP, the decrease was only detected in R1 cells at 
4h after TRAIL treatment. Here, the level of another IAP was analyzed, as seen in 
Figure 41B, cIAP1 is not involved in sensitizing R1 cells to TRAIL as their levels 
remained unchanged with TRAIL treatment. Similar to the results earlier, only FLIP 




Figure 41: TRAIL downregulates the anti-apoptotic proteins in the cisplatin-resistant cells. A, 
A549 WT, R1 and R2 cells were treated with the indicated doses of TRAIL for 24 h. Whole cell lysates 
were then collected to assay for cFLIP, cIAP2 and XIAP by Western blot analysis. GAPDH was used 
as loading control. B, Kinetics (2, 4 and 8h) of cFLIP, cIAP1, cIAP2 and XIAP following TRAIL 






4.3.2 JNK and ERK activation do not have a role in mediating TRAIL-induced 
apoptosis in R1 cells 
In addition to IAPs, PI3K/AKT, JNK and MAPKs signaling have been shown to 
mediate the downstream events of TRAIL signaling (Falschlehner et al., 2007). To 
ascertain the role of the various kinases in mediating TRAIL-induced apoptosis in R1 
cells, we checked for JNK, ERK and AKT protein and their phosphorylation status 
following TRAIL stimulation. In agreement with previous reports, TRAIL induced a 
robust and sustained activation of JNK and ERK1/2 in the R1 cells, which was not 
observed in the WT cells. In contrast, AKT did not exhibit any activation in response 
to TRAIL in both WT and the cisplatin-resistant cells (Figure 42A). 
To delineate the functional role of JNK and ERK in TRAIL-induced apoptosis in R1 
cells, we preincubated the cells with the respective pharmacological inhibitors against 
JNK (SP600125) and ERK1/2 (PD98059), and assessed the effects of these inhibitors 
on TRAIL-mediated cell death by MTT cell viability assay. Clearly demonstrated in 
Figure 42B, SP600125 has a slight protective effect on TRAIL-induced cell death. At 
20 and 40 μM SP600125, there was a ~10% increase in cell viability with 
combination treatment as compared to TRAIL alone. In contrast, PD98059 has no 





Figure 42: TRAIL induces apoptosis independent of JNK and ERK activation in cisplatin-
resistant cells. A, A549 WT and R1 cells were treated with the indicated doses of TRAIL for 2 and 4h. 
Whole cell lysates were then collected to assay for phosphorylated and unphosphorylated JNK, ERK 
and AKT by Western blot analysis. GAPDH was used as loading control. R1 cells were preincubated 
with B, SP600125, a JNK inhibitor and C, PD98059 for 1h followed with 24h treatment of TRAIL at 
the indicated doses. Cell viability were then determined using MTT assay. Data are expressed as means 






4.4 Intracellular ROS play a key role in sensitization of cisplatin-resistant cells 
to TRAIL-mediated apoptosis 
4.4.1 TRAIL induces intracellular ROS/RNS accumulation in R1 cells 
Numerous experimental data from earlier literature have shown that ROS play an 
important role in the induction of death receptor-mediated apoptosis (Lee et al., 2002; 
Um et al., 1996; Watson et al., 1997). Thus, we investigate if intracellular ROS were 
generated concomitantly with TRAIL treatment. As seen in Figure 43A, treatment of 
R1 cells with TRAIL resulted in a significant time-dependent increase in intracellular 
ROS/ RNS accumulation, demonstrated by the enhancement of DCFDA fluorescence. 
The increase in intracellular ROS/ RNS accumulation was evident as early as 2h (~ 
38% in TRAIL as compared to 17% in control) and by 4h, the levels reached a high of 
84%. By comparison, there was no increase in DCFDA fluorescence in response to 
TRAIL in the WT cells, suggesting no intracellular ROS/RNS was produced with 
TRAIL treatment in these cells. Figure 43B shows a bar graph representative of the 
average fold difference in ROS/RNS levels between control and TRAIL-treated 
samples, calculated from the G-mean values of DCFDA fluorescence obtained from 
three independent experiments. It clearly illustrates that TRAIL induced a 




Figure 43: TRAIL induces general intracellular ROS/RNS accumulation in cisplatin-resistant R1 
cells. WT and R1 cells were treated with 50ng/ml of TRAIL for 2 and 4h. Cells were harvested for 
flow cytometric analysis for ROS production using redox sensitive probe, DCFDA. A, A density plot; 
y-axis: forward scatter, x-axis: DCFDA fluorescence  B, A representative bar graph was plotted with 
the G-mean values relative to untreated control, Data are expressed as means ± S.D of at least three 
independent experiments. Statistical significance between R1 control and treated samples were 
determined by unpaired t-test.  *, p< 0.05compared with R1 control. 
 
Next, we also assayed for the production of mitochondrial O2•- using MitoSOX Red 
and analyzed with flow cytometry. Antimycin A, an inhibitor of complex III of the 
mitochondrial electron transport chain, was used as a positive control. In both cell 
lines, TRAIL has no significant effect on the mitochondrial O2•- production (Figure 
44). Figure 44b shows a bar graph representative of the average fold difference in 
mitochondrial O2•- levels calculated from G-mean values obtained from three 




intracellular ROS/RNS in R1 cells, but not in WT cells. Since more than one type of 
reactive species (ROS and RNS) are involved, we use the term “intracellular reactive 
species (RS)” to refer to the TRAIL-induced intracellular “ROS”.  
 
Figure 44: TRAIL-induced intracellular “ROS” accumulation is not mitochondrial-derived. WT 
and R1 cells were treated with 50ng/ml of TRAIL for 2 and 4h. Cells were harvested and analyzed by 
flow cytometry for mitochondrial O2•
-
 with MitoSOX Red. A, A density plot; y-axis: forward scatter, 
x-axis: MitoSOX fluorescence  B, A representative bar graph was plotted with the G-mean values 
relative to untreated control. Antimycins A (AA) is used as a positive control for mitochondrial O2•
-
 
production. The bars are expressed as means ± S.D of at least three independent experiments. Statistical 
significance between control and treated samples were determined by unpaired t-test.  *, p< 







4.4.2 Elucidating the role of intracellular RS in TRAIL-induced apoptosis in 
R1 cells 
As mentioned previously, there are many different types of RS produced in living 
systems, and each species of RS has their own distinct characteristics and requires 
specific antioxidant defence to effectively remove them. To delineate the functional 
relevance of RS in TRAIL-mediated cell death, it is imperative to characterize the 
type of RS generated. Given that DCFDA detects a broad range of RS, such as H2O2, 
ONOO-, peroxyl and hydroxyl radicals, we used a few commercially available 
antioxidants to selectively eliminate each RS and help us identify the possible species 
produced by TRAIL and its role in TRAIL-induced apoptosis in R1 cells. 
4.4.2.1 Elimination studies with antioxidants indicate that H2O2 is not responsible 
for the TRAIL-induced RS production. 
One of the most widely used application for DCFDA is the detection of intracellular 
H2O2 and thus we began our investigation with H2O2 as the first candidate. To 
determine if H2O2 is the main RS involved in TRAIL-mediated cytotoxicity, we 
preincubated the R1 cells with catalase, an enzyme, which catalyzes the 
decomposition of H2O2 to oxygen and water, and its effects on TRAIL-mediated cell 
death, was assessed. Catalase did not confer any protection to R1 cells against 
TRAIL-mediated cell death (Figure 45A). On the contrary, the protective effect of 
catalase was evident with exogenous H2O2 treatment (Figure 45A), which was 
included as a positive control to validate the functional activity of catalase. Next, to 
ascertain that H2O2 is not the main RS generated by TRAIL induction, we evaluated 
the effects of catalase on TRAIL-induced intracellular RS production. Clearly 
illustrated in Figure 45B, catalase failed to eliminate the intracellular RS generated by 
TRAIL. In stark comparison, catalase was able to abolish the increase in DCFDA 
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fluorescence with extracellular H2O2 trigger. Since the intracellular RS accumulation 
mediated by TRAIL cannot be eliminated by catalase, H2O2 is not the main RS 
generated by TRAIL induction.  
 
Figure 45: H2O2 is not responsible for TRAIL-induced intracellular ROS accumulation in 
cisplatin-resistant R1 cells.  A, R1 cells were preincubated with the indicated doses (k=1000 units) of 
catalase for 1h followed with 50 and 100 ng/ml of TRAIL for 24h. Cell viability was measured by 
MTT assay and expressed as % of untreated control. Data are expressed as means ± SD of at least three 
independent experiments. Statistical significance between H2O2 versus catalase+H2O2 treatment was 
determined by unpaired t-test.  *, p< 0.01 . B, R1 cells were preincubated with 2000 units of catalase 
for 1h followed with 50 ng/ml of TRAIL for 4h. Cells were harvested for flow cytometric analysis for 
ROS production using redox sensitive probe DCFDA. y-axis: forward scatter, x-axis: DCFDA 




4.4.2.2 Peroxynitrite is the main component of the intracellular RS generated by 
TRAIL signaling. 
Next, we tested for ONOO- production by using a highly specific ONOO- scavenger, 
FeTPPS, which is a ferric porphyrin complex that catalytically decomposes ONOO- 
to nitrate (Misko et al., 1998). Preincubation with FeTPPS prior to TRAIL treatment 
successfully inhibit the loss of cell death in a dose dependent manner in R1 cells, 
compared to TRAIL treatment alone (Figure 46A). To further confirm that the 
observed FeTPPS–mediated cytoprotective effect was indeed a function of its 
antioxidant property and not a side effect of iron loading, we repeated the experiment 
replacing FeTPPS with a compound containing ferric ion, iron(III) chloride (FeCl3), 
as a negative control. With FeCl3, there was no rescue of R1 cells from TRAIL-
mediated cell death, suggesting that FeTPPS inhibition of cell death is indeed 
attributed to its ONOO- scavenging property(Figure 46B). 
To establish the role of ONOO- in mediating TRAIL-induced cytotoxicity, it was 
important to determine if FeTPPS-inhibition of cell death triggered by TRAIL was a 
consequence of its ability to inhibit the RS production induced by TRAIL. Indeed, 
FeTPPS was able to abolish, to a large extent, the intracellular RS accumulation 
induced by TRAIL, and thus we confirmed that ONOO- is the main species induced 
by TRAIL stimulation in R1 cells (Figure 46C). Figure 46D shows a bar graph 
representative of the average fold difference in DCFDA fluorescence levels calculated 




Figure 46: ONOO- is the main component of the intracellular RS generated by TRAIL signaling. 
R1 cells were preincubated with the indicated doses of  A, FeTPPS or  B, FeCl3 (50 μM) for 1h and 
followed with 50 and 100 ng/ml of TRAIL for 24h. Cell viability was measured by MTT assay and 
expressed as % of untreated control. Data are expressed as means ± SD of at least three independent 
experiments. In all panels, data are expressed as means ± SD of at least three independent experiments. 
Statistical significance between TRAIL versus TRAIL +FeTTPS treatments were determined by 
unpaired t-test.  *, p< 0.05 compared with TRAIL 50, ##, p<0.01 compared with TRAIL 100.  For 
intracellular ROS analysis, R1 cells were preincubated with 50 μM of FeTPPs for 1h followed with 
50ng/ml of TRAIL for 4h. Cells were subsequently harvested and analyzed by flow cytometry for 
intracellular ROS production using redox sensitive probe DCFDA. C, A density plot, y-axis: forward 
scatter, x-axis: DCFDA fluorescence. D, A bar graph was plotted with the G-mean values relative to 
untreated control. Data are expressed as means ± SD of 3 independent experiments. Statistical 
significance between TRAIL versus TRAIL +FeTTPS treatments were determined by unpaired t-test.  




ONOO- belongs to the group of reactive nitrogen species and has shown to undergo 
rapid protonation and cause the nitration of lipids and proteins, as well as deamination 
of DNA. One of the most studied reaction is its nitration effect on proteins, which 
leads to the conversion of tyrosine to 3-nitrotyrosine and thus it is widely used as a 
biomarker of ONOO- production (Radi et al., 2001). Hence, to further confirm that 
ONOO- is produced, we compared the 3-nitrotyrosine protein profile of the whole cell 
lysates between the control and TRAIL stimulated cells. As can be seen in Figure 47, 
following TRAIL treatment, there was a time- and dose-dependent increase in 3-
nitrotyrosine modified proteins in R1 cells. In contrast, levels of 3-nitrotyrosine 
modified proteins remained unchanged with TRAIL treatment. Extracellular ONOO- 
was added to cells as a positive control and bovine serum albumin (BSA) was treated 
in vitro as a functional validation of the ONOO-. 
Taken together, the data provide strong evidence showing that ONOO- is produced 
along with TRAIL treatment in R1 cells. 
 
Figure 47: TRAIL increases 3-nitrotyrosine modified proteins in cisplatin-resistant cells. A549 
WT and R1 cells were treated with the indicated doses of TRAIL for 4 and 8h. Whole cell lysates were 
then collected to assay for 3-nitrotyrosine modified proteins (3-NT) by Western blot analysis. 
Exogenous peroxynitrite (PN) at 400 μM was used as a positive control for 3NT modifications of BSA. 
GAPDH was used as loading control. 
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4.4.2.3 FeTPPS significantly inhibits TRAIL-induced apoptosis 
Having ascertained that ONOO-is generated by TRAIL treatment, we exploited the 
ONOO- scavenger, FeTPPS, to study the role of ONOO- in mediating TRAIL-
induced apoptosis. Corroborating the cell viability data, when ONOO- levels were 
scavenged with FeTPPS, TRAIL elicited apoptotic hallmarks in R1 cells were 
dramatically reduced. As can be seen in Figure 48, FeTPPS was shown to 
significantly inhibit DNA fragmentation (Figure 48A), the proteolytic processing of 
caspases (Figure 48B) and their activation (Figure 48C), triggered by TRAIL-induced 
apoptosis in R1 cells. Furthermore, FeTPPS preincubation was able to significantly 






Figure 48: FeTPPs significantly inhibits TRAIL-induced apoptosis R1 cells were preincubated with 
50 μM of FeTPPs for 1h followed with 50ng/ml of TRAIL for 4h. A, DNA content was analyzed by 
flow cytometry after staining with propidium iodide (PI) as described in Materials and Methods. Cell 
cycle profiles obtained from one set of experiment are shown here; they are representative of 3 
independent experiments. y-axis: events, x-axis: PI lin fluorescence. B, Cell lysates were subjected to 
Western blot analysis for the assessment of caspase-3 and caspase-8 processing as well as PARP 
cleavage. GAPDH was used as loading control. C, Total cell lysates were used to assess caspase-3, -6, -
8, and -9 activation levels using fluorescence-conjugated substrates. Caspase activity was normalized to 
total protein and expressed as fold increase over untreated cells from each time-point. The bars 
represent means ± SD of three independent experiments. Statistical significance between TRAIL and 
TRAIL+FeTPPs treatments were determined by unpaired t-test. *, p< 0.05 compared with TRAIL 2h 





Figure 49: FeTPPS restored the long-term clonogenic abilities of R1 cells following TRAIL 
treatment. Cells were preincubated with 50 μM of FeTPPS for 1h followed with TRAIL treatment for 
4h before being re-seeded onto 100mm Petri dishes and allowed to form colonies for over 10 days. 
Following which, colonies formed were stained with crystal violet for assessment. Data shown are 
representative of at least 3 independent experiments. 
 
4.4.2.4 The cIAP2 and XIAP protein levels were restored by FeTPPS 
As shown earlier, TRAIL treatment resulted in a decrease in FLIP, XIAP and cIAP2 
protein levels in R1 cells, and hence lowering the threshold for apoptosis execution. 
Thus, we investigate if ONOO- had a role in regulating these proteins thus sensitizing 
R1 cells to TRAIL-induced apoptosis. As illustrated in Figure 50, FeTPPS was able to 
abolish the TRAIL-mediated decrease of the anti-apoptotic proteins, cIAP and XIAP. 





Figure 50: FeTPPS abolished TRAIL downregulation of  the cIAP2 and XIAP in the cisplatin-
resistant R1 cells. R1 cells were preincubated with 50 μM of FeTPPS for 1h followed with 50 and 100 
ng/ml of TRAIL treatment for 4h. Whole cell lysates were then collected to assay for cFLIP, cIAP2 and 
XIAP by Western blot analysis. GAPDH was used as loading control.  
 
4.4.3 Discovering the source of ONOO- 
There are reportedly a few mechanisms known to generate ONOO- anion in the cell 
but most literature has largely focused on the reaction of nitric oxide with O2•- 
(Beckman et al., 1990; Pryor and Squadrito, 1995). And hence, we examined the 
redox systems that are responsible for the possible sources of nitric oxide and O2•- in 
R1 cells. 
4.4.3.1 Assessment of nitric oxide production in R1 cells with TRAIL stimulation 
Given that nitric oxide is a substrate for ONOO-formation, intracellular nitric oxide 
should also be potentially regulated by TRAIL stimulation. As such, we analyzed the 
effects of TRAIL on nitric oxide (NO) production. To monitor the intracellular NO 
levels in the cells, we stained the cells with a redox sensitive probe, 4,5-
diaminofluorescein (DAF), which reacts with NO to yield fluorescence and 
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subsequently analyzed by flow cytometry (Kojima et al., 1999; Rathel et al., 2003). 
Compared to WT cells, TRAIL treatment (4h) resulted in enhanced DAF fluorescence 
in R1 cells, indicating that TRAIL mediates accumulation of NO in R1 cells but not in 
WT cells(Figure 51A). And Figure 51B, shows a bar graph representative of the flow 
cytometry analysis using the G-mean values obtained from the DAF fluorescence. 
Having established that NO is generated by TRAIL in R1, it was of interest to identify 
its possible sources of production. 
 
Figure 51: Increase in intracellular NO levels with TRAIL treatment in cisplatin-resistant R1 
cells. R1 cells were treated with 50ng/ml of TRAIL for 4h. Cells were subsequently harvested and 
analyzed by flow cytometry for ROS production using NO specific probe DAF. A, A density plot, y-
axis: forward scatter, x-axis: DAF fluorescence B, A bar graph was plotted with the G-mean values 
relative to untreated control. Data are expressed as means ± SD of at least three independent 
experiments. Statistical significance between control and treated samples were determined by unpaired 
t-test.  *, p< 0.05compared with R1 control 
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In vivo, NO is synthesized mostly by nitric oxide synthase (NOS) enzymes. There are 
three types of NOS; endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible 
NOS (iNOS). Since ONOO- is produced in this system upon TRAIL induction, we 
performed a kinetic analysis of the iNOS levels following TRAIL treatment. R1 cells 
showed a dose and time-dependent increase in iNOS levels after TRAIL stimulation. 
Increase in iNOS levels were observed as early as 4h and peaked at 8h after TRAIL 
treatment (100 μM). In striking contrast, iNOS was barely detectable in WT cells even 
following TRAIL treatment (Figure 52).  
These data provide strong evidence that TRAIL promotes nitric oxide production 
through the upregulation of iNOS. 
 
 
Figure 52: Time-dependent increase of iNOS induction with TRAIL treatment in cisplatin-
resistant R1 cells. A549 WT and R1 cells were treated with 50 and 100 ng/ml of TRAIL treatment for 
4 and 8h. Whole cell lysates were then collected to assay for iNOS by Western blot analysis. GAPDH 
was used as loading control.  
 
4.4.3.2 Assessment of Intracellular O2•
- 
production in R1 cells with TRAIL 
stimulation 
Since ONOO- is a product from the reaction of nitric oxide and O2•-, we next assessed 
the effects of TRAIL on the levels of O2•-. Intracellular O2•- levels can be detected by 
lucigenin, a chemiluminescent probe, which reacts with O2•- to emit photons and 
detected by a luminometer (Li et al., 1998b; Minkenberg and Ferber, 1984). A kinetic 
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analysis of the O2•- levels was performed following TRAIL induction. Results 
showed that in R1 cells, TRAIL induced a transient increase in O2•-  levels at 2h, but 
the levels fell below that of the control cells by 4h and the O2•-  levels remained low 
up to 6h (Figure 53). Conversely, there was no significant change observed in O2•- 
levels in the WT cells with TRAIL. Since mitochondria are major sites of ROS 
production, we proceed with the assessment of mitochondrial O2•- levels with 
increasing doses of TRAIL (50 and 100ng/ml) at 2 and 4h. Corroborating data 
obtained earlier (Figure 44), we observed no significant difference in mitochondrial 
O2•- levels was observed in R1 cells even at higher doses of TRAIL (Figure 54).   
 
Figure 53: TRAIL induces a transient burst of intracellular O2•- which subsequently decreases in 
cisplatin-resistant R1 cells. A549 WT and R1 cells were treated with 50 ng/ml of TRAIL for varying 
time points. Cells were subsequently lysed with ATP lysis buffer and assayed for O2•- production via a 
lucigenin-based chemiluminescence method. A Cu/ZnSOD inhibitor, DDC (200 μM), was used as a 
positive control for the assay. Samples were normalized prior to initiation of experiment. In all panels, 
data are expressed as means ± SD of at least three independent experiments. Statistical significance 
between control and treated samples were determined by unpaired t-test.  **, p< 0.01 compared with 






Figure 54: TRAIL-induced intracellular O2•- accumulation is not mitochondrial-derived. A549 
R1 cells were treated with 50 and 100ng/ml of TRAIL for 2 and 4h. Cells were harvested and analyzed 
by flow cytometry for mitochondrial O2•- with MitoSOX Red. A density plot; y-axis: forward scatter, 
x-axis: MitoSOX fluorescence. Data shown are representative of at least 3 independent experiments. 
 
Although the effects of TRAIL on O2•- anion levels were not as pronounced as that 
observed for nitric oxide, nonetheless, a distinct trend was observed in the R1 cells. 
Since the intracellular O2•- accumulation is not mitochondrial derived, we 
investigated the other possible redox systems responsible for the TRAIL-mediated 
changes in O2•- levels.  
The production of O2•- in the living systems has been extensively studied. There is a 
group of antioxidant enzymes important for regulating the O2•- levels in vivo. This 
group of enzyme is known as the superoxide dismutases (SOD), which are highly 
efficient in the dismutation of O2•- to H2O2. To determine if SOD play a role in 
regulated the O2•- levels in response to TRAIL, we examined the protein levels of 
Cu/ZnSOD (a cytosolic SOD) and MnSOD (a mitochondrial SOD) following TRAIL 
induction. The results showed that there was no observable difference in Cu/ZnSOD 
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and MnSOD protein levels between the TRAIL-treated and control R1 cells (Figure 
55A). Similar results were observed in WT cells (Figure 55A). To further validate its 
role in TRAIL-regulation of O2•- anion levels, we assessed the overall activity of the 
SOD. As can be seen in Figure 55B and Figure 55C, WT cells have no change in both 
mitochondrial and cytosolic SOD activities in response to TRAIL respectively. By 
comparison, both population of SOD in R1 cells showed an increase in SOD activities 






Figure 55: MnSOD and Cu/ZnSOD are not responsible for TRAIL-induced intracellular O2•- 
accumulation in cisplatin-resistant R1 cells. A, A549 WT and R1 cells were treated with the 
indicated doses of TRAIL for 2 and 4h. Whole cell lysates were then collected to assay for MnSOD 
and Cu/ZnSOD by Western blot analysis. GAPDH was used as loading control. SOD activity; WT and 
R1 cells were treated for the indicated times with 50 ng/ml of TRAIL following which, cells were 
fractionated to obtain the mitochondrial and cytosolic fractions and subjected to SOD acitivity 
colorimetric-based assay (Cayman) B, mitochondrial and C, cytosolic SOD activities relative to 
untreated control. Data are expressed as means ± SD of at least three independent experiments.  
 
Next, another mechanism important for intracellular O2•- synthesis in vivo is the 
NADPH oxidase (NOX) complexes. Their function is best characterized in the 
phagocytes, which generate RS to kill pathogen in inflammatory responses. However, 
different NOX complexes have also been found to be present in many other human 
cells. To investigate if NOX is the main source of O2•- mediated by TRAIL, we 
performed a luminescence-based assay to determine the effect of TRAIL on activity 
of NOX in the cells. Clearly illustrated in Figure 56, TRAIL treatment enhanced the 
general NOX activity in the R1 cells, demonstrated by the increase in the 
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luminescence detection. On the other hand, no significant change in NOX activity was 
observed in WT cells in response to TRAIL. Phorbol myristate acetate (PMA), a PKC 
activator, which has been shown to promote the NOX assembly and its activation, 
was used as a positive control for this assay. These findings suggest that NOX could 
be responsible for the increase in O2•- levels detected in the early time points after 
TRAIL treatment. 
Taken together, these data suggest that the O2•- anion is induced in R1 cells following 
exposure to TRAIL, and contribute to the production ONOO- following TRAIL 
stimulation. 
 
Figure 56: Increased NADPH oxidase activity with  TRAIL treatment in cisplatin-resistant R1 
cells. A549 A, WT and B, R1 cells were exposed to 50ng/ml of TRAIL for 2 and 4h, homogenized and 
added to mix of phosphate buffer with 100 μM NADPH (substrate) and 5 μM lucigenin (electron 
acceptor) and assayed for O2•- production by measuring the chemiluminescence for 10min. Samples 
were normalized prior to initiation of experiment. In all panels, data are expressed as means ± SD of at 
least three independent experiments. Statistical significance between control and treated samples were 
determined by unpaired t-test.  *, p< 0.01 compared with R1 control. 
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4.4.4 ONOO- production is a caspase-dependent event 
Thus far, it is clear that ONOO- plays a critical role in mediating TRAIL induced 
apoptosis, however, we have yet to determine the if ONOO- was simultaneously 
produced with TRAIL initiation or a consequence of TRAIL downstream signaling 
events. To answer this, we preincubated R1 cells with ZVAD, pan-caspase inhibitor, 
and assess the effects of ZVAD on ONOO- production by TRAIL stimulation. The 
results showed that TRAIL-induced ONOO- production is completely abolished by 
ZVAD, suggesting that ONOO- production is downstream of caspase activation 
(Figure 57A). To further support this finding, we investigate the effects of ZVAD on 
iNOS protein expression following TRAIL treatment. In agreement with the previous 







Figure 57: TRAIL-induced ONOO- production is a caspase-dependent event. A, WT and R1 cells 
were pretreated with 50 μM of ZVAD for 1h followed with 50 ng/ml of TRAIL for 2 and 4h. Cells 
were harvested and analyzed by flow cytometry for intracellular ROS production with DCFDA. 
(density plot; y-axis: forward scatter, x-axis: DAF fluorescence) Data shown are representative of at 
least 3 independent experiments. B, R1 cells were pretreated with 50 μM of ZVAD for 1h followed 
with 50ng/ml of TRAIL for 8h. Cell lysates were collected and assayed for iNOS by Western blot. 




















5 Cisplatin resistance confers refractory cancer cells sensitivity to TRAIL, a 
phenomenon not exclusive to A549 NSCLC model 
To ascertain that TRAIL sensitivity in cisplatin-resistant refractory cells is not 
exclusive to A549 WT and its cisplatin-resistant cells, we tested our hypothesis in two 
other cell line systems; another NSCLC model, H2030, and an ovarian cancer model, 
A2780. In these two models, the cisplatin-resistant cells derived from the parental cell 
lines are heterogeneous population of cells that are just selected over a long period of 
time with low doses of cisplatin. As such, they are not homogenous clones; and since 
cancer is a heterogeneous disease, data obtained on these models may have better 
clinical value.  
5.1 Human NSCLC cells H2030 
The parental cell line is obtained from ATCC (H2030WT) and its cisplatin-resistant 
(H2030CR) cells are generated in our lab using a low dose of 2.5 μM over a period of 
4 months. Figure 58A and B, shows the morphology of the H2030WT and H2030CR 
cells. Similar to R1, H2030CR cells showed a lower rate of proliferation as compared 





Figure 58: General characteristics of the NSCLC H2030 WT and cisplatin-resistant, H2030CR 
cells. Representative photomicrographs NSCLC H2030 A, WT and B, CR cells with phase-contrast 
microscopy (Magnification: 40X) C, H2030WT and H2030CR cells were seeded at the same 
confluency (0.05x10
6
) and the cell number is monitored every 24h up to 96h. The growth curve of each 
cell line is plotted and compared between the 2 cell lines. The bars represent means ± SD of at least 3 
independent experiments. Statistical significance between H2030WT and H2030CR cells were 
determined by unpaired t-test.  **, p< 0.01, ***, p<0.005 compared with H2030 WT cells at each 
timepoint. 
 
Overall, the H2030CR cells exhibit similar cisplatin-resistant properties as that 
observed in R1 cells. To begin, the H2030CR cells are insensitive to cisplatin 
treatment (up to 75uM, Figure 59A) and they also exhibit cross-resistance to 
carboplatin (up to 1mM, Figure 59B), as demonstrated by the MTT cell viability 
assay. In contrast, the WT cells showed a dose-dependent decrease in cell viability 
with both cisplatin and carboplatin treatment. Furthermore, in agreement with the R1 
data, H2030CR cells are more sensitive to TRAIL-induced apoptosis as compared to 
the cisplatin sensitive WT cells (Figure 59C).  
Corroborating the MTT data, the cell cycle profile showed that H230WT cells were 
sensitive to cisplatin treatment (Figure 60A), as demonstrated by the accumulation of 
sub-G1 population, and resistant to TRAIL treatment (Figure 60B). On the other 
hand, the reverse was observed for H2030CR cells, hence the H2030 model exhibit 




Figure 59: Cell viability of H2030 WT and cisplatin-resistant, CR cells with platinum drugs and 
TRAIL. H2030 WT and the cisplatin-resistant, CR cells were treated with A, cisplatin (μM) B, 
carboplatin (mM) and C, TRAIL (ng/ml) with the indicated doses for 24h. Cell viability was measured 
by MTT assay and expressed as % of untreated control. In all panels, the bars represent means ± SD of 
at least 3 independent experiments. Statistical significance of control and treated samples were 
determined by unpaired t-test.  *, p < 0.05, and **, p < 0.01 compared with H2030WT control; #, 







Figure 60: Cell cycle analysis of H2030 WT and cisplatin-resistant CR cells with cisplatin and 
TRAIL. H2030 WT and cisplatin-resistant CR cells were treated with the indicated doses of  A, 
cisplatin for 24h and B, TRAIL for 4h. DNA content was analyzed by flow cytometry after staining 
with propidium iodide (PI) as described in Materials and Methods. Cell cycle profiles obtained from 
one set of experiment are shown here; they are representative of 3 independent experiments. 





Next, we also compared the proteolytic processing of the main caspases (caspase-3,-
8,-9) following cisplatin and TRAIL treatment between the WT and CR cells. 
Likewise, results observed are in agreement with that observed in the A549 model 
(Figure 61). 
 
Figure 61: Effects of cisplatin and TRAIL on processing and activation of procaspases in the 
H2303 WT and cisplatin-resistant CR cells. H2030 WT and CR cells were treated with the indicated 
doses of cisplatin for 24h (left panel) and TRAIL for 4h (right panel). Whole cell lysates were then 
collected to assay for caspase-3, caspase-8 and caspase-9 processing as well as PARP cleavage by 








5.2 Human Ovarian cancer cell A2780 
In ovarian cancer, the first-line chemotherapy of choice is often platinum-based 
therapy and the emergence of cancer relapse is a major problem in this type of cancer. 
Hence, we used an ovarian cancer cell line A2780, and its cisplatin-resistant variant, 
A2780CR, as a second model to validate our hypothesis. 
Figure 62A and B show the morphological characteristics of the two cell lines, A2780 
WT and CR, respectively. Similar to R1 and H2030CR cells, A2780CR also exhibits 
slower growth rate as compared to its parental A2780 WT cells (Figure 62C). 
 
 
Figure 62: General characteristics of ovarian A2780 WT and cisplatin-resistant, A2780CR cells.  
Representative photomicrographs of ovarian A2780 A, WT and B, CR cells with phase-contrast 
microscopy (Magnification: 40X) C, A2780WT, CR cells were seeded at the same confluency 
(0.05x10
6
) and the cell number is monitored every 24h up to 72h. The growth curve of each cell line is 
plotted and compared between the 2 cell lines. The bars represent means ± SD of at least 3 independent 
experiments. Statistical significance between A2780 WT and A2780 CR cells were determined by 
unpaired t-test. **, p< 0.01, ***, p<0.005 compared with A2780 WT cells at each timepoint. 
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Again, in agreement with our observations with the A549 and H2030 models, the 
cisplatin-sensitive A2780WT cells are susceptible to both cisplatin and carboplatin 
treatment, but resistant to TRAIL treatment (Figure 63). On the other hand, cisplatin-
resistant A2780CR is resistant to cisplatin and carboplatin treatment but sensitive to 
TRAIL treatment. This finding is further supported by the cell cycle analysis (Figure 
64) and the western blot analysis of the proteolytic processing of caspase-3, -8, -9 
(Figure 65). 
Taken together, we have compelling evidence showing a correlation of cisplatin 
resistance with TRAIL sensitivity. The mechanisms that confer cisplatin resistance in 




Figure 63: Cell viability of ovarian A2780 WT and cisplatin-resistant, CR cells with platinum 
drugs and TRAIL.A2780 WT and the cisplatin-resistant, CR cells were treated with A, cisplatin (μM) 
B, carboplatin (mM) and C, TRAIL (ng/ml) with the indicated doses for 24h. Cell viability was 
measured by MTT assay and expressed as % of untreated control. In all panels, the bars represent 
means ± SD of at least 3 independent experiments. Statistical significance between A2780 WT and 
A2780 CR cells were determined by unpaired t-test. *, p< 0.05, **, p<0.01 compared with A2780 WT 





Figure 64: Cell cycle analysis of ovarian A2780 WT and CR cells with cisplatin and TRAIL. 
A2780 WT and CR cells were treated with the indicated doses of  A, cisplatin for 24h and B, TRAIL 
for 4h. DNA content was analyzed by flow cytometry after staining with propidium iodide (PI) as 
described in Materials and Methods. Cell cycle profiles obtained from one set of experiment are shown 






Figure 65: Effects of cisplatin and TRAIL on processing and activation of procaspases in ovarian 
A2780 WT and cisplatin-resistant CR cells. A2780 WT and cisplatin-resistant CR cells were treated 
with the indicated doses of cisplatin for 24h (left panel) and TRAIL for 4h (right panel). Whole cell 
lysates were then collected to assay for caspase-3, caspase-8 and caspase-9 processing as well as PARP 
cleavage by Western blot analysis. GAPDH was used as loading control. 
 
6 TRAIL a potential second line therapy to cisplatin-resistant refractory cells. 
In clinical practice, platinum-based drugs remain as the first-line therapy for NSCLC 
patients, therefore, we propose the use of TRAIL in combination with cisplatin as a 
potential chemotherapy regimen for patients in the clinic. To test the feasibility of the 
treatment, we subjected the cells with a combination of TRAIL and cisplatin of 
various concentrations, at which, each individual treatment alone elicits little or no 
cytotoxicity, and assessed the effects of the drug combinations. As can be seen in all 
three cell models, a combination of TRAIL and cisplatin treatment enhanced cell 
death in these cisplatin-resistant cells. The IC50 for R1 cells is 40ng/ml of TRAIL and 
40 μM of cisplatin (Figure 66A), IC50 for H2030 CR is 20ng/ml of TRAIL and 20 μM 
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of cisplatin (Figure 66B), and lastly, IC50 for A2780 CR is 40ng/ml of TRAIL and 20 
μM of cisplatin (Figure 66C).  
To further confirm the efficacy of this drug combination, we examined the 
downstream caspases which are responsible for executing cell death. The results 
showed that for all the three cell line models, TRAIL and cisplatin combination 
therapy significantly enhanced the proteolytic processing of caspase -8 and -3 as 
compared to treatment with one agent alone (R1 cells; Figure 66D , H2030CR cells; 











Figure 66: TRAIL sensitizes cisplatin-resistant cells to cisplatin treatment A, A549 R1 B, H2030 
CR and C, A2780 CR cells were pretreated with varying doses of TRAIL for 2h and followed with the 
indicated doses of cisplatin for 24h. Cell viability was measured by MTT assay and expressed as % of 
untreated control. In all panels, the bars represent mean ±SD of at least 3 independent experiments. 
Statistical significance between the various combination treatments to individual cisplatin treatments of 
the 3 cisplatin-resistant cell lines were determined by unpaired t-test. *, p< 0.05, compared with A549 
R1 cisplatin 10 μM. * and * p<0.01 compared with A549 R1 cisplatin 20 and 40 μM respectively. #, p< 
0.05, # p< 0.01 compared with H2030 CR cisplatin 10 and 20 μM respectively, Δ, p< 0.05, Δ p< 0.01 
compared with compared with A2780 CR cisplatin 10 and 20 μM respectively,  D A549 R1 E, H2030 
CR and F, A2780 CR cells were pretreated with varying doses of TRAIL for 2h and followed with the 
indicated doses of cisplatin for 24h. Whole cell lysates were then collected to assay for caspase-3, 
caspase-8 and caspase-9 processing as well as PARP cleavage by Western blot analysis. GAPDH was 

















1 Lung cancer model for the study of cisplatin resistance 
Lung cancer is the leading cause of cancer-related death in the world and NSCLC 
accounts for approximately 75–80% of all lung cancer (Bunn et al., 1998; Siegel et 
al., 2012). Besides surgery, platinum-based chemotherapy regimens are the standard 
first-line of treatment for patients with advanced NSCLC (Spira and Ettinger, 2004), 
however, due to the development of resistance to chemotherapy, the prognosis for 
advance NSCLC patients remains poor. Therefore in this study, we chose a NSCLC 
cell line, A549, and its derived cisplatin-resistant clones, R1 and R2, to emulate the 
refractory disease condition in an effort to understand the mechanism of acquired 
resistance to cisplatin.  
2 Characterization of the cisplatin-resistant cells in this study 
2.1 Validating the cisplatin resistance of the cell models used 
In this study, two newly established cell lines, R1 and R2, were used. Each cell line 
represents a homogenous population of cells that were derived from individual clones 
following long term exposure of the A549 parental WT cells to cisplatin (see Material 
and Methods: section 4). To begin the study, it is imperative that we first validate the 
resistance of R1 and R2 cells to cisplatin. In an attempt to characterize their overall 
resistance, we performed a general assessment of their physiological responses to 
cisplatin by measuring the short term viability, long term clonogenic potential and the 
ability to escape cisplatin-induced apoptosis.  
In the cisplatin-sensitive parental WT cells, a cell cycle arrest preceding cisplatin-
mediated apoptosis was observed following cisplatin treatment, which have been 
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previously reported by other groups (Barry et al., 1990; Wagner and Karnitz, 2009). 
In this regard, cell cycle arrest is described as an essential part of signal transduction 
pathways mediated during the cisplatin-induced apoptosis (Oshita and Eastman, 1993; 
Sorenson et al., 1990). Cisplatin induces G2-phase arrest  (sometimes preceded by S-
phase arrest) for allowing for DNA repair to occur before progressing through the cell 
cycle and when DNA damage is irreparable, cell death is induced. In contrast, the 
cisplatin-resistant cells showed an initial cell cycle arrest but the signal was not 
sufficient to induce cisplatin-mediated apoptosis as shown by the absence of DNA 
fragmentation, caspase activation and PARP cleavage, suggesting that the cisplatin-
resistant cells either have inherent properties or acquired mechanisms that evade 
cisplatin-mediated cytotoxicity (Perego et al., 1996; Perego et al., 1997; Reed, 1995). 
In addition to this, our data clearly demonstrated that these cisplatin-resistant cells are 
much more robust in the presence of cisplatin, as shown by their higher survival in 
cell viability assay and greater clonogenic potential in culture as compared to the WT 
cells.  
Numerous studies have also reported high levels of intracellular ROS production with 
cisplatin treatment and in fact, established the role of ROS in meditating cisplatin-
induced apoptosis (Berndtsson et al., 2007; Davis et al., 2001; Pierce et al., 1991). 
Consistent with earlier findings, we observed high levels of intracellular ROS 
production in the WT cells with cisplatin treatment. Herein, we demonstrated that the 
cisplatin-resistant cells were able to block the intracellular ROS produced by cisplatin 
treatment, suggesting antioxidant defence mechanisms in these cells are inherently 
altered to maintain low levels of intracellular ROS conducive for survival (Godwin et 
al., 1992; Kidani et al., 2009; Meijer et al., 1990).  
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2.2 The cisplatin-resistant cells show cross resistance to other conventional 
chemotherapeutic drugs 
To date, several studies have found cisplatin-resistant cells to exhibit cross resistance 
to other platinum drug especially, a second generation platinum drug, carboplatin 
(Johnson et al., 1997; Jones et al., 1993; Rixe et al., 1996), furthermore, the acquired 
resistance to platinum drugs has inevitably rendered these cells resistant to a broad 
range of chemotherapy drugs, a phenomenon known as multidrug resistance 
(Gottesman, 2002; Gottesman and Pastan, 1988; Johnson et al., 1997). This is not 
surprising as the mode of actions for these conventional drugs are predominantly 
genotoxic stress-induced cell death, and hence, the mechanisms that confer cisplatin 
resistance are likely to protect these cells from other genotoxic-based drugs 
(Gottesman, 2002; Gottesman and Pastan, 1988; Szakacs et al., 2004). And in 
agreement to these findings, we also present viability data that strongly suggest that 
R1 and R2 cells displayed cross resistance to carboplatin and the panel of other 
chemotherapeutic drugs screened in this study. 
2.3 Mechanism of cisplatin resistance in this study 
Many efforts have been made to unravel the mechanisms underlying cisplatin 
resistance and a number of mechanisms have been identified thus far. Briefly, the 
most commonly reported mechanisms include; 1) reduced uptake and accumulation of 
the platinum drugs in the cell, through the expression of ATP-binding cassette (ABC) 
transporters which have been shown to actively expel cytotoxic drugs out of the cells, 
(Cui et al., 1999; Gottesman et al., 1994; Szakacs et al., 2004), 2) increased repair of 
platinum-induced DNA damage and genetic alterations of proteins important for cell 
cycle regulation and genome stability, allowing these cells to escape genotoxic stress-
induced cell death (Chu and Chang, 1990; Ferry et al., 2000; Wang and Figg, 2008), 
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3) the inactivation of drugs by glutathione /metallothionein conjugation and hence 
decreases the effective dose of cisplatin for cytotoxicity (Godwin et al., 1992; Hao et 
al., 1994; Meijer et al., 1990), 4) increased survival signals, such as constitutive 
activation of Ras/ MAPK and PI3K-Akt pathways and 5) inhibition of apoptosis 
(Asechi et al., 2010; Cetintas et al., 2012; Fraser et al., 2008; Lin et al., 2011; Peng et 
al., 2010). 
2.3.1 Reduced rate of proliferation in cisplatin-resistant cells 
Since the above mechanisms have been extensively characterized, we directed our 
study to explore other possible mechanisms that could contribute to resistance of these 
cells. A very evident phenotype that these cisplatin-resistant cells exhibited was their 
retarded growth rates compared to the WT cells. With regards to this, some other 
groups have reported higher proliferation rates in cells with acquired resistance to 
cisplatin (Behrens et al., 1987; Zhang et al., 2006). Nonetheless, we also found 
several groups reporting similar observation as ours (Eckstein et al., 2009; Frenzel et 
al., 1995). In addition, several lines of evidence in the literature seem to support that 
slower growth rate may contribute to cisplatin resistance. Notably, a study by 
Bertolini et al. has shown that lung cancer cells enriched in CD133, a marker of 
cancer stem cell, are more resistant to cisplatin (Bertolini et al., 2009). Cancer stem 
cells may have been reported to exhibit increased expression of ABC transport 
proteins, however, another distinct characteristic of stem cells is their low 
proliferation rates. In support of a stem-like property in cisplatin resistance, cisplatin-
resistant cells have been described to activate EMT signaling that allows them to 
revert into a mesenchymal-like tumor cell with lower proliferation rates (Haslehurst et 
al., 2012; Mani et al., 2008). Another study conducted by Tsai et al. showed positive 
correlation between HER-2/neu expression, chemoresistance, and long doubling times 
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in NSCLC (Tsai et al., 1996). Together, these findings substantiate the possibility that 
low proliferation rates may partly render them resistant to the genotoxic effect of 
cisplatin, which acts primarily on actively dividing cells. Since we postulate that this 
phenotype augments the survival of these resistant cells in cisplatin treatment, we 
examined the different factors that could account for the difference in proliferation 
rates between the WT and cisplatin-resistant cells. Considering that the experiments 
were carried out in cell culture conditions, most of the external factors for growth 
were well-controlled and hence we explored the molecular difference in metabolism 
between the cisplatin-resistant and parental WT cells in this study. 
2.3.2 Metabolic differences between the WT and cisplatin-resistant cells 
In a resting cell, mitochondria are the main power energy source providing up to 90% 
of ATP required to sustain all cellular processes (Rolfe and Brown, 1997). As such, it 
is important to assess the mitochondrial functions following the acquisition of 
resistance to cisplatin. Early evidence for mitochondrial dysfunction in cisplatin 
resistance was a study by Andrews and Albright (1992), who demonstrated alterations 
in mitochondria membrane potential in cisplatin-resistant ovarian cancer cells, which 
has also been confirmed by our study and others (Hirama et al., 2006; Zinkewich-
Peotti and Andrews, 1992). And following that, more evidence accrued to suggest 
mitochondria as possible targets of cisplatin as manifested in the alterations of its 
physiology and functions following cisplatin treatment (Harper et al., 2002; Hirama et 
al., 2006; Isonishi et al., 2001). Therefore, we proposed that the mitochondria might 
be a critical determinant for acquiring resistance to cisplatin. There are many methods 
to assess mitochondrial dysfunction, but since the main physiological function of 
mitochondria is the generation of ATP through oxidative phosphorylation, we began 
by comparing the respiratory function between the cisplatin-resistant and WT cells. 
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Indeed, our findings demonstrated that the cisplatin-resistant cells have lower oxygen 
consumption rate and lower enzymatic activities of the electron transport chain 
complex I, II and IV, suggesting that the mitochondiral ATP production by oxidative 
phosphorylation is far less efficient in these cisplatin-resistant cells compared to the 
WT cells. In addition, we also observed that the cisplatin-resistant cells are highly 
dependent on glucose for survival, suggesting that these cells preferentially utilize 
glycolysis as the primary source of energy production, a Warburg effect, which has 
been observed in drug-resistant cells compared to the drug-sensitive cells (Harper et 
al., 2002). Despite higher rate of glycolysis, the total intracellular ATP level was 
lower in the cisplatin-resistant cells, indicating that this surrogate source of energy is 
still insufficient to achieve the levels of the WT cells. So the question is why is there a 
shift in energy source production from efficient respiration to highly inefficient, high-
rate glycolysis to produce ATP, which eventually leads to lower total content of ATP 
in the cells? There are a few explanations addressing this phenomenon, foremost, Otto 
Warburg’s postulation that the mitochondria are malfunction in cancer cells, and 
hence glycolysis serves as an alternative mechanism for cells to harness energy 
(Lopez-Rios et al., 2007; Warburg et al., 1927), as described in our earlier findings, 
another alternative explanation by later studies reveal the possibility that this 
mechanism allows the cells to bypass the mitochondria, a main site for intracellular 
ROS production and hence allows cells to continue respiring with less ROS generated 
(Kroemer and Pouyssegur, 2008). 
2.3.3 ROS regulatory function of mitochondria 
 
Thus this led us to the assessment of mitochondrial functions in the generation and 
detoxification of ROS and its role in regulating general intracellular ROS levels in 
stress conditions. In normal conditions, mitochondrial respiratory transport chains are 
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major sites of ROS production in the cells, and to cope with the ROS, mitochondria 
house antioxidant defences to eliminate the ROS produced during oxidative 
phosphorylation. MnSOD, Prx3, Prx5 and Trx2 are examples of these antioxidant 
defences in the mitochondria, which function to maintain low levels of ROS in the 
mitochondria and at the cellular level (Jezek and Hlavata, 2005). During 
chemotherapy, anticancer drugs, such as cisplatin, have been extensively shown to 
produce oxidative stress in cancer patients (Berndtsson et al., 2007; Bragado et al., 
2007). As mentioned earlier, intracellular ROS are directly involved in mediating 
cisplatin-induced cell death and in order to acquire resistance against the drugs, it is 
necessary for the cells to evolve antioxidant defences against the cisplatin-induced 
ROS production. In this regard, we have demonstrated that MnSOD protein levels are 
significantly increased in the cisplatin-resistant cells and as a result, these cells have a 
much lower basal mitochondrial O2•- levels. And since SOD catalyzes the 
decomposition of O2•- to H2O2, the overall intracellular H2O2 levels are higher in the 
cisplatin-resistant cells. The shift of one species of ROS to another species still 
doesn’t quite explain how it provides cisplatin-resistant cells better survival advantage 
in the face of cisplatin stimulation. One postulation is that this overall increase in 
intracellular H2O2 may be a mechanism to constitutively tune up the antioxidant 
defences in the cisplatin-resistant cells, such as increased glutathione synthesis, and 
increase in catalase activity in the cisplatin-resistant cells (Spitz et al., 1993). 
Therefore, when they are exposed to cisplatin trigger, these resistant cells have ample 
defences against ROS assault, allowing them to maintain low levels of ROS following 




2.3.4 Mitochondria and their apoptotic functions 
 
Besides its respiratory functions, mitochondria are crucial in regulating apoptosis. The 
mitochondrial apoptotic pathway involves the release of apoptogenic factors into the 
cytosol and this process is tightly regulated by the Bcl-2 family proteins (Green and 
Reed, 1998; Kroemer et al., 1998). Hence, it is not surprising that many studies have 
described alterations in the Bcl-2 family protein expression in neoplasia as well as 
chemotherapy-refractory cancer cells to evade apoptosis (Hanahan and Weinberg, 
2011). It has been reported that the anti-apoptotic Bcl-2 protein is upregulated in 
cisplatin-resistant bladder and ovarian cancer cells (Cho et al., 2006; Wang et al., 
2009b) While in other studies, the other anti-apoptotic Bcl-XL protein is markedly 
increased in the osteosarcoma resistant sublines (Perego et al., 1997). In other 
instances, pro-apoptotic proteins are also affected; Bax and Bim downregulation in 
cisplatin-resistant cells have been previously reported (Perego et al., 1996; Wang et 
al., 2011). Interestingly, in our study, we have found that Bcl-2 is inversely correlated 
to cisplatin resistance; cisplatin-resistant cells appeared to have lower levels of Bcl-2 
proteins. This has also been previously reported in an ovarian cisplatin-resistant 
model (Beale et al., 2000). Such cases are often reported in a wild-type p53 
background as p53 has been shown to negatively regulate Bcl-2 protein (Haldar et al., 
1994; Wu et al., 2001). Meanwhile, we showed that Bcl-XL levels are unchanged 
across the cell lines, and herein described for the first time, a compensatory increase 
in the anti-apoptotic protein Mcl-1 in the cisplatin-resistant cells. The anti-apoptotic 
role of Mcl-1 has been studied extensively in hematopoiesis, early embryonic 
development and neuronal development and function (Arbour et al., 2008; Opferman 
et al., 2003; Rinkenberger et al., 2000). In cancer biology, it has been shown to play a 
critical role in the development and maintenance of acute myeloid leukemia (Glaser et 
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al., 2012), furthermore, several lines of evidence have started to outline its importance 
in chemoresistance (Campbell et al., 2010; Wuilleme-Toumi et al., 2005).  In a recent 
study, the authors revealed an unprecedented role of Mcl-1 in facilitating normal 
mitochondrial functions and bioenergetics, depending on its localization in the 
mitochondria (Perciavalle et al., 2012). Matrix- localized Mcl-1, with a mitochondria-
targeting sequence is important for normal mitochondrial bioenergetics, while anti-
apoptotic activity of Mcl-1 requires its localization to the outer mitochondria 
membrane. In this regard, we have yet to define the functional role of Mcl-1 in our 
model, since both the anti-apoptotic and mitochondrial functions are key drivers in 
this study. Last but not least, we also found that Bax levels are extremely low in the 
cisplatin-resistant cell lines, another contributing factor to the failure to engage the 
mitochondrial apoptotic mechanism. Overall, there are no general consenus on the 
alteration profile of these proteins in determining acquisition of chemoresistance in 
cancer, emphasizing once again the heterogeneous nature of cancer. Nonetheless, all 
these data are indicative that the mitochondrial apoptotic pathway in the cisplatin-
resistant cells is compromised and hence allowing them to evade cisplatin-mediated 
apoptosis.  
 
This study has largely focused on the mitochondrial dysfunction in association with 
acquired resistance to cisplatin. We have provided preliminary evidence to 
demonstrate that the mitochondria are functionally different in the cisplatin-resistant 
cells from their cisplatin-sensitive WT counterparts, and as a result, rendering the 
cells more resistant to cisplatin trigger. However, the mechanism through which 
cisplatin causes mitochondrial dysfunction remains elusive. Future studies 
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determining the cisplatin-mediated molecular events to mitochondrial toxicity are 
essential for deeper molecular understanding.  
3 TRAIL: a potential therapy in refractory NSCLC A549 cells 
3.1 TRAIL induce classical apoptosis in the cisplatin-resistant cells 
In the second part of this study, we focused on identifying a potential therapy to 
combat cisplatin resistance in the refractory cells. Since we have demonstrated earlier 
that the mitochondrial apoptotic pathway is severely compromised in the cisplatin-
resistant cells, we proposed the use of an anticancer agent that does not engage the 
mitochondria. And the death receptor agonists appear to be a suitable choice, 
considering mitochondria have been shown to be dispensable in the extrinsic 
apoptotic pathway (Scaffidi et al., 1998; Strasser et al., 2000). In this study, we 
utilized the death receptor agonists, TRAIL and FasL, to induce cell death of the 
cisplatin-resistant cells. To our surprise, we found that the cisplatin-resistant cells are 
highly sensitive to TRAIL and FasL triggers, in short term viability as well as long 
term clonogenic assays. And subsequently, we chose TRAIL as the main model for 
the rest of the study. Several lines of evidence suggest that TRAIL could serve as a 
promising anticancer agent for the following reasons:  
1) TRAIL targets cancer cells more selectively than normal cells and hence 
represents a more targeted approach as compared to conventional 
chemotherapies which often elicit systemic toxicity (Ashkenazi et al., 1999; 
Marini et al., 2005). 
2) The extrinsic pathway has been shown to trigger apoptosis independently of 
p53, and since more than 50% of NSCLC harbours p53 mutations, this is a 
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very attractive therapeutic strategy(Ahrendt et al., 2000; Haupt et al., 2003; 
Hollstein et al., 1994). 
3) Compared to FasL therapy which induced severe hepatotoxicity, TRAIL has 
been previously described by several studies to induce potent antitumor 
activity but minimal cytotoxicity in normal cells (Wiley et al., 1995). 
Many research groups have capitalized on these unique properties and designed 
chemotherapeutic drug regimens with TRAIL agonists (monoclonal antibodies 
targeting DR4 or/and DR5) in preclinical models and achieved encouraging results 
(Ashkenazi and Herbst, 2008). Clinical trials for TRAIL agonists are currently on- 
going to determine its therapeutic efficacy as single agents or in combination with 
standard chemotherapies.  
While TRAIL is generally known for its apoptotic inducing function, recent studies 
have characterized a new form of cell death, termed necroptosis, which also engages 
the stimulation of the death receptors (Degterev et al., 2005; Galluzzi and Kroemer, 
2008). However, necroptosis is mechanistically distinct from apoptosis and necrosis, 
and there are experimental methods to distinguish between these forms of cell death 
(Galluzzi et al., 2012). For that reason, it is important to characterize the cell death 
induced by TRAIL in the cisplatin-resistant cells. Using several molecular 
approaches, we demonstrated that TRAIL-mediated cell death in cisplatin-resistant 
cells displayed classical hallmarks of apoptosis observed by: 1) DNA fragmentation, 
2) externalization of PS, 3) robust and early caspase 8, 3, 6 and 9 activation, 4) 
MOMP and 5) Bid cleavage.  
We also showed that the cell death is essentially caspase-dependent, as preincubation 
with the pan-caspase inhibitor, ZVAD, effectively inhibited cell death induced by 
TRAIL. Since previous studies have characterized two pathways of extrinsic 
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apoptosis by death receptors where in 1) type I cells, apoptosis is triggered in a 
mitochondria-independent manner, while in 2) type II cells, initial caspase activation 
is weak and requires the amplification signal from mitochondria mediated by tBid, to 
trigger apoptosis, we proceeded to determine which cell type the cisplatin-resistant 
cells belong to. Our experimental data initially suggested the involvement of 
mitochondria in TRAIL-mediated apoptosis, which is evidently shown by MOMP, 
Bid cleavage to tBid and cytochrome c release, however, these features are also often 
reported in type I cells (Scaffidi et al., 1999). So to further confirm the type of TRAIL 
signaling pathway, we transiently overexpressed Bcl-2, which function to block 
mitochondrial activation in type II cells, in the cisplatin-resistant cells. However, we 
found that Bcl-2 failed to protect the cells from TRAIL-induced apoptosis and hence 
we confirmed that the cisplatin-resistant cells exhibit a type I cell mediated extrinsic 
apoptotic pathways. 
Although the death receptor signaling pathway has been shown to modulate 
necroptosis, the above findings do not support the possibility of necroptosis for the 
following reasons; there was robust activation of caspase-8 by TRAIL, which is 
absent in necroptosis. It is clear that necroptosis occurs in the absence of caspase 









Other studies reproduced the same findings using pharmacological inhibitor of 
caspases, ZVAD, cotreatment with TNF and Fas agonists (Kaiser et al., 2011; Oberst 
et al., 2011; Zhang et al., 2011). Therefore, necroptosis is postulated as a surrogate 
mechanism to induce cell death when caspases are inhibited. The second reason is that 
Bcl-2 overexpression did not confer protection against TRAIL-mediated cell death in 
the cisplatin-resistant cells, while it has been reported that proteins of the Bcl-2 family 
have been shown to inhibit necroptosis. In a study by Ono et al. (2010), the authors 
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showed that they were able to block necroptosis with Bcl-xl overexpression, although 
the role of the Bcl-2 family proteins in necroptosis remain poorly understood. 
Meanwhile, more experiments can be performed to exclude necroptosis, such as loss 
of function experiments using necrostatin-1 and knockdown of RIP1/3 proteins.  
Herein, we have demonstrated that TRAIL mediates classical apoptosis in the 
cisplatin-resistant cells and together, these findings serve to support TRAIL as a 
potential second line therapy for cisplatin-resistant NSCLC cells. 
3.2 Mechanisms that confers TRAIL sensitivity in cisplatin-resistant cells 
3.2.1 Distribution of TRAIL receptors to the lipid rafts in the cisplatin-resistant 
cells 
Since the cisplatin-resistant cells are highly responsive to TRAIL-induced cell death, 
we explored the mechanisms that could possibly confer sensitivity to cisplatin-
resistant cells. Our first initiative was to examine the proteins involved in the 
formation of DISC. We found that the TRAIL receptors, DR4 and DR5, were both 
upregulated in the cisplatin-resistant cells as compared to the WT cells. In agreement 
with our data, Kondo et al. (2006b) has also reported cisplatin-dependent upregulation 
of DR4 and DR5, and hence they were able to sensitize squamous cell carcinoma with 
cisplatin and TRAIL combination therapy in xenograft models. The upregulation of 
DR4 and DR5 by cisplatin can be attributed to the tumor suppressor p53, which has 
been reportedly shown to induce the expression of these genes in response to cellular 
stress (Vousden and Lu, 2002). Despite the increase in the total protein expression of 
DR4 and DR5 in the cisplatin-resistant cells, we do not observe a corresponding 
increase in the surface expression of DR4 and DR5 on the membrane of the cells. In 
fact, the surface expressions of both receptors were lower than that of the WT cells. 
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One plausible explanation could be due to deficient transport of death receptors or 
activation of mechanisms favouring death receptors endocytosis, but these 
mechanisms are often found in cells resistant to TRAIL treatment (LeBlanc and 
Ashkenazi, 2003; Wenger et al., 2006). A second explanation could be that the 
distribution of death receptors on the plasma membrane is altered in cisplatin-resistant 
cells, thus enhancing TRAIL initiated signals. There are several lines of evidence in 
support of the second model. Firstly, cisplatin has been previously shown to induce 
the redistribution of death receptors into lipid rafts in colorectal cancer cells (Lacour 
et al., 2004). Furthermore, several studies have shown that distribution of death 
receptors and assembly of DISC in the lipid rafts promotes death receptor-mediated 
apoptosis while those in the nonrafts inhibit caspase 8 activation (Muppidi and Siegel, 
2004; Muppidi et al., 2004; Song et al., 2007). In this study, we have demonstrated 
that TRAIL receptor DR4 is predominantly found in the lipid rafts in unstimulated 
cisplatin-resistant cells as compared to the WT cells. Also, following TRAIL 
stimulation, the DISC components; caspase 8 and FADD were rapidly recruited to the 
lipid rafts in R1 cells, but not in the WT cells.  
Lipid rafts are microdomains enriched in sphingolipids and cholesterol, found on the 
plasma membrane, and these rafts serve as a platform for signaling process, which has 
been previously described for B-cell receptor, T-cell receptor and death receptors, by 
bringing the receptors in close proximity with the signaling partners in the lipid rafts 
(Dykstra et al., 2003). We further confirm the role of lipid rafts in facilitating TRAIL 
signaling by using a commonly used cholesterol-binding oligosaccharide, MCD, 
which disrupts the lipid rafts by depleting the cholesterol levels. Disruption of the 
lipid rafts with MCD did not significantly rescue the overall cell death induced by 
TRAIL, however, there was less caspase-8 and PARP cleavage detected in MCD and 
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TRAIL combination treatment compared to TRAIL treatment alone. One plausible 
explanation for the failure of MCD to rescue TRAIL-induced cell death is that MCD 
on its own elicited cell death in the cells. This cytotoxic effect of MCD has been 
described by other groups as well, suggesting that lipid rafts are important for cell 
viability or MCD has other side effects besides cholesterol depletion (Kilsdonk et al., 
1995; Simons and Toomre, 2000). Despite the cytotoxicity induced by MCD, when 
comparing the cell viability data of MCD (4mM) control and MCD with TRAIL 
combination treatment, the cell viability was almost comparable, more experiments 
will be required to confirm the inhibitory effects of MCD on TRAIL. Nonetheless, 
these data show that the localization of the DR4 and DISC assembly in the lipid rafts 
greatly enhances TRAIL-mediated signaling in the cisplatin-resistant cells. These 
findings also corroborate findings from previous studies showing that cisplatin can 
induce redistribution of Fas and TRAIL receptors into lipid rafts and hence augments 
TRAIL-induced apoptosis (Huang et al., 2010; Lacour et al., 2004; Xu et al., 2011a).  
 
In this study, while validating the distribution of DR4 in lipid rafts, with caveolin-1, 
we serendipitously found that the caveolin-1 staining patterns in the WT cells and the 
cisplatin-resistant cells are very different, suggesting that the nature of the lipid rafts 
between these two cell lines are distinctively different. Since cholesterol is one of the 
main component of lipid raft, we compared the total cholesterol content between the 
cells. We found that the cisplatin-resistant cells have higher levels of cholesterol 
compared to WT cells. These findings corroborated with other studies that showed 
that cells with higher membrane cholesterol levels have more rafts formation, thus 
explaining the difference in the nature of the lipid rafts and distribution of plasma 
membrane proteins between the two cell lines (Li et al., 2006). In addition to death 
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receptors and caveolin, mislocalization of other plasma membrane proteins (e.g. 
MRP1) has also been documented in cisplatin-resistant cells (Liang et al., 2003). 
However, the exact mechanism of how the TRAIL receptor DR4 is localized at the 
lipid rafts in unstimulated cisplatin-resistant cells remains unknown and future studies 
on the effects of cisplatin on plasma membrane structure and composition are 
necessary to provide better understanding of the localization of the death receptor into 
the lipid rafts. 
 
Although we have established that the localization of the TRAIL receptors augments 
TRAIL-induced apoptosis in cisplatin-resistant cells, we have yet to identify the role 
of the receptors in mediating the sensitivity of the cells to TRAIL. Hence we 
performed loss-of-functions experiments using monoclonal blocking antibodies 
against DR4 or DR5 and the transient knockdown of DR4 or DR5. We observed that 
in both experiments, abrogation of DR4 function was able to confer significant 
survival advantage to the cisplatin-resistant cells, whereas no rescue was observed 
with DR5 inhibition. This observation suggests that DR4 plays a more important role 
as compared to DR5 in conveying TRAIL-induced signals in the cisplatin-resistant 
cells. The dominance role of DR4 over DR5 has also been reported by Kurbanov et al. 
(2005). In their study, they found that DR4 expression in melanoma cells was not as 
prevalent as DR5; only 2 out of 7 melanoma cell lines exhibited DR4 expression. 
However, they demonstrated that only the DR4 positive melanoma cells were highly 
sensitive to TRAIL- induced apoptosis and in contrast, the DR4 negative cells were 
resistant or less responsive to TRAIL. Several studies from other groups also showed 
DR4 as the main effector in TRAIL-induced apoptosis in other cell line models (Jin et 
al., 2004; Kazhdan and Marciniak, 2004; Kim et al., 2000). 
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In addition to DR4 and DR5, TRAIL also interacts with two other receptors, DcR1 
and DcR2. These are decoy receptors that lack cytoplasmic domain and death domain 
respectively, thereby inhibiting TRAIL-induced apoptosis by competing with DR4 
and DR5 for binding to TRAIL (LeBlanc and Ashkenazi, 2003; Strasser et al., 2000). 
In this study, we have yet to determine if DcR1 and DcR2 are involved in sensitizing 
the cisplatin-resistant cells to TRAIL. 
3.2.2 TRAIL downregulates cFLIP, cIAP2 and XIAP in cisplatin-resistant cells 
Another important determinant of TRAIL sensitivity is a group of anti-apoptotic 
proteins that inhibit the downstream effectors in TRAIL signaling pathways, these 
includes cFLIP, a modulator of caspase 8, and IAPs (XIAP, cIAP1, cIAP2), that either 
directly inhibit caspases or inhibit the procaspases (Deveraux and Reed, 1999). One of 
the most common causes of chemoresistance to anticancer drugs in patients is the 
abnormally high expressions of these anti-apoptotic proteins. Several studies have 
demonstrated that high expressions of cFLIP and IAPs induce TRAIL resistance and 
inhibition of these proteins greatly enhances TRAIL-induced apoptosis in cells 
(Mitsiades et al., 2002; Yamaguchi et al., 2005; Zhang and Fang, 2005). While other 
groups have to use small molecule inhibitors to target these anti-apoptotic proteins to 
sensitize cells to TRAIL-induced cell death (Vogler et al., 2009), we demonstrated 
that TRAIL treatment was able to significantly decrease the levels of cFLIP, XIAP 
and cIAP2 in the cisplatin-resistant cells, reiterating the potential of TRAIL as a 
therapeutic strategy for refractory cells. 
3.2.3 The role of OONO- in TRAIL-induced apoptosis: A new player 
The role of RS in mediating death receptors-induced apoptosis has been extensively 
studied. Early studies have first demonstrated the involvement of RS by blocking 
death-receptor-induced apoptosis with antioxidants, glutathione and NAC (Um et al., 
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1996; Watson et al., 1997; Wedi et al., 1999). Since our study had shown earlier that 
the cisplatin-resistant cells were insensitive to cisplatin-induced RS production due to 
stronger antioxidant defences, we were expecting TRAIL to induce apoptosis 
independent of RS in the cisplatin-resistant cells. Surprisingly, we found the exact 
opposite; the cisplatin-resistant cells produced massive amount of RS with TRAIL 
induction, which was quite baffling. One plausible explanation is that the nature of the 
RS generated by cisplatin is fundamentally different from that generated from TRAIL. 
Since the tool we used in this study is a general oxidative stress indicator, DCFDA, 
which detects a broad range of RS, includes hypochlorite anion, hydroxyl radical, 
OONO- and H2O2 (Table 2), cisplatin could have induced a distinctively different 
species of RS as compared to TRAIL and therefore, the antioxidant defences acquired 
by the cisplatin-resistant cells might be inadequate against the RS produced by 
TRAIL.  
Reactive Oxygen 
Species (ROS)  




100 µM of H2O2   190 2 
Hydroxyl radical 
(HO•)  
100 µM of ferrous perchlorate (II) and 1 mM of 
H2O2  
7400 730 




3 µM (final) of 
–
OCl  86 6 





100 µM of 2,2'-azobis(2-amidinopropane), 






3 µM (final) of ONOO–  6600 120 
Singlet oxygen (
1
O2)  100 µM of 3-(1,4-dihydro-1,4-epidioxy-1-




)  100 µM KO2  67 8 
Autooxidation  2.5 hours exposure to fluorescent light source  2000 <1 
 
* 10 µm of HPF or DCF (2',7'-dichlorofluorescein) were added to sodium phosphate buffer (0.1 M, pH 7.4); 
ROS were generated as indicated; and fluorescence was measured using excitation/emission wavelengths of 
490/515 nm (for and HPF) or 500/520 nm (for DCF).  
Table 2: Comparison of the fluorescence response of the redox sensitive probes to various 




However, there was no increase in mitochondrial O2•- levels with TRAIL treatment in 
the cisplatin-resistant cells, suggesting that the TRAIL-induced RS accumulation is 
independent of the mitochondria. While it is well documented that RS are produced 
concomitantly with death receptor induction and play a role in regulating death 
receptor-induced apoptosis, the mechanism of ROS production induced by death 
receptors is still poorly understood (Herrera et al., 2001; Simon et al., 2000). Some 
studies have demonstrated that the ROS could be mitochondrial-derived, while others 
reported that the NADPH oxidase (NOX) could be responsible for the death receptor-
mediated ROS generation (Shen and Pervaiz, 2006; Ventura et al., 2004). Herein, we 
attempted to identify the species and source of RS generated by TRAIL in the 
cisplatin-resistant cells. 
By elimination studies with commercially available antioxidants, we demonstrated 
that H2O2 is not the species generated by TRAIL, since catalase neither inhibited 
TRAIL-induced RS production nor rescued the cells from TRAIL-induced 
cytotoxicity. We used another general antioxidant, NAC, which have been shown to 
scavenge several RS such as hypochlorite anion, hydroxyl radical, OONO- anion and 
H2O2, however, there was only a slight rescue of the cisplatin-resistant cells from 
TRAIL-induced cell death. No doubt NAC is routinely used as an antioxidant to 
effectively decrease the toxic effects of RS, however, it is a broad range antioxidant 
with varying activities with different types of RS and therefore the effect might be 
under-represented (Aruoma et al., 1989). 
Finally, when we used a specific OONO- scavenger, FeTPPs, the accumulation of RS 
generated by TRAIL was significantly reduced. As compared to NAC, FeTPPs might 
be a better scavenger of OONO- as it has been shown to react directly and 
catalytically decompose OONO- to nitrates and hence the inhibitory effect is more 
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potent (Jensen and Riley, 2002; Salvemini et al., 1998). We further confirmed 
OONO- production by checking for nitrotyrosine modified proteins, which is a stable 
biomarker for OONO- production, in the cisplatin-resistant cells. Herein, we 
demonstrate for the first time that TRAIL induces production of OONO-. Other 
studies have previously described OONO- production with TNFα, predominantly by 
inflammatory cells at the site of injury, but not in TRAIL (Matata and Galinanes, 
2002; Phares et al., 2007). To delineate the functional relevance of OONO- in 
TRAIL-induced apoptosis in the cisplatin-resistant cells, we investigated the effects of 
FeTPPs on TRAIL-induced apoptotic signaling. We showed that preincubation with 
FeTPPs conferred better cell survival to TRAIL-treated cisplatin-resistant cells in a 
dose-dependent manner, indicating that OONO- plays an important role in mediating 
TRAIL-induced apoptosis. Indeed, further investigations demonstrated that FeTPPs 
was able to significantly suppress TRAIL downstream pathways, as shown by the 
decrease in DNA fragmentation, proteolytic processing of caspases and their 
activities. A study by Zhuang and Simon (2000) has shown that OONO- is able to 
augment FAS-induced apoptosis by adding OONO- in combination with FAS 
treatment, further supporting our data on the role of OONO- in enhancing TRAIL-
induced apoptosis. In addition, we also demonstrated that FeTPPs was able to block 
TRAIL-induced downregulation of XIAP and cIAP2, suggesting that XIAP and 
cIAP2 may be regulated by OONO-. 
Potential source(s) of O2
- 
and NO responsible for the formation of peroxynitrtrite 
The finding that TRAIL induces OONO- interests us to investigate the source of its 
production. Production of OONO- is best characterized by the reaction of NO and O2
-
 
radicals (Pryor and Squadrito, 1995). Here, we showed that NO was indeed produced 
upon TRAIL induction in the cisplatin-resistant cells using a specific fluorescence 
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probe for NO, DAF. Furthermore, we demonstrated that there was a time-dependent 
increase in the protein expression of iNOS with TRAIL induction, suggesting that 
iNOS may be responsible for the TRAIL-induced NO production. This finding is 
supported by a study by Zauli et al. (2003), where the authors described NO 
production by TRAIL in an endothelial cell model.  In similar studies, authors were 
able to sensitize cells to death receptors-induced apoptosis by inducing NO 
production by overexpressing NOS or using NO donors (Garban and Bonavida, 1999; 
Hayden et al., 2001; Lee et al., 2001; Selleri et al., 1997).  
In addition to NO, we also investigated the source of O2•
- 
responsible for formation of 
OONO-. By using a general O2•
- 
indicator, lucigenin, we confirmed that there was a 
transient increase in intracellular O2
- 
production with TRAIL treatment however, as 
mentioned in introduction, there are several sources of O2•
- 
sources. So to narrow 
down the possible source, we first checked if the intracellular O2•
- 
is accumulated in 
the mitochondria of TRAIL-triggered cisplatin-resistant cells and found that TRAIL-
induced intracellular O2•
- 
increase is not mitochondrial-derived. However, we also 
cannot completely dismiss the possibility of mitochondrial production of O2•
- 
with 
TRAIL, because in this model, MnSOD is highly expressed in the cisplatin-resistant 
cells and therefore, the resultant O2•
- 
produced by mitochondria might be scavenged 
upon production and hence impossible for us to detect. Nonetheless, we can only 
conclude that intracellular O2•
- 
accumulation is not a mitochondria-dependent event. 
This led us to examine for the possible cytosolic sources of O2•
- 
and finally we 
demonstrated that TRAIL significantly increased NOX activity in a time-dependent 
manner in the cisplatin-resistant cells, resulting in intracellular O2•
-
 accumulation. 
Consistent with our data, other groups have also reported the production O2•
-
 by NOX 
in TNF family signaling pathways (Kim et al., 2007; Reinehr et al., 2005).  
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3.2.4 OONO- production is a caspase-dependent event 
Finally, to delineate the sequential events of the TRAIL-mediated signaling events in 
the cisplatin cells, we ask the question if OONO- production is a caspase-mediated 
event.  And we showed that caspase inhibition by ZVAD was able to abrogate the 
OONO- production and the induction of iNOS mediated by TRAIL. Previous studies 
have observed similar induction of caspase activation and iNOS induction, however, 
the exact mechanisms are poorly understood (Binder et al., 1999). 
3.2.5 JNK and ERK activation does not contribute to TRAIL-induced 
apoptosis. 
It has originally been shown that ERKs are important for cell survival (Zhuang and 
Schnellmann, 2006) whereas JNKs and p38-MAPKs were deemed important 
transducers for stressful signals and thus involved in apoptosis. However, studies have 
shown that these kinases have dual roles in determining the ultimate fate of a cell; 
depending upon the context i.e. cell type and its intracellular mileu, or the type of 
extracellular signals that triggers the kinases. All three kinases have been found be 
activated in response to TRAIL stimulation, though they are conflicting reports 
suggesting that ERK, JNK or p38 signaling can either suppress, or enhance the 
apoptotic efficacy of TRAIL (Jin et al., 2007; Lee et al., 2006; Mucha et al., 2009; 
Secchiero et al., 2003; Shenoy et al., 2009; Soderstrom et al., 2002; Tran et al., 2001; 
Wang et al., 2009a; Zou et al., 2004). In this study, TRAIL-induced  massive 
accumulation of OONO- resulted in the activation of the stress-activated kinases and 
MAPK such as JNK, ERK1/2 (Pacher et al., 2007). However, these kinases do not 
seem to play a direct role in mediating cytotoxicity as inhibition of these kinases did 
not rescue the cisplatin-resistant cells from TRAIL-mediated apoptosis.  
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3.3 Recapitulating the effects of TRAIL in different cisplatin-resistant cell 
models. 
 
Having witnessed the ability of TRAIL to effectively induce apoptosis in cisplatin-
resistant clones derived from A549, we proceeded to validate the cytotoxic potential 
in other models to ensure these findings are not exclusive to A549 cells. Hence, we 
used another NSCLC model, H2030 cells, which have been previously characterized 
to possess a p53 G262V mutation and KRAS G12C mutation. Similarly, we generated 
a cisplatin-resistant cell line (H23030CR) from the parental H2030 cells. In contrast 
to R1 and R2 cells, the H2030CR cells represent a heterogeneous population of 
cisplatin-resistant cells as no individual clones were selected. To support the data 
observed with A549 and its cisplatin-resistant derived clones, heterogeneous 
populations were chosen over homogenous populations for the creation of H2030CR 
to provide an unbiased assessment of the effects of TRAIL on the cisplatin-resistant 
cells by ruling out the effects observed in the cisplatin-resistant cells as that due to 
alterations in a single cell following cisplatin exposure. Like R1 and R2 cells, we 
demonstrated that H2030CR cells also have a reduced proliferation rate. In addition, 
the H2030CR cells are unaffected by cisplatin and carboplatin but highly sensitive to 
TRAIL.  
To further extrapolate this TRAIL-sensitive characteristic in cisplatin-resistant 
refractory cells in other cancer models, we used an ovarian cancer model, A2780, and 
its established cisplatin-resistant line, A2780CR. Similar to the findings for NSCLC 
models, we also observed comparable trend in the growth rate and good response with 
TRAIL. Taken together, these results reiterate the efficacy of TRAIL as a potential 
therapy for cisplatin-resistant cells, regardless of the cancer model. 
194 
 
3.4 TRAIL in combination therapy with cisplatin 
Although we have demonstrated that TRAIL treatment alone effectively eradicates the 
cisplatin-resistant cells, we wanted to evaluate the effects of TRAIL in combination 
therapy with cisplatin, since the currently approved standard first-line therapy for 
NSCLC are predominantly platinum-based regimens. Indeed, TRAIL sensitizes the 
cisplatin-resistant cells to cisplatin. Our data is supported by other studies performed 
to investigate the combination of TRAIL and cisplatin therapy (Kondo et al., 2006a; 
Vondalova Blanarova et al., 2011; Xu et al., 2011b). These findings again support the 
feasibility of TRAIL as a second-line therapy for the refractory cancer cells. 
Over the past decades, although extensive research on TRAIL for cancer therapy has 
shown promising results, it has yet to be approved by the U.S. Food and Drug 
Administration (FDA) for treatment of cancer. This may be due to the less than 
satisfactory clinical responses observed in the trials (Ashkenazi and Herbst, 2008). 
Findings from this study suggest that the therapeutic efficacy of TRAIL might be 
enhanced if the patient selection criteria are optimized in the clinical trials. As seen in 
some cases, careful selection of patients for clinical trials may prove to be more 
superior. For example, a class of anticancer drugs that experience therapeutic success 
based on patient selection criteria is the EGFR tyrosine kinase inhibitors, gefitinib and 
erlotinib, which responded well with a subset of advanced NSCLC patients with 
EGFR mutations in the kinase domain (Lynch et al., 2004; Paez et al., 2004; Sordella 
et al., 2004). Another example is the use of Trastuzumab for breast cancer treatment, 
resulted in significantly improves disease-free survival in patients with HER2-positive 
breast cancer (Piccart-Gebhart et al., 2005; Romond et al., 2005). Similarly, we might 




Summary of TRAIL mechanism in cisplatin-resistant cells 
Taken together, our findings have highlighted several alterations in mitochondrial 
function in cisplatin-resistant cells and these suggest that mitochondria could be 
important molecular determinants of chemoresistance in NSCLC. Interestingly, the 
acquisition of resistance to cisplatin has unexpectedly rendered these refractory cells 
sensitive to TRAIL-induced apoptosis. We outlined the mechanisms by which 
cisplatin-resistant cells have been bestowed to facilitate TRAIL signaling to induce 
apoptosis (Figure 67). In the cisplatin-sensitive WT cells, the TRAIL receptors are 
functionally intact, however, they exist as isolated units of receptors on the surface of 
the plasma membrane. Upon TRAIL ligation, the receptors oligomerize in the 
nonrafts, where the DISC formation is impeded by cFLIP, RIP and possibly other 
IAPs. Therefore, no caspase activation is initiated. In contrast, the TRAIL receptors in 
cisplatin-resistant cells are pre-associated in complexes in lipid rafts on the plasma 
membrane. This complex greatly facilitates TRAIL signal transduction. Upon TRAIL 
ligation, DISC formation is rapidly initiated and a caspase cascade is strongly 
activated. The caspases, which are main executors of cell death, mediate the 
physiological changes for apoptosis and production of NO and O2•
- 
resulting in the 
formation of OONO-, a strong oxidant hence amplifying the apoptosis signal 




Figure 67: Schematic diagram illustrating the different mechanisms of TRAIL signaling in the cisplatin-sensitive WT cells and the 
cisplatin-resistant R1 cells. In the WT cells, the TRAIL receptors are isolated and upon TRAIL ligation, the receptors oligomerize to form 
the DISC and subsequently activation of procaspase 8. However, due to high levels of anti-apoptotic signals, apoptosis fail to initiate. In R1 
cells, TRAIL receptors are preassociated in the lipid rafts, and hence are “primed” for rapid activation. Upon ligation, the apoptotic signals 
are transduced promptly with an amplification signal via peroxynitrite formation and ultimately resulting in apoptosis. 
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CONCLUDING REMARKS  
 
Chemoresistance remains one of the main reasons for chemotherapy failure in the 
treatment of cancer, especially in patients with advanced metastatic disease. Due to 
the diverse and multifactorial nature of drug resistance, there are no consensus 
biomarkers and the exact mechanism of resistance is still elusive. Hence, in to order to 
resolve the problem of chemoresistance, we have to further investigate how 
chemoresistance evolve and if possible, define a set of consensus biomarkers to 
predict resistance and perhaps design new therapeutic regimens for chemoresistant 
cells. 
 In this regard, we use a NSCLC cisplatin-resistant model to emulate the refractory 
disease condition in an effort to understand the mechanism of acquired resistance to 
cisplatin, since cisplatin is one of the most commonly used broad spectrum drug for 
solid tumors. Preliminary findings from this study demonstrate alterations in the 
energy metabolism and mitochondrial function of the cisplatin-resistant cells and we 
propose that mitochondrial dysfunction could contribute to the acquisition of cisplatin 
resistance. These findings may pave the way for future work on deciphering the role 
of mitochondria in determining cisplatin treatment outcome.  
 
In the second part of the study, we found that TRAIL can effectively induce apoptosis 
in the cisplatin-resistant cells. Here, we showed that the TRAIL receptors are 
redistributed into the lipid rafts on the plasma membrane which greatly enhance 
TRAIL-induced apoptotic signaling in the cisplatin-resistant cells. In addition, we 
discovered that TRAIL was able to induce caspase-dependent intracellular 
198 
 
peroxynitrite production, which function as an important mediator of cell death, in the 
cisplatin-resistant cells. Finally, this study has proven TRAIL to be a promising 
secondary line of treatment, either as a monotherapy or combination therapy, for 
refractory NSCLC and possibly other cisplatin-resistant models. Future studies with 
animal models or clinical samples may help to substantiate our findings and develop 


























Adrain, C., Creagh, E.M., and Martin, S.J. (2001). Apoptosis-associated release of Smac/DIABLO 
from mitochondria requires active caspases and is blocked by Bcl-2. The EMBO journal 20, 6627-
6636. 
 
Aggarwal, S. (2010). Targeted cancer therapies. Nature reviews Drug discovery 9, 427-428. 
 
Ahmad, K.A., Iskandar, K.B., Hirpara, J.L., Clement, M.V., and Pervaiz, S. (2004). Hydrogen 
peroxide-mediated cytosolic acidification is a signal for mitochondrial translocation of Bax during 
drug-induced apoptosis of tumor cells. Cancer research 64, 7867-7878. 
 
Ahmad, K.A., Wang, G., and Ahmed, K. (2006). Intracellular hydrogen peroxide production is an 
upstream event in apoptosis induced by down-regulation of casein kinase 2 in prostate cancer cells. 
Molecular cancer research : MCR 4, 331-338. 
 
Ahrendt, S.A., Chow, J.T., Yang, S.C., Wu, L., Zhang, M.J., Jen, J., and Sidransky, D. (2000). 
Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small 
cell lung cancer. Cancer research 60, 3155-3159. 
 
Al-Bahlani, S., Fraser, M., Wong, A.Y., Sayan, B.S., Bergeron, R., Melino, G., and Tsang, B.K. 
(2011). P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-
dependent mechanism. Oncogene 30, 4219-4230. 
 
Alnemri, E.S. (1997). Mammalian cell death proteases: a family of highly conserved aspartate 
specific cysteine proteases. Journal of cellular biochemistry 64, 33-42. 
 
Alnemri, E.S., Livingston, D.J., Nicholson, D.W., Salvesen, G., Thornberry, N.A., Wong, W.W., 
and Yuan, J. (1996). Human ICE/CED-3 protease nomenclature. Cell 87, 171. 
 
Andrews, P.A., and Albright, K.D. (1992). Mitochondrial defects in cis-
diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer research 52, 1895-
1901. 
 
Arbour, N., Vanderluit, J.L., Le Grand, J.N., Jahani-Asl, A., Ruzhynsky, V.A., Cheung, E.C., 
Kelly, M.A., MacKenzie, A.E., Park, D.S., Opferman, J.T., et al. (2008). Mcl-1 is a key regulator 
of apoptosis during CNS development and after DNA damage. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 28, 6068-6078. 
 
Arts, H.J., Hollema, H., Lemstra, W., Willemse, P.H., De Vries, E.G., Kampinga, H.H., and Van 
der Zee, A.G. (1999). Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in 
response to chemotherapy and prognosis. International journal of cancer Journal international du 
cancer 84, 234-238. 
 
Arumugam, T., Ramachandran, V., Fournier, K.F., Wang, H., Marquis, L., Abbruzzese, J.L., 
Gallick, G.E., Logsdon, C.D., McConkey, D.J., and Choi, W. (2009). Epithelial to mesenchymal 
transition contributes to drug resistance in pancreatic cancer. Cancer research 69, 5820-5828. 
 
Aruoma, O.I., Halliwell, B., Hoey, B.M., and Butler, J. (1989). The antioxidant action of N-
acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and 
hypochlorous acid. Free radical biology & medicine 6, 593-597. 
 
Asechi, H., Hatano, E., Nitta, T., Tada, M., Iwaisako, K., Tamaki, N., Nagata, H., Narita, M., 
Yanagida, A., Ikai, I., et al. (2010). Resistance to cisplatin-induced apoptosis via PI3K-dependent 
survivin expression in a rat hepatoma cell line. International journal of oncology 37, 89-96. 
 





Ashkenazi, A., and Dixit, V.M. (1999). Apoptosis control by death and decoy receptors. Current 
opinion in cell biology 11, 255-260. 
 
Ashkenazi, A., and Herbst, R.S. (2008). To kill a tumor cell: the potential of proapoptotic receptor 
agonists. The Journal of clinical investigation 118, 1979-1990. 
 
Ashkenazi, A., Holland, P., and Eckhardt, S.G. (2008). Ligand-based targeting of apoptosis in 
cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related 
apoptosis-inducing ligand (rhApo2L/TRAIL). Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 26, 3621-3630. 
 
Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., Blackie, C., Chang, 
L., McMurtrey, A.E., Hebert, A., et al. (1999). Safety and antitumor activity of recombinant 
soluble Apo2 ligand. The Journal of clinical investigation 104, 155-162. 
 
Asselin, E., Mills, G.B., and Tsang, B.K. (2001). XIAP regulates Akt activity and caspase-3-
dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. 
Cancer research 61, 1862-1868. 
 
Baker, S.J., and Reddy, E.P. (1998). Modulation of life and death by the TNF receptor 
superfamily. Oncogene 17, 3261-3270. 
 
Bakhshi, A., Jensen, J.P., Goldman, P., Wright, J.J., McBride, O.W., Epstein, A.L., and 
Korsmeyer, S.J. (1985). Cloning the chromosomal breakpoint of t(14;18) human lymphomas: 
clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41, 899-906. 
 
Balligand, J.L., Ungureanu-Longrois, D., Simmons, W.W., Pimental, D., Malinski, T.A., 
Kapturczak, M., Taha, Z., Lowenstein, C.J., Davidoff, A.J., Kelly, R.A., et al. (1994). Cytokine-
inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and 
regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. 
The Journal of biological chemistry 269, 27580-27588. 
 
Bankey, P.E., Mazuski, J.E., Ortiz, M., Fulco, J.M., and Cerra, F.B. (1990). Hepatic acute phase 
protein synthesis is indirectly regulated by tumor necrosis factor. J Trauma 30, 1181-1187; 
discussion 1187-1188. 
 
Barnhart, B.C., Alappat, E.C., and Peter, M.E. (2003). The CD95 type I/type II model. Semin 
Immunol 15, 185-193. 
 
Barry, M.A., Behnke, C.A., and Eastman, A. (1990). Activation of programmed cell death 
(apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochemical 
pharmacology 40, 2353-2362. 
 
Beale, P.J., Rogers, P., Boxall, F., Sharp, S.Y., and Kelland, L.R. (2000). BCL-2 family protein 
expression and platinum drug resistance in ovarian carcinoma. British journal of cancer 82, 436-
440. 
 
Beckman, J.S., Beckman, T.W., Chen, J., Marshall, P.A., and Freeman, B.A. (1990). Apparent 
hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide 
and superoxide. Proceedings of the National Academy of Sciences of the United States of America 
87, 1620-1624. 
 
Behrens, B.C., Hamilton, T.C., Masuda, H., Grotzinger, K.R., Whang-Peng, J., Louie, K.G., 
Knutsen, T., McKoy, W.M., Young, R.C., and Ozols, R.F. (1987). Characterization of a cis-
diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of 
platinum analogues. Cancer research 47, 414-418. 
 
Benson, A.B., 3rd, Schrag, D., Somerfield, M.R., Cohen, A.M., Figueredo, A.T., Flynn, P.J., 
Krzyzanowska, M.K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004). American Society 
of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. 
201 
 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, 
3408-3419. 
 
Bernard, D., Quatannens, B., Vandenbunder, B., and Abbadie, C. (2001). Rel/NF-kappaB 
transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. The Journal of 
biological chemistry 276, 27322-27328. 
 
Berndtsson, M., Hagg, M., Panaretakis, T., Havelka, A.M., Shoshan, M.C., and Linder, S. (2007). 
Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated 
with damage to nuclear DNA. International journal of cancer Journal international du cancer 120, 
175-180. 
 
Bertolini, G., Roz, L., Perego, P., Tortoreto, M., Fontanella, E., Gatti, L., Pratesi, G., Fabbri, A., 
Andriani, F., Tinelli, S., et al. (2009). Highly tumorigenic lung cancer CD133+ cells display stem-
like features and are spared by cisplatin treatment. Proceedings of the National Academy of 
Sciences of the United States of America 106, 16281-16286. 
 
Bianchi, K., and Meier, P. (2009). A tangled web of ubiquitin chains: breaking news in TNF-R1 
signaling. Molecular cell 36, 736-742. 
 
Bin, L., Thorburn, J., Thomas, L.R., Clark, P.E., Humphreys, R., and Thorburn, A. (2007). Tumor-
derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor 
by competing for ligand binding. The Journal of biological chemistry 282, 28189-28194. 
 
Binder, C., Schulz, M., Hiddemann, W., and Oellerich, M. (1999). Caspase-activation and 
induction of inducible nitric oxide-synthase during TNF alpha-triggered apoptosis. Anticancer 
research 19, 1715-1720. 
 
Blankenship, J.W., Varfolomeev, E., Goncharov, T., Fedorova, A.V., Kirkpatrick, D.S., Izrael-
Tomasevic, A., Phu, L., Arnott, D., Aghajan, M., Zobel, K., et al. (2009). Ubiquitin binding 
modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). The 
Biochemical journal 417, 149-160. 
 
Blommaart, E.F., Luiken, J.J., and Meijer, A.J. (1997). Autophagic proteolysis: control and 
specificity. The Histochemical journal 29, 365-385. 
 
Bodmer, J.L., Holler, N., Reynard, S., Vinciguerra, P., Schneider, P., Juo, P., Blenis, J., and 
Tschopp, J. (2000). TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nature cell 
biology 2, 241-243. 
 
Bogdan, C. (2001). Nitric oxide and the immune response. Nature immunology 2, 907-916. 
 
Bragado, P., Armesilla, A., Silva, A., and Porras, A. (2007). Apoptosis by cisplatin requires p53 
mediated p38alpha MAPK activation through ROS generation. Apoptosis : an international journal 
on programmed cell death 12, 1733-1742. 
 
Breathnach, O.S., Freidlin, B., Conley, B., Green, M.R., Johnson, D.H., Gandara, D.R., O'Connell, 
M., Shepherd, F.A., and Johnson, B.E. (2001). Twenty-two years of phase III trials for patients 
with advanced non-small-cell lung cancer: sobering results. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 19, 1734-1742. 
 
Brown, D.A., and Rose, J.K. (1992). Sorting of GPI-anchored proteins to glycolipid-enriched 
membrane subdomains during transport to the apical cell surface. Cell 68, 533-544. 
Bubici, C., Papa, S., Dean, K., and Franzoso, G. (2006). Mutual cross-talk between reactive 
oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 
25, 6731-6748. 
 
Bunn, P.A., Jr., Vokes, E.E., Langer, C.J., and Schiller, J.H. (1998). An update on North American 




Buttke, T.M., and Sandstrom, P.A. (1994). Oxidative stress as a mediator of apoptosis. 
Immunology today 15, 7-10. 
 
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D.A., and Stella, A.M. (2007). 
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nature reviews 
Neuroscience 8, 766-775. 
 
Campbell, K.J., Bath, M.L., Turner, M.L., Vandenberg, C.J., Bouillet, P., Metcalf, D., Scott, C.L., 
and Cory, S. (2010). Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of 
hematopoietic stem/progenitor cells, and enhances drug resistance. Blood 116, 3197-3207. 
 
Camussi, G., Bussolino, F., Salvidio, G., and Baglioni, C. (1987). Tumor necrosis factor/cachectin 
stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells 
to synthesize and release platelet-activating factor. The Journal of experimental medicine 166, 
1390-1404. 
 
Cetintas, V.B., Kucukaslan, A.S., Kosova, B., Tetik, A., Selvi, N., Cok, G., Gunduz, C., and 
Eroglu, Z. (2012). Cisplatin resistance induced by decreased apoptotic activity in non-small-cell 
lung cancer cell lines. Cell biology international 36, 261-265. 
 
Chance, B., Sies, H., and Boveris, A. (1979). Hydroperoxide metabolism in mammalian organs. 
Physiological reviews 59, 527-605. 
 
Chaney, S.G., Campbell, S.L., Bassett, E., and Wu, Y. (2005). Recognition and processing of 
cisplatin- and oxaliplatin-DNA adducts. Critical reviews in oncology/hematology 53, 3-11. 
 
Chang, H.Y., and Yang, X. (2000). Proteases for cell suicide: functions and regulation of caspases. 
Microbiology and molecular biology reviews : MMBR 64, 821-846. 
 
Chen, C.J., Chin, J.E., Ueda, K., Clark, D.P., Pastan, I., Gottesman, M.M., and Roninson, I.B. 
(1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (P-
glycoprotein) gene from multidrug-resistant human cells. Cell 47, 381-389. 
 
Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee, C., Pandey, S.K., Nwokorie, C., 
Onwudiwe, N., and Srivastava, R.K. (2001). Constitutively active Akt is an important regulator of 
TRAIL sensitivity in prostate cancer. Oncogene 20, 6073-6083. 
 
Cheng, J., Zhou, T., Liu, C., Shapiro, J.P., Brauer, M.J., Kiefer, M.C., Barr, P.J., and Mountz, J.D. 
(1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 
263, 1759-1762. 
 
Cheng, X., Kinosaki, M., Murali, R., and Greene, M.I. (2003). The TNF receptor superfamily: role 
in immune inflammation and bone formation. Immunologic research 27, 287-294. 
 
Chipuk, J.E., and Green, D.R. (2008). How do BCL-2 proteins induce mitochondrial outer 
membrane permeabilization? Trends in cell biology 18, 157-164. 
 
Cho, H.J., Kim, J.K., Kim, K.D., Yoon, H.K., Cho, M.Y., Park, Y.P., Jeon, J.H., Lee, E.S., Byun, 
S.S., Lim, H.M., et al. (2006). Upregulation of Bcl-2 is associated with cisplatin-resistance via 
inhibition of Bax translocation in human bladder cancer cells. Cancer letters 237, 56-66. 
 
Chu, G., and Chang, E. (1990). Cisplatin-resistant cells express increased levels of a factor that 
recognizes damaged DNA. Proceedings of the National Academy of Sciences of the United States 
of America 87, 3324-3327. 
 
Clayer, M., Bouralexis, S., Evdokiou, A., Hay, S., Atkins, G.J., and Findlay, D.M. (2001). 
Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach 




Cole, S.P., Bhardwaj, G., Gerlach, J.H., Mackie, J.E., Grant, C.E., Almquist, K.C., Stewart, A.J., 
Kurz, E.U., Duncan, A.M., and Deeley, R.G. (1992). Overexpression of a transporter gene in a 
multidrug-resistant human lung cancer cell line. Science 258, 1650-1654. 
 
Collins, J.A., Schandi, C.A., Young, K.K., Vesely, J., and Willingham, M.C. (1997). Major DNA 
fragmentation is a late event in apoptosis. The journal of histochemistry and cytochemistry : 
official journal of the Histochemistry Society 45, 923-934. 
 
Courjault, F., Leroy, D., Coquery, L., and Toutain, H. (1993). Platinum complex-induced 
dysfunction of cultured renal proximal tubule cells. A comparative study of carboplatin and 
transplatin with cisplatin. Arch Toxicol 67, 338-346. 
 
Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J.J., and Smyth, M.J. (2002). 
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing 
ligand-deficient mice. J Immunol 168, 1356-1361. 
 
Cruet-Hennequart, S., Villalan, S., Kaczmarczyk, A., O'Meara, E., Sokol, A.M., and Carty, M.P. 
(2009). Characterization of the effects of cisplatin and carboplatin on cell cycle progression and 
DNA damage response activation in DNA polymerase eta-deficient human cells. Cell Cycle 8, 
3039-3050. 
 
Cui, W., Yazlovitskaya, E.M., Mayo, M.S., Pelling, J.C., and Persons, D.L. (2000). Cisplatin-
induced response of c-jun N-terminal kinase 1 and extracellular signal--regulated protein kinases 1 
and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Molecular carcinogenesis 29, 
219-228. 
 
Cui, Y., Konig, J., Buchholz, J.K., Spring, H., Leier, I., and Keppler, D. (1999). Drug resistance 
and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, 
MRP2, permanently expressed in human and canine cells. Molecular pharmacology 55, 929-937. 
 
Cullen, K.J., Yang, Z., Schumaker, L., and Guo, Z. (2007). Mitochondria as a critical target of the 
chemotheraputic agent cisplatin in head and neck cancer. Journal of bioenergetics and 
biomembranes 39, 43-50. 
 
Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J.J., and Reed, E. (1994). Messenger RNA 
levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based 
chemotherapy. The Journal of clinical investigation 94, 703-708. 
 
Danial, N.N., and Korsmeyer, S.J. (2004). Cell death: critical control points. Cell 116, 205-219. 
 
Dasika, G.K., Lin, S.C., Zhao, S., Sung, P., Tomkinson, A., and Lee, E.Y. (1999). DNA damage-
induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. 
Oncogene 18, 7883-7899. 
 
Davis, W., Jr., Ronai, Z., and Tew, K.D. (2001). Cellular thiols and reactive oxygen species in 
drug-induced apoptosis. The Journal of pharmacology and experimental therapeutics 296, 1-6. 
 
de Laat, W.L., Jaspers, N.G., and Hoeijmakers, J.H. (1999). Molecular mechanism of nucleotide 
excision repair. Genes & development 13, 768-785. 
 
De Ruysscher, D., Botterweck, A., Dirx, M., Pijls-Johannesma, M., Wanders, R., Hochstenbag, 
M., Dingemans, A.M., Bootsma, G., Geraedts, W., Simons, J., et al. (2009). Eligibility for 
concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, 
population-based study. Annals of oncology : official journal of the European Society for Medical 
Oncology / ESMO 20, 98-102. 
 
Debatin, K.M., Fahrig-Faissner, A., Enenkel-Stoodt, S., Kreuz, W., Benner, A., and Krammer, 
P.H. (1994). High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency 




Declercq, W., Vanden Berghe, T., and Vandenabeele, P. (2009). RIP kinases at the crossroads of 
cell death and survival. Cell 138, 229-232. 
 
Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., Mukherjee, C., Shi, 
Y., Gelinas, C., Fan, Y., et al. (2006). Autophagy promotes tumor cell survival and restricts 
necrosis, inflammation, and tumorigenesis. Cancer cell 10, 51-64. 
 
Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G.D., Mitchison, 
T.J., Moskowitz, M.A., and Yuan, J. (2005). Chemical inhibitor of nonapoptotic cell death with 
therapeutic potential for ischemic brain injury. Nature chemical biology 1, 112-119. 
 
Demarcq, C., Bunch, R.T., Creswell, D., and Eastman, A. (1994). The role of cell cycle 
progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell growth & 
differentiation : the molecular biology journal of the American Association for Cancer Research 5, 
983-993. 
 
Denault, J.B., Eckelman, B.P., Shin, H., Pop, C., and Salvesen, G.S. (2007). Caspase 3 attenuates 
XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9. The Biochemical 
journal 405, 11-19. 
 
Denault, J.B., and Salvesen, G.S. (2002). Caspases: keys in the ignition of cell death. Chemical 
reviews 102, 4489-4500. 
 
Deng, Y., Ren, X., Yang, L., Lin, Y., and Wu, X. (2003). A JNK-dependent pathway is required 
for TNFalpha-induced apoptosis. Cell 115, 61-70. 
 
Denu, J.M., and Tanner, K.G. (1998). Specific and reversible inactivation of protein tyrosine 
phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for 
redox regulation. Biochemistry 37, 5633-5642. 
 
Deveraux, Q.L., and Reed, J.C. (1999). IAP family proteins--suppressors of apoptosis. Genes & 
development 13, 239-252. 
 
Deveraux, Q.L., Roy, N., Stennicke, H.R., Van Arsdale, T., Zhou, Q., Srinivasula, S.M., Alnemri, 
E.S., Salvesen, G.S., and Reed, J.C. (1998). IAPs block apoptotic events induced by caspase-8 and 
cytochrome c by direct inhibition of distinct caspases. The EMBO journal 17, 2215-2223. 
 
Deveraux, Q.L., Takahashi, R., Salvesen, G.S., and Reed, J.C. (1997). X-linked IAP is a direct 
inhibitor of cell-death proteases. Nature 388, 300-304. 
 
Devesa, S.S., Bray, F., Vizcaino, A.P., and Parkin, D.M. (2005). International lung cancer trends 
by histologic type: male:female differences diminishing and adenocarcinoma rates rising. 
International journal of cancer Journal international du cancer 117, 294-299. 
 
Diasio, R.B., and Harris, B.E. (1989). Clinical pharmacology of 5-fluorouracil. Clinical 
pharmacokinetics 16, 215-237. 
 
Dolcet, X., Llobet, D., Pallares, J., Rue, M., Comella, J.X., and Matias-Guiu, X. (2005). FLIP is 
frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced 
apoptosis. Lab Invest 85, 885-894. 
 
Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000). Smac, a mitochondrial protein that promotes 
cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42. 
 
Dykstra, M., Cherukuri, A., Sohn, H.W., Tzeng, S.J., and Pierce, S.K. (2003). Location is 
everything: lipid rafts and immune cell signaling. Annual review of immunology 21, 457-481. 
 
Earnshaw, W.C., Martins, L.M., and Kaufmann, S.H. (1999). Mammalian caspases: structure, 




Eckardt, J.R., Bentsion, D.L., Lipatov, O.N., Polyakov, I.S., Mackintosh, F.R., Karlin, D.A., 
Baker, G.S., and Breitz, H.B. (2009). Phase II study of picoplatin as second-line therapy for 
patients with small-cell lung cancer. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 27, 2046-2051. 
 
Eckelman, B.P., Salvesen, G.S., and Scott, F.L. (2006). Human inhibitor of apoptosis proteins: 
why XIAP is the black sheep of the family. EMBO reports 7, 988-994. 
 
Eckstein, N., Servan, K., Hildebrandt, B., Politz, A., von Jonquieres, G., Wolf-Kummeth, S., 
Napierski, I., Hamacher, A., Kassack, M.U., Budczies, J., et al. (2009). Hyperactivation of the 
insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance 
of ovarian cancer cells. Cancer research 69, 2996-3003. 
 
Ellis, H.M., and Horvitz, H.R. (1986). Genetic control of programmed cell death in the nematode 
C. elegans. Cell 44, 817-829. 
Emery, J.G., McDonnell, P., Burke, M.B., Deen, K.C., Lyn, S., Silverman, C., Dul, E., 
Appelbaum, E.R., Eichman, C., DiPrinzio, R., et al. (1998). Osteoprotegerin is a receptor for the 
cytotoxic ligand TRAIL. The Journal of biological chemistry 273, 14363-14367. 
 
Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. (1998). A 
caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 
43-50. 
 
Evdokiou, A., Bouralexis, S., Atkins, G.J., Chai, F., Hay, S., Clayer, M., and Findlay, D.M. 
(2002). Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone 
cells, to Apo2L/TRAIL-induced apoptosis. International journal of cancer Journal international du 
cancer 99, 491-504. 
 
Fabio Arnesano, G.N. (2009). Mechanistic insight into the cellular uptake and processing of 
cisplatin 30 years after its approval by FDA. Coordination Chemistry Reviews 253, 2070–2081. 
 
Falschlehner, C., Emmerich, C.H., Gerlach, B., and Walczak, H. (2007). TRAIL signalling: 
decisions between life and death. The international journal of biochemistry & cell biology 39, 
1462-1475. 
 
Ferry, K.V., Hamilton, T.C., and Johnson, S.W. (2000). Increased nucleotide excision repair in 
cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochemical pharmacology 60, 1305-
1313. 
 
Fesik, S.W. (2000). Insights into programmed cell death through structural biology. Cell 103, 273-
282. 
 
Fisher, G.H., Rosenberg, F.J., Straus, S.E., Dale, J.K., Middleton, L.A., Lin, A.Y., Strober, W., 
Lenardo, M.J., and Puck, J.M. (1995). Dominant interfering Fas gene mutations impair apoptosis 
in a human autoimmune lymphoproliferative syndrome. Cell 81, 935-946. 
 
Fisher, M.J., Virmani, A.K., Wu, L., Aplenc, R., Harper, J.C., Powell, S.M., Rebbeck, T.R., 
Sidransky, D., Gazdar, A.F., and El-Deiry, W.S. (2001). Nucleotide substitution in the ectodomain 
of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clinical cancer 
research : an official journal of the American Association for Cancer Research 7, 1688-1697. 
 
Fra, A.M., Williamson, E., Simons, K., and Parton, R.G. (1995). De novo formation of caveolae in 
lymphocytes by expression of VIP21-caveolin. Proceedings of the National Academy of Sciences 
of the United States of America 92, 8655-8659. 
 
Fraser, M., Bai, T., and Tsang, B.K. (2008). Akt promotes cisplatin resistance in human ovarian 
cancer cells through inhibition of p53 phosphorylation and nuclear function. International journal 




Frenzel, K.R., Saller, R.M., Kummermehr, J., and Schultz-Hector, S. (1995). Quantitative 
distinction of cisplatin-sensitive and -resistant mouse fibrosarcoma cells grown in multicell tumor 
spheroids. Cancer research 55, 386-391. 
 
Fridovich, I. (1978a). The biology of oxygen radicals. Science 201, 875-880. 
 
Fridovich, I. (1978b). Superoxide radicals, superoxide dismutases and the aerobic lifestyle. 
Photochemistry and photobiology 28, 733-741. 
 
Friesen, C., Herr, I., Krammer, P.H., and Debatin, K.M. (1996). Involvement of the CD95 (APO-
1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2, 574-577. 
 
Fuchs, Y., and Steller, H. (2011). Programmed cell death in animal development and disease. Cell 
147, 742-758. 
 
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., 
Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003). Multi-institutional randomized phase II 
trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The 
IDEAL 1 Trial) [corrected]. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology 21, 2237-2246. 
 
Fulda, S., Meyer, E., and Debatin, K.M. (2002). Inhibition of TRAIL-induced apoptosis by Bcl-2 
overexpression. Oncogene 21, 2283-2294. 
 
Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K.M. (1997). The CD95 (APO-1/Fas) 
system mediates drug-induced apoptosis in neuroblastoma cells. Cancer research 57, 3823-3829. 
 
Galluzzi, L., and Kroemer, G. (2008). Necroptosis: a specialized pathway of programmed necrosis. 
Cell 135, 1161-1163. 
 
Galluzzi, L., Vitale, I., Abrams, J.M., Alnemri, E.S., Baehrecke, E.H., Blagosklonny, M.V., 
Dawson, T.M., Dawson, V.L., El-Deiry, W.S., Fulda, S., et al. (2012). Molecular definitions of 
cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell 
death and differentiation 19, 107-120. 
 
Ganz, P.A., Desmond, K.A., Leedham, B., Rowland, J.H., Meyerowitz, B.E., and Belin, T.R. 
(2002). Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. 
Journal of the National Cancer Institute 94, 39-49. 
 
Garban, H.J., and Bonavida, B. (1999). Nitric oxide sensitizes ovarian tumor cells to Fas-induced 
apoptosis. Gynecologic oncology 73, 257-264. 
 
Gemba, M., and Sugihara, K. (1986). Evaluation of cisplatin-induced lipid peroxidation in rat renal 
tissues by means of slice technique. Developments in toxicology and environmental science 14, 
169-177. 
 
Geserick, P., Drewniok, C., Hupe, M., Haas, T.L., Diessenbacher, P., Sprick, M.R., Schon, M.P., 
Henkler, F., Gollnick, H., Walczak, H., et al. (2008). Suppression of cFLIP is sufficient to 
sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 27, 3211-
3220. 
 
Glaser, S.P., Lee, E.F., Trounson, E., Bouillet, P., Wei, A., Fairlie, W.D., Izon, D.J., Zuber, J., 
Rappaport, A.R., Herold, M.J., et al. (2012). Anti-apoptotic Mcl-1 is essential for the development 
and sustained growth of acute myeloid leukemia. Genes & development 26, 120-125. 
 
Godwin, A.K., Meister, A., O'Dwyer, P.J., Huang, C.S., Hamilton, T.C., and Anderson, M.E. 
(1992). High resistance to cisplatin in human ovarian cancer cell lines is associated with marked 
increase of glutathione synthesis. Proceedings of the National Academy of Sciences of the United 




Goldstein, J.C., Waterhouse, N.J., Juin, P., Evan, G.I., and Green, D.R. (2000). The coordinate 
release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nature cell 
biology 2, 156-162. 
 
Goldstraw, P., Ball, D., Jett, J.R., Le Chevalier, T., Lim, E., Nicholson, A.G., and Shepherd, F.A. 
(2011). Non-small-cell lung cancer. Lancet 378, 1727-1740. 
 
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D.J., Groome, P.A., Rami-Porta, R., Postmus, 
P.E., Rusch, V., and Sobin, L. (2007). The IASLC Lung Cancer Staging Project: proposals for the 
revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM 
Classification of malignant tumours. Journal of thoracic oncology : official publication of the 
International Association for the Study of Lung Cancer 2, 706-714. 
 
Gonzalez, V.M., Fuertes, M.A., Alonso, C., and Perez, J.M. (2001). Is cisplatin-induced cell death 
always produced by apoptosis? Molecular pharmacology 59, 657-663. 
Gottesman, M.M. (2002). Mechanisms of cancer drug resistance. Annual review of medicine 53, 
615-627. 
 
Gottesman, M.M., Mickisch, G.H., and Pastan, I. (1994). In vivo models of P-glycoprotein-
mediated multidrug resistance. Cancer treatment and research 73, 107-128. 
 
Gottesman, M.M., and Pastan, I. (1988). Resistance to multiple chemotherapeutic agents in human 
cancer cells. Trends in pharmacological sciences 9, 54-58. 
 
Gottlieb, T.M., and Oren, M. (1998). p53 and apoptosis. Seminars in cancer biology 8, 359-368. 
 
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N.D., Kanchi, K.L., Maher, C.A., 
Fulton, R., Fulton, L., Wallis, J., et al. (2012). Genomic landscape of non-small cell lung cancer in 
smokers and never-smokers. Cell 150, 1121-1134. 
 
Gowen, L.C., Avrutskaya, A.V., Latour, A.M., Koller, B.H., and Leadon, S.A. (1998). BRCA1 
required for transcription-coupled repair of oxidative DNA damage. Science 281, 1009-1012. 
 
Green, D., and Kroemer, G. (1998). The central executioners of apoptosis: caspases or 
mitochondria? Trends in cell biology 8, 267-271. 
 
Green, D.R., and Evan, G.I. (2002). A matter of life and death. Cancer cell 1, 19-30. 
 
Green, D.R., and Kroemer, G. (2004). The pathophysiology of mitochondrial cell death. Science 
305, 626-629. 
 
Green, D.R., and Reed, J.C. (1998). Mitochondria and apoptosis. Science 281, 1309-1312. 
 
Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., 
Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995). The transmembrane form of tumor 
necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 
793-802. 
 
Gridelli, C., De Marinis, F., Di Maio, M., Cortinovis, D., Cappuzzo, F., and Mok, T. (2011). 
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with 
activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 71, 
249-257. 
 
Griendling, K.K., Minieri, C.A., Ollerenshaw, J.D., and Alexander, R.W. (1994). Angiotensin II 
stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. 
Circulation research 74, 1141-1148. 
 
Gross, A., McDonnell, J.M., and Korsmeyer, S.J. (1999). BCL-2 family members and the 




Guinea Viniegra, J., Hernandez Losa, J., Sanchez-Arevalo, V.J., Parada Cobo, C., Fernandez 
Soria, V.M., Ramon y Cajal, S., and Sanchez-Prieto, R. (2002). Modulation of PI3K/Akt pathway 
by E1a mediates sensitivity to cisplatin. Oncogene 21, 7131-7136. 
 
Guseva, N.V., Rokhlin, O.W., Taghiyev, A.F., and Cohen, M.B. (2008). Unique resistance of 
breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L). Breast 
Cancer Res Treat 107, 349-357. 
 
Haddad, J.J. (2004). Redox and oxidant-mediated regulation of apoptosis signaling pathways: 
immuno-pharmaco-redox conception of oxidative siege versus cell death commitment. 
International immunopharmacology 4, 475-493. 
 
Hakem, R., Hakem, A., Duncan, G.S., Henderson, J.T., Woo, M., Soengas, M.S., Elia, A., de la 
Pompa, J.L., Kagi, D., Khoo, W., et al. (1998). Differential requirement for caspase 9 in apoptotic 
pathways in vivo. Cell 94, 339-352. 
 
Haldar, S., Negrini, M., Monne, M., Sabbioni, S., and Croce, C.M. (1994). Down-regulation of 
bcl-2 by p53 in breast cancer cells. Cancer research 54, 2095-2097. 
 
Halliwell, B. (1991). Reactive oxygen species in living systems: source, biochemistry, and role in 
human disease. The American journal of medicine 91, 14S-22S. 
 
Halliwell, B. (2006). Reactive species and antioxidants. Redox biology is a fundamental theme of 
aerobic life. Plant physiology 141, 312-322. 
 
Halliwell, B. (2007). Oxidative stress and cancer: have we moved forward? The Biochemical 
journal 401, 1-11. 
 
Halliwell, B., and Gutteridge, J.M. (1984). Oxygen toxicity, oxygen radicals, transition metals and 
disease. The Biochemical journal 219, 1-14. 
 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-
674. 
 
Hande, K.R. (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J 
Cancer 34, 1514-1521. 
 
Hannemann, J., and Baumann, K. (1988). Cisplatin-induced lipid peroxidation and decrease of 
gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. 
Toxicology 51, 119-132. 
 
Hao, X.Y., Bergh, J., Brodin, O., Hellman, U., and Mannervik, B. (1994). Acquired resistance to 
cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of 
glutathione-linked detoxification enzymes. Carcinogenesis 15, 1167-1173. 
 
Harder, T., and Simons, K. (1997). Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol 
microdomains. Current opinion in cell biology 9, 534-542. 
 
Harper, M.E., Antoniou, A., Villalobos-Menuey, E., Russo, A., Trauger, R., Vendemelio, M., 
George, A., Bartholomew, R., Carlo, D., Shaikh, A., et al. (2002). Characterization of a novel 
metabolic strategy used by drug-resistant tumor cells. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology 16, 1550-1557. 
 
Haslehurst, A.M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., Childs, T., Chen, J., Li, J., 
Weberpals, J., et al. (2012). EMT transcription factors snail and slug directly contribute to cisplatin 
resistance in ovarian cancer. BMC cancer 12, 91. 
 
Hatefi, Y. (1985). The mitochondrial electron transport and oxidative phosphorylation system. 




Haupt, S., Berger, M., Goldberg, Z., and Haupt, Y. (2003). Apoptosis - the p53 network. Journal of 
cell science 116, 4077-4085. 
 
Hay, B.A. (2000). Understanding IAP function and regulation: a view from Drosophila. Cell death 
and differentiation 7, 1045-1056. 
 
Hayden, M.A., Lange, P.A., and Nakayama, D.K. (2001). Nitric oxide and cyclic guanosine 
monophosphate stimulate apoptosis via activation of the Fas-FasL pathway. The Journal of 
surgical research 101, 183-189. 
 
Hayes, J.D., and Pulford, D.J. (1995). The glutathione S-transferase supergene family: regulation 
of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. 
Critical reviews in biochemistry and molecular biology 30, 445-600. 
 
He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., and Wang, X. (2009). Receptor interacting 
protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137, 1100-1111. 
 
Herrera, B., Alvarez, A.M., Sanchez, A., Fernandez, M., Roncero, C., Benito, M., and Fabregat, I. 
(2001). Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced 
by transforming growth factor (beta) in fetal hepatocytes. FASEB journal : official publication of 
the Federation of American Societies for Experimental Biology 15, 741-751. 
 
Hertel, L.W., Boder, G.B., Kroin, J.S., Rinzel, S.M., Poore, G.A., Todd, G.C., and Grindey, G.B. 
(1990). Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). 
Cancer research 50, 4417-4422. 
 
Hirama, M., Isonishi, S., Yasuda, M., and Ishikawa, H. (2006). Characterization of mitochondria in 
cisplatin-resistant human ovarian carcinoma cells. Oncology reports 16, 997-1002. 
 
Holcik, M., and Sonenberg, N. (2005). Translational control in stress and apoptosis. Nature 
reviews Molecular cell biology 6, 318-327. 
 
Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J.L., Schneider, 
P., Seed, B., and Tschopp, J. (2000). Fas triggers an alternative, caspase-8-independent cell death 
pathway using the kinase RIP as effector molecule. Nature immunology 1, 489-495. 
 
Hollstein, M., Rice, K., Greenblatt, M.S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-
Sorensen, B., Montesano, R., and Harris, C.C. (1994). Database of p53 gene somatic mutations in 
human tumors and cell lines. Nucleic acids research 22, 3551-3555. 
 
Holmgren, A. (1995). Thioredoxin structure and mechanism: conformational changes on oxidation 
of the active-site sulfhydryls to a disulfide. Structure 3, 239-243. 
 
Holmgren, A., and Bjornstedt, M. (1995). Thioredoxin and thioredoxin reductase. Methods in 
enzymology 252, 199-208. 
 
Hopkins-Donaldson, S., Ziegler, A., Kurtz, S., Bigosch, C., Kandioler, D., Ludwig, C., 
Zangemeister-Wittke, U., and Stahel, R. (2003). Silencing of death receptor and caspase-8 
expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell death and 
differentiation 10, 356-364. 
 
Horak, P., Pils, D., Haller, G., Pribill, I., Roessler, M., Tomek, S., Horvat, R., Zeillinger, R., 
Zielinski, C., and Krainer, M. (2005a). Contribution of epigenetic silencing of tumor necrosis 
factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. 
Molecular cancer research : MCR 3, 335-343. 
 
Horak, P., Pils, D., Kaider, A., Pinter, A., Elandt, K., Sax, C., Zielinski, C.C., Horvat, R., 
Zeillinger, R., Reinthaller, A., et al. (2005b). Perturbation of the tumor necrosis factor--related 
apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of 
210 
 
the functional receptors DR4 and DR5. Clinical cancer research : an official journal of the 
American Association for Cancer Research 11, 8585-8591. 
 
Horvitz, H.R. (1999). Genetic control of programmed cell death in the nematode Caenorhabditis 
elegans. Cancer research 59, 1701s-1706s. 
 
Hotte, S.J., Hirte, H.W., Chen, E.X., Siu, L.L., Le, L.H., Corey, A., Iacobucci, A., MacLean, M., 
Lo, L., Fox, N.L., et al. (2008). A phase 1 study of mapatumumab (fully human monoclonal 
antibody to TRAIL-R1) in patients with advanced solid malignancies. Clinical cancer research : an 
official journal of the American Association for Cancer Research 14, 3450-3455. 
 
Hsu, H., Shu, H.B., Pan, M.G., and Goeddel, D.V. (1996). TRADD-TRAF2 and TRADD-FADD 
interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84, 299-308. 
 
Huang, C.R., Jin, Z.X., Dong, L., Tong, X.P., Yue, S., Kawanami, T., Sawaki, T., Sakai, T., Miki, 
M., Iwao, H., et al. (2010). Cisplatin augments FAS-mediated apoptosis through lipid rafts. 
Anticancer research 30, 2065-2071. 
 
Huang, C.S., Chang, L.S., Anderson, M.E., and Meister, A. (1993). Catalytic and regulatory 
properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. The Journal of 
biological chemistry 268, 19675-19680. 
 
Huang, J.C., Zamble, D.B., Reardon, J.T., Lippard, S.J., and Sancar, A. (1994). HMG-domain 
proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by 
human excision nuclease. Proceedings of the National Academy of Sciences of the United States 
of America 91, 10394-10398. 
 
Huang, P., Chubb, S., Hertel, L.W., Grindey, G.B., and Plunkett, W. (1991). Action of 2',2'-
difluorodeoxycytidine on DNA synthesis. Cancer research 51, 6110-6117. 
 
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.L., 
Schroter, M., Burns, K., Mattmann, C., et al. (1997). Inhibition of death receptor signals by 
cellular FLIP. Nature 388, 190-195. 
 
Ishida, S., Lee, J., Thiele, D.J., and Herskowitz, I. (2002). Uptake of the anticancer drug cisplatin 
mediated by the copper transporter Ctr1 in yeast and mammals. Proceedings of the National 
Academy of Sciences of the United States of America 99, 14298-14302. 
 
Ishikawa, T. (1992). The ATP-dependent glutathione S-conjugate export pump. Trends in 
biochemical sciences 17, 463-468. 
 
Isonishi, S., Saitou, M., Yasuda, M., and Tanaka, T. (2001). Mitochondria in platinum resistant 
cells. Human cell 14, 203-210. 
 
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y., 
and Nagata, S. (1991). The polypeptide encoded by the cDNA for human cell surface antigen Fas 
can mediate apoptosis. Cell 66, 233-243. 
 
Jacobson, M.D., Weil, M., and Raff, M.C. (1997). Programmed cell death in animal development. 
Cell 88, 347-354. 
 
Jamieson, E.R., and Lippard, S.J. (1999). Structure, Recognition, and Processing of Cisplatin-DNA 
Adducts. Chemical reviews 99, 2467-2498. 
 
Jedlitschky, G., Leier, I., Buchholz, U., Center, M., and Keppler, D. (1994). ATP-dependent 
transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer 
research 54, 4833-4836. 
 
Jensen, M.P., and Riley, D.P. (2002). Peroxynitrite decomposition activity of iron porphyrin 




Jezek, P., and Hlavata, L. (2005). Mitochondria in homeostasis of reactive oxygen species in cell, 
tissues, and organism. The international journal of biochemistry & cell biology 37, 2478-2503. 
 
Jin, C.Y., Moon, D.O., Lee, J.D., Heo, M.S., Choi, Y.H., Lee, C.M., Park, Y.M., and Kim, G.Y. 
(2007). Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated 
apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells. 
Carcinogenesis 28, 1058-1066. 
 
Jin, Z., McDonald, E.R., 3rd, Dicker, D.T., and El-Deiry, W.S. (2004). Deficient tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in 
human colon cancer cells selected for resistance to TRAIL-induced apoptosis. The Journal of 
biological chemistry 279, 35829-35839. 
 
Johnson DH, B.W., Carbone DP, et al. (2008). Cancer of the lung: non-small cell lung cancer and 
small cell lung cancer., Vol chap 76 (Churchill Livingstone Elsevier). 
 
Johnson, D.H., Fehrenbacher, L., Novotny, W.F., Herbst, R.S., Nemunaitis, J.J., Jablons, D.M., 
Langer, C.J., DeVore, R.F., 3rd, Gaudreault, J., Damico, L.A., et al. (2004). Randomized phase II 
trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone 
in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 22, 2184-2191. 
 
Johnson, S.W., Laub, P.B., Beesley, J.S., Ozols, R.F., and Hamilton, T.C. (1997). Increased 
platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to 
various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer research 57, 
850-856. 
Jones, M., Siracky, J., Kelland, L.R., and Harrap, K.R. (1993). Acquisition of platinum drug 
resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma 
xenografts. British journal of cancer 67, 24-29. 
 
Joza, N., Susin, S.A., Daugas, E., Stanford, W.L., Cho, S.K., Li, C.Y., Sasaki, T., Elia, A.J., 
Cheng, H.Y., Ravagnan, L., et al. (2001). Essential role of the mitochondrial apoptosis-inducing 
factor in programmed cell death. Nature 410, 549-554. 
 
Kaiser, W.J., Upton, J.W., Long, A.B., Livingston-Rosanoff, D., Daley-Bauer, L.P., Hakem, R., 
Caspary, T., and Mocarski, E.S. (2011). RIP3 mediates the embryonic lethality of caspase-8-
deficient mice. Nature 471, 368-372. 
 
Kallio, M.J., Nieminen, M., and Eriksson, J.E. (2001). Human inhibitor of apoptosis protein (IAP) 
survivin participates in regulation of chromosome segregation and mitotic exit. FASEB journal : 
official publication of the Federation of American Societies for Experimental Biology 15, 2721-
2723. 
 
Kang, J., Bu, J., Hao, Y., and Chen, F. (2005). Subtoxic concentration of doxorubicin enhances 
TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis 
8, 274-279. 
 
Kanzawa, F., Hoshi, A., and Kuretani, K. (1980). Mechanism of cytotoxicity of 5-fluorouracil: 
distinction between the irreversible cytotoxic effect of 5-fluorouridine and the reversible cytotoxic 
effect of 5-fluoro-2'-deoxyuridine on murine lymphoma L5178Y cells in culture. Journal of cancer 
research and clinical oncology 98, 85-90. 
 
Kataoka, T., Budd, R.C., Holler, N., Thome, M., Martinon, F., Irmler, M., Burns, K., Hahne, M., 
Kennedy, N., Kovacsovics, M., et al. (2000). The caspase-8 inhibitor FLIP promotes activation of 
NF-kappaB and Erk signaling pathways. Curr Biol 10, 640-648. 
 
Katayama, H., Sasai, K., Kawai, H., Yuan, Z.M., Bondaruk, J., Suzuki, F., Fujii, S., Arlinghaus, 
R.B., Czerniak, B.A., and Sen, S. (2004). Phosphorylation by aurora kinase A induces Mdm2-




Katsikis, P.D., Wunderlich, E.S., Smith, C.A., and Herzenberg, L.A. (1995). Fas antigen 
stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-
infected individuals. The Journal of experimental medicine 181, 2029-2036. 
 
Kazhdan, I., and Marciniak, R.A. (2004). Death receptor 4 (DR4) efficiently kills breast cancer 
cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL). Cancer gene therapy 11, 691-698. 
 
Kelland, L. (2007a). Broadening the clinical use of platinum drug-based chemotherapy with new 
analogues. Satraplatin and picoplatin. Expert opinion on investigational drugs 16, 1009-1021. 
 
Kelland, L. (2007b). The resurgence of platinum-based cancer chemotherapy. Nature reviews 
Cancer 7, 573-584. 
 
Kerr, J.F., Wyllie, A.H., and Currie, A.R. (1972). Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics. British journal of cancer 26, 239-257. 
 
Kidani, A., Izumi, H., Yoshida, Y., Kashiwagi, E., Ohmori, H., Tanaka, T., Kuwano, M., and 
Kohno, K. (2009). Thioredoxin2 enhances the damaged DNA binding activity of mtTFA through 
direct interaction. International journal of oncology 35, 1435-1440. 
 
Kilsdonk, E.P., Yancey, P.G., Stoudt, G.W., Bangerter, F.W., Johnson, W.J., Phillips, M.C., and 
Rothblat, G.H. (1995). Cellular cholesterol efflux mediated by cyclodextrins. The Journal of 
biological chemistry 270, 17250-17256. 
 
Kim, H., Tu, H.C., Ren, D., Takeuchi, O., Jeffers, J.R., Zambetti, G.P., Hsieh, J.J., and Cheng, 
E.H. (2009). Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates 
mitochondrial apoptosis. Molecular cell 36, 487-499. 
 
Kim, K., Fisher, M.J., Xu, S.Q., and el-Deiry, W.S. (2000). Molecular determinants of response to 
TRAIL in killing of normal and cancer cells. Clinical cancer research : an official journal of the 
American Association for Cancer Research 6, 335-346. 
 
Kim, Y.S., Morgan, M.J., Choksi, S., and Liu, Z.G. (2007). TNF-induced activation of the Nox1 
NADPH oxidase and its role in the induction of necrotic cell death. Molecular cell 26, 675-687. 
 
Klionsky, D.J., and Ohsumi, Y. (1999). Vacuolar import of proteins and organelles from the 
cytoplasm. Annual review of cell and developmental biology 15, 1-32. 
 
Kojima, H., Urano, Y., Kikuchi, K., Higuchi, T., Hirata, Y., and Nagano, T. (1999).  
 
Fluorescent Indicators for Imaging Nitric Oxide Production. Angew Chem Int Ed Engl 38, 3209-
3212. 
 
Komatsu, M., Waguri, S., Koike, M., Sou, Y.S., Ueno, T., Hara, T., Mizushima, N., Iwata, J., 
Ezaki, J., Murata, S., et al. (2007). Homeostatic levels of p62 control cytoplasmic inclusion body 
formation in autophagy-deficient mice. Cell 131, 1149-1163. 
 
Kondo, K., Yamasaki, S., Inoue, N., Sugie, T., Teratani, N., Kan, T., and Shimada, Y. (2006a). 
Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. Surgery today 
36, 966-974. 
 
Kondo, K., Yamasaki, S., Sugie, T., Teratani, N., Kan, T., Imamura, M., and Shimada, Y. (2006b). 
Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by 
TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. International 




Koopman, G., Reutelingsperger, C.P., Kuijten, G.A., Keehnen, R.M., Pals, S.T., and van Oers, 
M.H. (1994). Annexin V for flow cytometric detection of phosphatidylserine expression on B cells 
undergoing apoptosis. Blood 84, 1415-1420. 
 
Koschny, R., Walczak, H., and Ganten, T.M. (2007). The promise of TRAIL--potential and risks 
of a novel anticancer therapy. J Mol Med (Berl) 85, 923-935. 
 
Kroemer, G., Dallaporta, B., and Resche-Rigon, M. (1998). The mitochondrial death/life regulator 
in apoptosis and necrosis. Annual review of physiology 60, 619-642. 
 
Kroemer, G., and Levine, B. (2008). Autophagic cell death: the story of a misnomer. Nature 
reviews Molecular cell biology 9, 1004-1010. 
 
Kroemer, G., and Pouyssegur, J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer 
cell 13, 472-482. 
 
Kuida, K., Zheng, T.S., Na, S., Kuan, C., Yang, D., Karasuyama, H., Rakic, P., and Flavell, R.A. 
(1996). Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 
384, 368-372. 
 
Kurbanov, B.M., Geilen, C.C., Fecker, L.F., Orfanos, C.E., and Eberle, J. (2005). Efficient 
TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL). The Journal of investigative dermatology 125, 1010-1019. 
 
Kuwana, T., Mackey, M.R., Perkins, G., Ellisman, M.H., Latterich, M., Schneiter, R., Green, D.R., 
and Newmeyer, D.D. (2002). Bid, Bax, and lipids cooperate to form supramolecular openings in 
the outer mitochondrial membrane. Cell 111, 331-342. 
 
Lacour, S., Hammann, A., Grazide, S., Lagadic-Gossmann, D., Athias, A., Sergent, O., Laurent, 
G., Gambert, P., Solary, E., and Dimanche-Boitrel, M.T. (2004). Cisplatin-induced CD95 
redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer research 64, 
3593-3598. 
 
Lassen, U., Osterlind, K., Hansen, M., Dombernowsky, P., Bergman, B., and Hansen, H.H. (1995). 
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 
to 18+ years--an analysis of 1,714 consecutive patients. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 13, 1215-1220. 
 
LeBlanc, H.N., and Ashkenazi, A. (2003). Apo2L/TRAIL and its death and decoy receptors. Cell 
death and differentiation 10, 66-75. 
 
Lee, M.W., Park, S.C., Kim, J.H., Kim, I.K., Han, K.S., Kim, K.Y., Lee, W.B., Jung, Y.K., and 
Kim, S.S. (2002). The involvement of oxidative stress in tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL)-induced apoptosis in HeLa cells. Cancer letters 182, 75-82. 
 
Lee, S.H., Shin, M.S., Kim, H.S., Lee, H.K., Park, W.S., Kim, S.Y., Lee, J.H., Han, S.Y., Park, 
J.Y., Oh, R.R., et al. (1999). Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung 
cancers. Cancer research 59, 5683-5686. 
 
Lee, T.J., Lee, J.T., Park, J.W., and Kwon, T.K. (2006). Acquired TRAIL resistance in human 
breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK 
activation. Biochem Biophys Res Commun 351, 1024-1030. 
 
Lee, Y.J., Lee, K.H., Kim, H.R., Jessup, J.M., Seol, D.W., Kim, T.H., Billiar, T.R., and Song, Y.K. 
(2001). Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent 
pathway in human colorectal carcinoma CX-1 cells. Oncogene 20, 1476-1485 
 
Letai, A., Bassik, M.C., Walensky, L.D., Sorcinelli, M.D., Weiler, S., and Korsmeyer, S.J. (2002). 
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype 




Levine, B., and Klionsky, D.J. (2004). Development by self-digestion: molecular mechanisms and 
biological functions of autophagy. Developmental cell 6, 463-477. 
 
Levkau, B., Herren, B., Koyama, H., Ross, R., and Raines, E.W. (1998). Caspase-mediated 
cleavage of focal adhesion kinase pp125FAK and disassembly of focal adhesions in human 
endothelial cell apoptosis. The Journal of experimental medicine 187, 579-586. 
Li, F., Ackermann, E.J., Bennett, C.F., Rothermel, A.L., Plescia, J., Tognin, S., Villa, A., 
Marchisio, P.C., and Altieri, D.C. (1999). Pleiotropic cell-division defects and apoptosis induced 
by interference with survivin function. Nature cell biology 1, 461-466. 
 
Li, H., Zhu, H., Xu, C.J., and Yuan, J. (1998a). Cleavage of BID by caspase 8 mediates the 
mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501. 
 
Li, Y., Zhu, H., Kuppusamy, P., Roubaud, V., Zweier, J.L., and Trush, M.A. (1998b). Validation 
of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion 
radical production by enzymatic and cellular systems. The Journal of biological chemistry 273, 
2015-2023. 
 
Li, Y.C., Park, M.J., Ye, S.K., Kim, C.W., and Kim, Y.N. (2006). Elevated levels of cholesterol-
rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-
depleting agents. The American journal of pathology 168, 1107-1118; quiz 1404-1105. 
 
Liang, X.J., Mukherjee, S., Shen, D.W., Maxfield, F.R., and Gottesman, M.M. (2006). Endocytic 
recycling compartments altered in cisplatin-resistant cancer cells. Cancer research 66, 2346-2353. 
 
Liang, X.J., Shen, D.W., Garfield, S., and Gottesman, M.M. (2003). Mislocalization of membrane 
proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer 
research 63, 5909-5916. 
 
Lieberthal, W., Triaca, V., and Levine, J. (1996). Mechanisms of death induced by cisplatin in 
proximal tubular epithelial cells: apoptosis vs. necrosis. The American journal of physiology 270, 
F700-708. 
 
Lin, Y., Choksi, S., Shen, H.M., Yang, Q.F., Hur, G.M., Kim, Y.S., Tran, J.H., Nedospasov, S.A., 
and Liu, Z.G. (2004). Tumor necrosis factor-induced nonapoptotic cell death requires receptor-
interacting protein-mediated cellular reactive oxygen species accumulation. The Journal of 
biological chemistry 279, 10822-10828. 
 
Lin, Y., Wang, Z., Liu, L., and Chen, L. (2011). Akt is the downstream target of GRP78 in 
mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. Lung Cancer 71, 291-
297. 
 
Liochev, S.I., and Fridovich, I. (1999). Superoxide and iron: partners in crime. IUBMB life 48, 
157-161. 
 
Liu, T., Brouha, B., and Grossman, D. (2004). Rapid induction of mitochondrial events and 
caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 23, 39-48. 
 
Liu, X., Kim, C.N., Yang, J., Jemmerson, R., and Wang, X. (1996a). Induction of apoptotic 
program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86, 147-157. 
 
Liu, Z.G., Hsu, H., Goeddel, D.V., and Karin, M. (1996b). Dissection of TNF receptor 1 effector 
functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell 
death. Cell 87, 565-576. 
 
Loe, D.W., Deeley, R.G., and Cole, S.P. (1998). Characterization of vincristine transport by the 
M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced 




Lopez-Rios, F., Sanchez-Arago, M., Garcia-Garcia, E., Ortega, A.D., Berrendero, J.R., Pozo-
Rodriguez, F., Lopez-Encuentra, A., Ballestin, C., and Cuezva, J.M. (2007). Loss of the 
mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer research 
67, 9013-9017. 
 
Lowe, S.W., and Lin, A.W. (2000). Apoptosis in cancer. Carcinogenesis 21, 485-495. 
 
Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. (1993). p53-dependent apoptosis 
modulates the cytotoxicity of anticancer agents. Cell 74, 957-967. 
 
Lum, J.J., DeBerardinis, R.J., and Thompson, C.B. (2005). Autophagy in metazoans: cell survival 
in the land of plenty. Nature reviews Molecular cell biology 6, 439-448. 
 
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998). Bid, a Bcl2 interacting 
protein, mediates cytochrome c release from mitochondria in response to activation of cell surface 
death receptors. Cell 94, 481-490. 
 
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., 
Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. (2004). Activating mutations in the 
epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to 
gefitinib. The New England journal of medicine 350, 2129-2139. 
 
Majno, G., and Joris, I. (1995). Apoptosis, oncosis, and necrosis. An overview of cell death. The 
American journal of pathology 146, 3-15. 
 
Mandic, A., Hansson, J., Linder, S., and Shoshan, M.C. (2003). Cisplatin induces endoplasmic 
reticulum stress and nucleus-independent apoptotic signaling. The Journal of biological chemistry 
278, 9100-9106. 
 
Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., 
Zhang, C.C., Shipitsin, M., et al. (2008). The epithelial-mesenchymal transition generates cells 
with properties of stem cells. Cell 133, 704-715. 
 
Mansouri, A., Zhang, Q., Ridgway, L.D., Tian, L., and Claret, F.X. (2003). Cisplatin resistance in 
an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP 
regulation. Oncology research 13, 399-404. 
 
Marchetti, P., Castedo, M., Susin, S.A., Zamzami, N., Hirsch, T., Macho, A., Haeffner, A., Hirsch, 
F., Geuskens, M., and Kroemer, G. (1996). Mitochondrial permeability transition is a central 
coordinating event of apoptosis. The Journal of experimental medicine 184, 1155-1160. 
 
Marini, P., Schmid, A., Jendrossek, V., Faltin, H., Daniel, P.T., Budach, W., and Belka, C. (2005). 
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC 
cancer 5, 5. 
 
Marletta, M.A. (1994). Nitric oxide synthase: aspects concerning structure and catalysis. Cell 78, 
927-930. 
 
Marsters, S.A., Sheridan, J.P., Pitti, R.M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., 
Gurney, A., Goddard, A.D., Godowski, P., et al. (1997). A novel receptor for Apo2L/TRAIL 
contains a truncated death domain. Curr Biol 7, 1003-1006. 
 
Matata, B.M., and Galinanes, M. (2002). Peroxynitrite is an essential component of cytokines 
production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA 
binding activity. The Journal of biological chemistry 277, 2330-2335. 
 
Matsumura, H., Shimizu, Y., Ohsawa, Y., Kawahara, A., Uchiyama, Y., and Nagata, S. (2000). 




Meijer, C., Mulder, N.H., Hospers, G.A., Uges, D.R., and de Vries, E.G. (1990). The role of 
glutathione in resistance to cisplatin in a human small cell lung cancer cell line. British journal of 
cancer 62, 72-77. 
 
Meister, A. (1988). Glutathione metabolism and its selective modification. The Journal of 
biological chemistry 263, 17205-17208. 
 
Merino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., and Micheau, O. (2006). 
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol 
Cell Biol 26, 7046-7055. 
 
Meyerson, M., Franklin, W.A., and Kelley, M.J. (2004). Molecular classification and molecular 
genetics of human lung cancers. Seminars in oncology 31, 4-19. 
 
Micheau, O., and Tschopp, J. (2003). Induction of TNF receptor I-mediated apoptosis via two 
sequential signaling complexes. Cell 114, 181-190. 
 
Mini, E., Nobili, S., Caciagli, B., Landini, I., and Mazzei, T. (2006). Cellular pharmacology of 
gemcitabine. Annals of oncology : official journal of the European Society for Medical Oncology / 
ESMO 17 Suppl 5, v7-12. 
 
Minkenberg, I., and Ferber, E. (1984). Lucigenin-dependent chemiluminescence as a new assay for 
NAD(P)H-oxidase activity in particulate fractions of human polymorphonuclear leukocytes. 
Journal of immunological methods 71, 61-67. 
 
Misko, T.P., Highkin, M.K., Veenhuizen, A.W., Manning, P.T., Stern, M.K., Currie, M.G., and 
Salvemini, D. (1998). Characterization of the cytoprotective action of peroxynitrite decomposition 
catalysts. The Journal of biological chemistry 273, 15646-15653. 
 
Mitsiades, N., Mitsiades, C.S., Poulaki, V., Anderson, K.C., and Treon, S.P. (2002). Intracellular 
regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human 
multiple myeloma cells. Blood 99, 2162-2171. 
 
Miyajima, A., Nakashima, J., Yoshioka, K., Tachibana, M., Tazaki, H., and Murai, M. (1997). 
Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder 
cancer cells. British journal of cancer 76, 206-210. 
 
Mizushima, N., and Klionsky, D.J. (2007). Protein turnover via autophagy: implications for 
metabolism. Annual review of nutrition 27, 19-40. 
 
Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, 
B., Margono, B., Ichinose, Y., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary 
adenocarcinoma. The New England journal of medicine 361, 947-957. 
 
Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E., and Adjei, A.A. (2008). Non-small cell lung 
cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic proceedings Mayo 
Clinic 83, 584-594. 
 
More, S.S., Li, S., Yee, S.W., Chen, L., Xu, Z., Jablons, D.M., and Giacomini, K.M. (2010). 
Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation 
platinum analogue. Molecular cancer therapeutics 9, 1058-1069. 
 
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. Journal of immunological methods 65, 55-63. 
 
Mucha, S.R., Rizzani, A., Gerbes, A.L., Camaj, P., Thasler, W.E., Bruns, C.J., Eichhorst, S.T., 
Gallmeier, E., Kolligs, F.T., Goke, B., et al. (2009). JNK inhibition sensitises hepatocellular 





Mukhopadhyay, P., Rajesh, M., Yoshihiro, K., Hasko, G., and Pacher, P. (2007). Simple 
quantitative detection of mitochondrial superoxide production in live cells. Biochemical and 
biophysical research communications 358, 203-208. 
 
Muller, M., Strand, S., Hug, H., Heinemann, E.M., Walczak, H., Hofmann, W.J., Stremmel, W., 
Krammer, P.H., and Galle, P.R. (1997). Drug-induced apoptosis in hepatoma cells is mediated by 
the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. The 
Journal of clinical investigation 99, 403-413. 
 
Muppidi, J.R., and Siegel, R.M. (2004). Ligand-independent redistribution of Fas (CD95) into 
lipid rafts mediates clonotypic T cell death. Nature immunology 5, 182-189. 
 
Muppidi, J.R., Tschopp, J., and Siegel, R.M. (2004). Life and death decisions: secondary 
complexes and lipid rafts in TNF receptor family signal transduction. Immunity 21, 461-465. 
 
Murphy, M.P., Holmgren, A., Larsson, N.G., Halliwell, B., Chang, C.J., Kalyanaraman, B., Rhee, 
S.G., Thornalley, P.J., Partridge, L., Gems, D., et al. (2011). Unraveling the biological roles of 
reactive oxygen species. Cell metabolism 13, 361-366. 
 
Muzio, M., Stockwell, B.R., Stennicke, H.R., Salvesen, G.S., and Dixit, V.M. (1998). An induced 
proximity model for caspase-8 activation. The Journal of biological chemistry 273, 2926-2930. 
 
Myhre, O., Andersen, J.M., Aarnes, H., and Fonnum, F. (2003). Evaluation of the probes 2',7'-
dichlorofluorescin diacetate, luminol, and lucigenin as indicators of reactive species formation. 
Biochemical pharmacology 65, 1575-1582. 
 
Nachmias, B., Ashhab, Y., Bucholtz, V., Drize, O., Kadouri, L., Lotem, M., Peretz, T., 
Mandelboim, O., and Ben-Yehuda, D. (2003). Caspase-mediated cleavage converts Livin from an 
antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer research 
63, 6340-6349. 
 
Nagata, S. (1994). Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. 
Philosophical transactions of the Royal Society of London Series B, Biological sciences 345, 281-
287. 
 
Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355-365. 
 
Nagata, S., and Golstein, P. (1995). The Fas death factor. Science 267, 1449-1456 
 
Nakano, S., and Gemba, M. (1989). Potentiation of cisplatin-induced lipid peroxidation in kidney 
cortical slices by glutathione depletion. Japanese journal of pharmacology 50, 87-92. 
 
Neill, S., Desikan, R., and Hancock, J. (2002). Hydrogen peroxide signalling. Current opinion in 
plant biology 5, 388-395. 
 
Ng, T.P. (1994). Silica and lung cancer: a continuing controversy. Annals of the Academy of 
Medicine, Singapore 23, 752-755. 
 
Nicholson, D.W. (1999). Caspase structure, proteolytic substrates, and function during apoptotic 
cell death. Cell death and differentiation 6, 1028-1042. 
 
Nicholson, D.W., and Thornberry, N.A. (1997). Caspases: killer proteases. Trends in biochemical 
sciences 22, 299-306. 
 
Oberst, A., Dillon, C.P., Weinlich, R., McCormick, L.L., Fitzgerald, P., Pop, C., Hakem, R., 
Salvesen, G.S., and Green, D.R. (2011). Catalytic activity of the caspase-8-FLIP(L) complex 




Oltvai, Z.N., Milliman, C.L., and Korsmeyer, S.J. (1993). Bcl-2 heterodimerizes in vivo with a 
conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619. 
 
Ono, K., Wang, X., Kim, S.O., Armstrong, L.C., Bornstein, P., and Han, J. (2010). Metaxin 
deficiency alters mitochondrial membrane permeability and leads to resistance to TNF-induced 
cell killing. Protein & cell 1, 161-173. 
 
Opferman, J.T., Letai, A., Beard, C., Sorcinelli, M.D., Ong, C.C., and Korsmeyer, S.J. (2003). 
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 
671-676. 
 
Orth, K., Chinnaiyan, A.M., Garg, M., Froelich, C.J., and Dixit, V.M. (1996). The CED-3/ICE-like 
protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. The Journal 
of biological chemistry 271, 16443-16446. 
 
Oshita, F., and Eastman, A. (1993). Gene-specific damage produced by cisplatin, ormaplatin and 
UV light in human cells as assayed by the polymerase chain reaction. Oncology research 5, 111-
118. 
 
Pacher, P., Beckman, J.S., and Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and 
disease. Physiological reviews 87, 315-424. 
 
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., 
Lindeman, N., Boggon, T.J., et al. (2004). EGFR mutations in lung cancer: correlation with 
clinical response to gefitinib therapy. Science 304, 1497-1500. 
 
Pai, E.F., and Schulz, G.E. (1983). The catalytic mechanism of glutathione reductase as derived 
from x-ray diffraction analyses of reaction intermediates. The Journal of biological chemistry 258, 
1752-1757. 
 
Pai, S.I., Wu, G.S., Ozoren, N., Wu, L., Jen, J., Sidransky, D., and El-Deiry, W.S. (1998). Rare 
loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer research 58, 
3513-3518. 
 
Pan, G., O'Rourke, K., Chinnaiyan, A.M., Gentz, R., Ebner, R., Ni, J., and Dixit, V.M. (1997). The 
receptor for the cytotoxic ligand TRAIL. Science 276, 111-113. 
 
Pankiv, S., Clausen, T.H., Lamark, T., Brech, A., Bruun, J.A., Outzen, H., Overvatn, A., Bjorkoy, 
G., and Johansen, T. (2007). p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of 
ubiquitinated protein aggregates by autophagy. The Journal of biological chemistry 282, 24131-
24145. 
 
Panner, A., James, C.D., Berger, M.S., and Pieper, R.O. (2005). mTOR controls FLIPS translation 
and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25, 8809-8823. 
 
Peng, D.J., Wang, J., Zhou, J.Y., and Wu, G.S. (2010). Role of the Akt/mTOR survival pathway in 
cisplatin resistance in ovarian cancer cells. Biochemical and biophysical research communications 
394, 600-605. 
 
Perciavalle, R.M., Stewart, D.P., Koss, B., Lynch, J., Milasta, S., Bathina, M., Temirov, J., 
Cleland, M.M., Pelletier, S., Schuetz, J.D., et al. (2012). Anti-apoptotic MCL-1 localizes to the 
mitochondrial matrix and couples mitochondrial fusion to respiration. Nature cell biology 14, 575-
583. 
 
Perego, P., Giarola, M., Righetti, S.C., Supino, R., Caserini, C., Delia, D., Pierotti, M.A., 
Miyashita, T., Reed, J.C., and Zunino, F. (1996). Association between cisplatin resistance and 
mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer 




Perego, P., Righetti, S.C., Supino, R., Delia, D., Caserini, C., Carenini, N., Bedogne, B., Broome, 
E., Krajewski, S., Reed, J.C., et al. (1997). Role of apoptosis and apoptosis-related proteins in the 
cisplatin-resistant phenotype of human tumor cell lines. Apoptosis : an international journal on 
programmed cell death 2, 540-548. 
 
Persons, D.L., Yazlovitskaya, E.M., and Pelling, J.C. (2000). Effect of extracellular signal-
regulated kinase on p53 accumulation in response to cisplatin. The Journal of biological chemistry 
275, 35778-35785. 
 
Phares, T.W., Fabis, M.J., Brimer, C.M., Kean, R.B., and Hooper, D.C. (2007). A peroxynitrite-
dependent pathway is responsible for blood-brain barrier permeability changes during a central 
nervous system inflammatory response: TNF-alpha is neither necessary nor sufficient. J Immunol 
178, 7334-7343. 
 
Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., 
Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005). Trastuzumab after adjuvant 
chemotherapy in HER2-positive breast cancer. The New England journal of medicine 353, 1659-
1672. 
 
Pierce, G.B., Parchment, R.E., and Lewellyn, A.L. (1991). Hydrogen peroxide as a mediator of 
programmed cell death in the blastocyst. Differentiation; research in biological diversity 46, 181-
186. 
 
Pitti, R.M., Marsters, S.A., Ruppert, S., Donahue, C.J., Moore, A., and Ashkenazi, A. (1996). 
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine 
family. The Journal of biological chemistry 271, 12687-12690. 
 
Poh, T.W., Huang, S., Hirpara, J.L., and Pervaiz, S. (2007). LY303511 amplifies TRAIL-induced 
apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial 
permeabilization. Cell death and differentiation 14, 1813-1825. 
 
Portilla, D., Li, S., Nagothu, K.K., Megyesi, J., Kaissling, B., Schnackenberg, L., Safirstein, R.L., 
and Beger, R.D. (2006). Metabolomic study of cisplatin-induced nephrotoxicity. Kidney 
international 69, 2194-2204. 
 
Powell, W.C., Fingleton, B., Wilson, C.L., Boothby, M., and Matrisian, L.M. (1999). The 
metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates 
epithelial cell apoptosis. Curr Biol 9, 1441-1447. 
 
Pryor, W.A., and Squadrito, G.L. (1995). The chemistry of peroxynitrite: a product from the 
reaction of nitric oxide with superoxide. The American journal of physiology 268, L699-722. 
 
Puthalakath, H., and Strasser, A. (2002). Keeping killers on a tight leash: transcriptional and post-
translational control of the pro-apoptotic activity of BH3-only proteins. Cell death and 
differentiation 9, 505-512. 
 
Radi, R., Beckman, J.S., Bush, K.M., and Freeman, B.A. (1991a). Peroxynitrite-induced 
membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Archives of 
biochemistry and biophysics 288, 481-487. 
 
Radi, R., Beckman, J.S., Bush, K.M., and Freeman, B.A. (1991b). Peroxynitrite oxidation of 
sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. The Journal of biological 
chemistry 266, 4244-4250. 
 
Radi, R., Peluffo, G., Alvarez, M.N., Naviliat, M., and Cayota, A. (2001). Unraveling peroxynitrite 
formation in biological systems. Free radical biology & medicine 30, 463-488. 
 
Rathel, T.R., Leikert, J.J., Vollmar, A.M., and Dirsch, V.M. (2003). Application of 4,5-
diaminofluorescein to reliably measure nitric oxide released from endothelial cells in vitro. 




Reed, J.C. (1995). Regulation of apoptosis by bcl-2 family proteins and its role in cancer and 
chemoresistance. Current opinion in oncology 7, 541-546. 
 
Reed, J.C. (2002). Apoptosis-based therapies. Nature reviews Drug discovery 1, 111-121. 
 
Reinehr, R., Becker, S., Eberle, A., Grether-Beck, S., and Haussinger, D. (2005). Involvement of 
NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. The 
Journal of biological chemistry 280, 27179-27194. 
 
Rhee, S.G., Bae, Y.S., Lee, S.R., and Kwon, J. (2000). Hydrogen peroxide: a key messenger that 
modulates protein phosphorylation through cysteine oxidation. Science's STKE : signal 
transduction knowledge environment 2000, pe1. 
 
Rhee, S.G., Kang, S.W., Chang, T.S., Jeong, W., and Kim, K. (2001). Peroxiredoxin, a novel 
family of peroxidases. IUBMB life 52, 35-41. 
 
Riedl, S.J., and Salvesen, G.S. (2007). The apoptosome: signalling platform of cell death. Nature 
reviews Molecular cell biology 8, 405-413. 
 
Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I.A., Debatin, K.M., Fischer, A., and de 
Villartay, J.P. (1995). Mutations in Fas associated with human lymphoproliferative syndrome and 
autoimmunity. Science 268, 1347-1349. 
 
Rinkenberger, J.L., Horning, S., Klocke, B., Roth, K., and Korsmeyer, S.J. (2000). Mcl-1 
deficiency results in peri-implantation embryonic lethality. Genes & development 14, 23-27. 
 
Rivera, M.P., and Mehta, A.C. (2007). Initial diagnosis of lung cancer: ACCP evidence-based 
clinical practice guidelines (2nd edition). Chest 132, 131S-148S. 
 
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., and Fojo, T. (1996). 
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines 
and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochemical 
pharmacology 52, 1855-1865. 
 
Roberts, J.J., and Thomson, A.J. (1979). The mechanism of action of antitumor platinum 
compounds. Progress in nucleic acid research and molecular biology 22, 71-133. 
 
Rodriguez-Enriquez, S., He, L., and Lemasters, J.J. (2004). Role of mitochondrial permeability 
transition pores in mitochondrial autophagy. The international journal of biochemistry & cell 
biology 36, 2463-2472. 
 
Rolfe, D.F., and Brown, G.C. (1997). Cellular energy utilization and molecular origin of standard 
metabolic rate in mammals. Physiological reviews 77, 731-758. 
 
Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, C.E., Jr., Davidson, N.E., Tan-Chiu, 
E., Martino, S., Paik, S., Kaufman, P.A., et al. (2005). Trastuzumab plus adjuvant chemotherapy 
for operable HER2-positive breast cancer. The New England journal of medicine 353, 1673-1684. 
 
Roos, W.P., and Kaina, B. (2006). DNA damage-induced cell death by apoptosis. Trends in 
molecular medicine 12, 440-450. 
 
Rose, W.C., and Basler, G.A. (1990). In vivo model development of cisplatin-resistant and -
sensitive A2780 human ovarian carcinomas. In Vivo 4, 391-396. 
 
Rosen, A., and Casciola-Rosen, L. (1997). Macromolecular substrates for the ICE-like proteases 




Rosenberg, B., Van Camp, L., Grimley, E.B., and Thomson, A.J. (1967). The inhibition of growth 
or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. The 
Journal of biological chemistry 242, 1347-1352. 
 
Rossin, A., Derouet, M., Abdel-Sater, F., and Hueber, A.O. (2009). Palmitoylation of the TRAIL 
receptor DR4 confers an efficient TRAIL-induced cell death signalling. The Biochemical journal 
419, 185-192, 182 p following 192. 
 
Rothe, M., Wong, S.C., Henzel, W.J., and Goeddel, D.V. (1994). A novel family of putative signal 
transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. 
Cell 78, 681-692. 
 
Rudel, T., and Bokoch, G.M. (1997). Membrane and morphological changes in apoptotic cells 
regulated by caspase-mediated activation of PAK2. Science 276, 1571-1574. 
 
Sakamuro, D., Elliott, K.J., Wechsler-Reya, R., and Prendergast, G.C. (1996). BIN1 is a novel 
MYC-interacting protein with features of a tumour suppressor. Nature genetics 14, 69-77. 
 
Salgo, M.G., Squadrito, G.L., and Pryor, W.A. (1995). Peroxynitrite causes apoptosis in rat 
thymocytes. Biochemical and biophysical research communications 215, 1111-1118. 
 
Salvemini, D., Wang, Z.Q., Stern, M.K., Currie, M.G., and Misko, T.P. (1998). Peroxynitrite 
decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proceedings of the 
National Academy of Sciences of the United States of America 95, 2659-2663. 
 
Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R., and 
Johnson, D.H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung 
cancer. The New England journal of medicine 355, 2542-2550. 
 
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., 
Krammer, P.H., and Peter, M.E. (1998). Two CD95 (APO-1/Fas) signaling pathways. The EMBO 
journal 17, 1675-1687. 
 
Scaffidi, C., Schmitz, I., Zha, J., Korsmeyer, S.J., Krammer, P.H., and Peter, M.E. (1999). 
Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. The Journal of 
biological chemistry 274, 22532-22538. 
 
Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., and 
Shepherd, F.A. (2009). The differential efficacy of pemetrexed according to NSCLC histology: a 
review of two Phase III studies. The oncologist 14, 253-263. 
 
Schweyer, S., Soruri, A., Heintze, A., Radzun, H.J., and Fayyazi, A. (2004). The role of reactive 
oxygen species in cisplatin-induced apoptosis in human malignant testicular germ cell lines. 
International journal of oncology 25, 1671-1676. 
 
Secchiero, P., Gonelli, A., Carnevale, E., Milani, D., Pandolfi, A., Zella, D., and Zauli, G. (2003). 
TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by 
activating the Akt and ERK pathways. Circulation 107, 2250-2256. 
 
Selleri, C., Sato, T., Raiola, A.M., Rotoli, B., Young, N.S., and Maciejewski, J.P. (1997). 
Induction of nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis in 
haemopoietic cells. British journal of haematology 99, 481-489. 
 
Sen, C.K. (2000). Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 36, 
1-30. 
 
Shen, D.W., Liang, X.J., Suzuki, T., and Gottesman, M.M. (2006). Identification by functional 
cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat 




Shen, H.M., and Pervaiz, S. (2006). TNF receptor superfamily-induced cell death: redox-
dependent execution. FASEB journal : official publication of the Federation of American Societies 
for Experimental Biology 20, 1589-1598. 
 
Shenoy, K., Wu, Y., and Pervaiz, S. (2009). LY303511 enhances TRAIL sensitivity of SHEP-1 
neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation 
and up-regulation of death receptors. Cancer Res 69, 1941-1950. 
 
Sheridan, J.P., Marsters, S.A., Pitti, R.M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, 
L., Gray, C.L., Baker, K., Wood, W.I., et al. (1997). Control of TRAIL-induced apoptosis by a 
family of signaling and decoy receptors. Science 277, 818-821 
 
Shi, Y., Frankel, A., Radvanyi, L.G., Penn, L.Z., Miller, R.G., and Mills, G.B. (1995). Rapamycin 
enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer research 55, 1982-1988. 
 
Shimodaira, H., Yoshioka-Yamashita, A., Kolodner, R.D., and Wang, J.Y. (2003). Interaction of 
mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to 
cisplatin. Proceedings of the National Academy of Sciences of the United States of America 100, 
2420-2425. 
 
Shin, M.S., Kim, H.S., Lee, S.H., Park, W.S., Kim, S.Y., Park, J.Y., Lee, J.H., Lee, S.K., Lee, 
S.N., Jung, S.S., et al. (2001). Mutations of tumor necrosis factor-related apoptosis-inducing ligand 
receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer 
research 61, 4942-4946. 
 
Siddik, Z.H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. 
Oncogene 22, 7265-7279. 
 
Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA: a cancer journal for 
clinicians 62, 10-29. 
 
Simon, H.U., Haj-Yehia, A., and Levi-Schaffer, F. (2000). Role of reactive oxygen species (ROS) 
in apoptosis induction. Apoptosis : an international journal on programmed cell death 5, 415-418. 
 
Simons, K., and Toomre, D. (2000). Lipid rafts and signal transduction. Nature reviews Molecular 
cell biology 1, 31-39. 
 
Simons, K., and van Meer, G. (1988). Lipid sorting in epithelial cells. Biochemistry 27, 6197-
6202. 
 
Soderstrom, T.S., Poukkula, M., Holmstrom, T.H., Heiskanen, K.M., and Eriksson, J.E. (2002). 
Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells 
abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and 
caspase-8. J Immunol 169, 2851-2860. 
 
Song, J.H., Tse, M.C., Bellail, A., Phuphanich, S., Khuri, F., Kneteman, N.M., and Hao, C. (2007). 
Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced 
apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer research 67, 
6946-6955. 
 
Song, K., Benhaga, N., Anderson, R.L., and Khosravi-Far, R. (2006). Transduction of tumor 
necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of 
syngeneic tumor growth in vivo. Cancer research 66, 6304-6311. 
 
Sordella, R., Bell, D.W., Haber, D.A., and Settleman, J. (2004). Gefitinib-sensitizing EGFR 
mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167. 
 
Sorenson, C.M., Barry, M.A., and Eastman, A. (1990). Analysis of events associated with cell 
cycle arrest at G2 phase and cell death induced by cisplatin. Journal of the National Cancer 




Sorenson, C.M., and Eastman, A. (1988). Influence of cis-diamminedichloroplatinum(II) on DNA 
synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster 
ovary cells. Cancer research 48, 6703-6707. 
 
Spear, N., Estevez, A.G., Johnson, G.V., Bredesen, D.E., Thompson, J.A., and Beckman, J.S. 
(1998). Enhancement of peroxynitrite-induced apoptosis in PC12 cells by fibroblast growth factor-
1 and nerve growth factor requires p21Ras activation and is suppressed by Bcl-2. Archives of 
biochemistry and biophysics 356, 41-45. 
 
Spira, A., and Ettinger, D.S. (2004). Multidisciplinary management of lung cancer. The New 
England journal of medicine 350, 379-392. 
 
Spitz, D.R., Phillips, J.W., Adams, D.T., Sherman, C.M., Deen, D.F., and Li, G.C. (1993). Cellular 
resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of 
increased catalase activity and total glutathione in hydrogen peroxide-resistant fibroblasts. Journal 
of cellular physiology 156, 72-79. 
 
Srinivasula, S.M., Ahmad, M., Fernandes-Alnemri, T., and Alnemri, E.S. (1998). Autoactivation 
of procaspase-9 by Apaf-1-mediated oligomerization. Molecular cell 1, 949-957. 
 
Srinivasula, S.M., Hegde, R., Saleh, A., Datta, P., Shiozaki, E., Chai, J., Lee, R.A., Robbins, P.D., 
Fernandes-Alnemri, T., Shi, Y., et al. (2001). A conserved XIAP-interaction motif in caspase-9 
and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410, 112-116. 
 
Stamler, J.S., Simon, D.I., Osborne, J.A., Mullins, M.E., Jaraki, O., Michel, T., Singel, D.J., and 
Loscalzo, J. (1992). S-nitrosylation of proteins with nitric oxide: synthesis and characterization of 
biologically active compounds. Proceedings of the National Academy of Sciences of the United 
States of America 89, 444-448. 
 
Stanger, B.Z., Leder, P., Lee, T.H., Kim, E., and Seed, B. (1995). RIP: a novel protein containing a 
death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81, 513-
523. 
 
Starakis, I. (2011). Targeted cancer therapies: current status and future directions. Current 
medicinal chemistry 18, 1573-1574. 
 
Strasser, A., O'Connor, L., and Dixit, V.M. (2000). Apoptosis signaling. Annual review of 
biochemistry 69, 217-245. 
 
Subramanian, J., and Govindan, R. (2007). Lung cancer in never smokers: a review. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 25, 561-570. 
 
Suda, T., Takahashi, T., Golstein, P., and Nagata, S. (1993). Molecular cloning and expression of 
the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178. 
 
Sundstrom, S., Bremnes, R.M., Kaasa, S., Aasebo, U., Hatlevoll, R., Dahle, R., Boye, N., Wang, 
M., Vigander, T., Vilsvik, J., et al. (2002). Cisplatin and etoposide regimen is superior to 
cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a 
randomized phase III trial with 5 years' follow-up. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology 20, 4665-4672. 
 
Susin, S.A., Lorenzo, H.K., Zamzami, N., Marzo, I., Snow, B.E., Brothers, G.M., Mangion, J., 
Jacotot, E., Costantini, P., Loeffler, M., et al. (1999). Molecular characterization of mitochondrial 
apoptosis-inducing factor. Nature 397, 441-446. 
 
Susin, S.A., Zamzami, N., and Kroemer, G. (1998). Mitochondria as regulators of apoptosis: doubt 




Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K., and Takahashi, R. (2001). A serine 
protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. 
Molecular cell 8, 613-621. 
 
Szakacs, G., Annereau, J.P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K.J.,  
Reinhold, W., Guo, Y., Kruh, G.D., Reimers, M., et al. (2004). Predicting drug sensitivity and 
resistance: profiling ABC transporter genes in cancer cells. Cancer cell 6, 129-137. 
 
Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C., and Gottesman, M.M. (2006). 
Targeting multidrug resistance in cancer. Nature reviews Drug discovery 5, 219-234. 
 
Tait, S.W., and Green, D.R. (2010). Mitochondria and cell death: outer membrane 
permeabilization and beyond. Nature reviews Molecular cell biology 11, 621-632. 
 
Takahara, P.M., Rosenzweig, A.C., Frederick, C.A., and Lippard, S.J. (1995). Crystal structure of 
double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377, 
649-652. 
 
Tanaka, M., Itai, T., Adachi, M., and Nagata, S. (1998). Downregulation of Fas ligand by 
shedding. Nat Med 4, 31-36. 
 
Tang, C.H., Parham, C., Shocron, E., McMahon, G., and Patel, N. (2011). Picoplatin overcomes 
resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and 
carboplatin. Cancer chemotherapy and pharmacology 67, 1389-1400. 
 
Tartaglia, L.A., Ayres, T.M., Wong, G.H., and Goeddel, D.V. (1993). A novel domain within the 
55 kd TNF receptor signals cell death. Cell 74, 845-853. 
 
Tartaglia, L.A., Weber, R.F., Figari, I.S., Reynolds, C., Palladino, M.A., Jr., and Goeddel, D.V. 
(1991). The two different receptors for tumor necrosis factor mediate distinct cellular responses. 
Proceedings of the National Academy of Sciences of the United States of America 88, 9292-9296. 
 
Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg, F., Zachariou, A., 
Lopez, J., MacFarlane, M., Cain, K., et al. (2011). The Ripoptosome, a signaling platform that 
assembles in response to genotoxic stress and loss of IAPs. Molecular cell 43, 432-448. 
 
Tran, S.E., Holmstrom, T.H., Ahonen, M., Kahari, V.M., and Eriksson, J.E. (2001). MAPK/ERK 
overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 276, 16484-
16490. 
 
Tsai, C.M., Chang, K.T., Wu, L.H., Chen, J.Y., Gazdar, A.F., Mitsudomi, T., Chen, M.H., and 
Perng, R.P. (1996). Correlations between intrinsic chemoresistance and HER-2/neu gene 
expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer 
cell lines. Cancer research 56, 206-209. 
 
Tsujimoto, Y., Cossman, J., Jaffe, E., and Croce, C.M. (1985). Involvement of the bcl-2 gene in 
human follicular lymphoma. Science 228, 1440-1443. 
 
Um, H.D., Orenstein, J.M., and Wahl, S.M. (1996). Fas mediates apoptosis in human monocytes 
by a reactive oxygen intermediate dependent pathway. J Immunol 156, 3469-3477. 
 
Vakkila, J., and Lotze, M.T. (2004). Inflammation and necrosis promote tumour growth. Nature 
reviews Immunology 4, 641-648. 
 
van der Vliet, A., Eiserich, J.P., Kaur, H., Cross, C.E., and Halliwell, B. (1996). Nitrotyrosine as 
biomarker for reactive nitrogen species. Methods in enzymology 269, 175-184. 
 
van Maanen, J.M., Retel, J., de Vries, J., and Pinedo, H.M. (1988). Mechanism of action of 
antitumor drug etoposide: a review. Journal of the National Cancer Institute 80, 1526-1533. 
225 
 
van Meerbeeck, J.P., Fennell, D.A., and De Ruysscher, D.K. (2011). Small-cell lung cancer. 
Lancet 378, 1741-1755. 
 
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., and Kroemer, G. (2010). Molecular 
mechanisms of necroptosis: an ordered cellular explosion. Nature reviews Molecular cell biology 
11, 700-714. 
 
Vargas-Roig, L.M., Gago, F.E., Tello, O., Aznar, J.C., and Ciocca, D.R. (1998). Heat shock 
protein expression and drug resistance in breast cancer patients treated with induction 
chemotherapy. International journal of cancer Journal international du cancer 79, 468-475. 
Vaux, D.L., and Silke, J. (2005). IAPs, RINGs and ubiquitylation. Nature reviews Molecular cell 
biology 6, 287-297. 
 
Vekris, A., Meynard, D., Haaz, M.C., Bayssas, M., Bonnet, J., and Robert, J. (2004). Molecular 
determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. 
Cancer research 64, 356-362. 
 
Ventura, J.J., Cogswell, P., Flavell, R.A., Baldwin, A.S., Jr., and Davis, R.J. (2004). JNK 
potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen 
species. Genes & development 18, 2905-2915. 
 
Vercammen, D., Beyaert, R., Denecker, G., Goossens, V., Van Loo, G., Declercq, W., Grooten, J., 
Fiers, W., and Vandenabeele, P. (1998). Inhibition of caspases increases the sensitivity of L929 
cells to necrosis mediated by tumor necrosis factor. The Journal of experimental medicine 187, 
1477-1485. 
 
Verhagen, A.M., Ekert, P.G., Pakusch, M., Silke, J., Connolly, L.M., Reid, G.E., Moritz, R.L., 
Simpson, R.J., and Vaux, D.L. (2000). Identification of DIABLO, a mammalian protein that 
promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53. 
 
Vermeulen, N.P., and Baldew, G.S. (1992). The role of lipid peroxidation in the nephrotoxicity of 
cisplatin. Biochemical pharmacology 44, 1193-1199. 
 
Villunger, A., Michalak, E.M., Coultas, L., Mullauer, F., Bock, G., Ausserlechner, M.J., Adams, 
J.M., and Strasser, A. (2003). p53- and drug-induced apoptotic responses mediated by BH3-only 
proteins puma and noxa. Science 302, 1036-1038. 
 
Virag, L., Szabo, E., Gergely, P., and Szabo, C. (2003). Peroxynitrite-induced cytotoxicity: 
mechanism and opportunities for intervention. Toxicology letters 140-141, 113-124. 
 
Vogelstein, B., Lane, D., and Levine, A.J. (2000). Surfing the p53 network. Nature 408, 307-310. 
 
Vogler, M., Walczak, H., Stadel, D., Haas, T.L., Genze, F., Jovanovic, M., Bhanot, U., Hasel, C., 
Moller, P., Gschwend, J.E., et al. (2009). Small molecule XIAP inhibitors enhance TRAIL-
induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer 
research 69, 2425-2434. 
 
Von Hoff, D.D. (1987). Whither carboplatin?--A replacement for or an alternative to cisplatin? 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 5, 169-
171. 
 
Vondalova Blanarova, O., Jelinkova, I., Szoor, A., Skender, B., Soucek, K., Horvath, V., 
Vaculova, A., Andera, L., Sova, P., Szollosi, J., et al. (2011). Cisplatin and a potent platinum(IV) 
complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with 
modulation of upstream events in the extrinsic apoptotic pathway. Carcinogenesis 32, 42-51. 
 
Vousden, K.H., and Lu, X. (2002). Live or let die: the cell's response to p53. Nature reviews 




Wagner, J.M., and Karnitz, L.M. (2009). Cisplatin-induced DNA damage activates replication 
checkpoint signaling components that differentially affect tumor cell survival. Molecular 
pharmacology 76, 208-214. 
 
Wagner, K.W., Punnoose, E.A., Januario, T., Lawrence, D.A., Pitti, R.M., Lancaster, K., Lee, D., 
von Goetz, M., Yee, S.F., Totpal, K., et al. (2007). Death-receptor O-glycosylation controls tumor-
cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13, 1070-1077. 
 
Wallace-Brodeur, R.R., and Lowe, S.W. (1999). Clinical implications of p53 mutations. Cellular 
and molecular life sciences : CMLS 55, 64-75. 
 
Wang, C., Chen, T., Zhang, N., Yang, M., Li, B., Lu, X., Cao, X., and Ling, C. (2009a). Melittin, a 
major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-
JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB. J Biol Chem 284, 3804-3813. 
 
Wang, D., and Lippard, S.J. (2005). Cellular processing of platinum anticancer drugs. Nature 
reviews Drug discovery 4, 307-320. 
 
Wang, J., Zhou, J.Y., and Wu, G.S. (2011). Bim protein degradation contributes to cisplatin 
resistance. The Journal of biological chemistry 286, 22384-22392. 
 
Wang, J., Zhou, J.Y., Zhang, L., and Wu, G.S. (2009b). Involvement of MKP-1 and Bcl-2 in 
acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 8, 3191-3198. 
 
Wang, S., and El-Deiry, W.S. (2003). TRAIL and apoptosis induction by TNF-family death 
receptors. Oncogene 22, 8628-8633. 
 
Wang, W., and Figg, W.D. (2008). Secondary BRCA1 and BRCA2 alterations and acquired 
chemoresistance. Cancer biology & therapy 7, 1004-1005. 
 
Wang, X., Chen, W., Zeng, W., Bai, L., Tesfaigzi, Y., Belinsky, S.A., and Lin, Y. (2008). Akt-
mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced 
cytotoxicity to lung cancer cells. Molecular cancer therapeutics 7, 1156-1163. 
 
Warburg, O., Wind, F., and Negelein, E. (1927). The Metabolism of Tumors in the Body. The 
Journal of general physiology 8, 519-530. 
 
Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., and Nagata, S. (1992). 
Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. 
Nature 356, 314-317. 
 
Watson, R.W., Rotstein, O.D., Jimenez, M., Parodo, J., and Marshall, J.C. (1997). Augmented 
intracellular glutathione inhibits Fas-triggered apoptosis of activated human neutrophils. Blood 89, 
4175-4181. 
 
Wedi, B., Straede, J., Wieland, B., and Kapp, A. (1999). Eosinophil apoptosis is mediated by 
stimulators of cellular oxidative metabolisms and inhibited by antioxidants: involvement of a thiol-
sensitive redox regulation in eosinophil cell death. Blood 94, 2365-2373. 
 
Wei, M.C. (2000). tBID, a membrane-targeted death ligand, oligomerizes BAK to release 
cytochrome c. Genes Dev 14, 2060-2071. 
 
Wei, M.C., Lindsten, T., Mootha, V.K., Weiler, S., Gross, A., Ashiya, M., Thompson, C.B., and 
Korsmeyer, S.J. (2000). tBID, a membrane-targeted death ligand, oligomerizes BAK to release 
cytochrome c. Genes & development 14, 2060-2071. 
 
Weinstein, I.B., and Joe, A.K. (2006). Mechanisms of disease: Oncogene addiction--a rationale for 




Weiss, R.B., and Christian, M.C. (1993). New cisplatin analogues in development. A review. 
Drugs 46, 360-377. 
 
Weiss, W. (1983). Environment and type of lung cancer. The American review of respiratory 
disease 128, 1099-1100. 
 
Wen, L.P., Fahrni, J.A., Troie, S., Guan, J.L., Orth, K., and Rosen, G.D. (1997). Cleavage of focal 
adhesion kinase by caspases during apoptosis. The Journal of biological chemistry 272, 26056-
26061. 
 
Wenger, T., Mattern, J., Penzel, R., Gassler, N., Haas, T.L., Sprick, M.R., Walczak, H., Krammer, 
P.H., Debatin, K.M., and Herr, I. (2006). Specific resistance upon lentiviral TRAIL transfer by 
intracellular retention of TRAIL receptors. Cell death and differentiation 13, 1740-1751. 
 
Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.P., Nicholl, J.K., Sutherland, G.R., 
Smith, T.D., Rauch, C., Smith, C.A., et al. (1995). Identification and characterization of a new 
member of the TNF family that induces apoptosis. Immunity 3, 673-682. 
 
Wiseman, H., and Halliwell, B. (1996). Damage to DNA by reactive oxygen and nitrogen species: 
role in inflammatory disease and progression to cancer. The Biochemical journal 313 ( Pt 1), 17-
29. 
 
Wong, E., and Giandomenico, C.M. (1999). Current status of platinum-based antitumor drugs. 
Chemical reviews 99, 2451-2466. 
 
Wright, C.W., and Duckett, C.S. (2005). Reawakening the cellular death program in neoplasia 
through the therapeutic blockade of IAP function. The Journal of clinical investigation 115, 2673-
2678. 
 
Wu, W., Wang, H.D., Guo, W., Yang, K., Zhao, Y.P., Jiang, Y.G., and He, P. (2010). Up-
regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells. Journal of 
experimental & clinical cancer research : CR 29, 49. 
 
Wu, Y., Mehew, J.W., Heckman, C.A., Arcinas, M., and Boxer, L.M. (2001). Negative regulation 
of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20, 240-251. 
 
Wuilleme-Toumi, S., Robillard, N., Gomez, P., Moreau, P., Le Gouill, S., Avet-Loiseau, H., 
Harousseau, J.L., Amiot, M., and Bataille, R. (2005). Mcl-1 is overexpressed in multiple myeloma 
and associated with relapse and shorter survival. Leukemia : official journal of the Leukemia 
Society of America, Leukemia Research Fund, UK 19, 1248-1252. 
 
Xia, Y., and Zweier, J.L. (1997). Superoxide and peroxynitrite generation from inducible nitric 
oxide synthase in macrophages. Proceedings of the National Academy of Sciences of the United 
States of America 94, 6954-6958. 
 
Xu, L., Qu, X.J., Liu, Y.P., Liu, J., Zhang, Y., Hou, K.Z., and Jiang, Y.H. (2011a). [Cisplatin 
enhances TRAIL-induced apoptosis in gastric cancer cells through clustering death receptor 4 into 
lipid rafts]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 33, 484-488. 
 
Xu, L., Yin, S., Banerjee, S., Sarkar, F., and Reddy, K.B. (2011b). Enhanced anticancer effect of 
the combination of cisplatin and TRAIL in triple-negative breast tumor cells. Molecular cancer 
therapeutics 10, 550-557. 
 
Yamaguchi, Y., Shiraki, K., Fuke, H., Inoue, T., Miyashita, K., Yamanaka, Y., Saitou, Y., 
Sugimoto, K., and Nakano, T. (2005). Targeting of X-linked inhibitor of apoptosis protein or 
survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing 




Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R.M., 
Okamoto, A., Yokota, J., Tanaka, T., et al. (2006). Unique microRNA molecular profiles in lung 
cancer diagnosis and prognosis. Cancer cell 9, 189-198. 
 
Yang, P., Schwartz, A.G., McAllister, A.E., Swanson, G.M., and Aston, C.E. (1999). Lung cancer 
risk in families of nonsmoking probands: heterogeneity by age at diagnosis. Genetic epidemiology 
17, 253-273. 
 
Youle, R.J., and Strasser, A. (2008). The BCL-2 protein family: opposing activities that mediate 
cell death. Nature reviews Molecular cell biology 9, 47-59. 
 
Zamble, D.B., Mu, D., Reardon, J.T., Sancar, A., and Lippard, S.J. (1996). Repair of cisplatin--
DNA adducts by the mammalian excision nuclease. Biochemistry 35, 10004-10013. 
 
Zauli, G., Pandolfi, A., Gonelli, A., Di Pietro, R., Guarnieri, S., Ciabattoni, G., Rana, R., Vitale, 
M., and Secchiero, P. (2003). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. 
Circulation research 92, 732-740. 
 
Zeng-Rong, N., Paterson, J., Alpert, L., Tsao, M.S., Viallet, J., and Alaoui-Jamali, M.A. (1995). 
Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to 
chemotherapy. Cancer research 55, 4760-4764. 
 
Zhang, H., Zhou, X., McQuade, T., Li, J., Chan, F.K., and Zhang, J. (2011). Functional 
complementation between FADD and RIP1 in embryos and lymphocytes. Nature 471, 373-376. 
 
Zhang, L., and Fang, B. (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. 
Cancer gene therapy 12, 228-237. 
 
Zhang, P., Zhang, Z., Zhou, X., Qiu, W., Chen, F., and Chen, W. (2006). Identification of genes 
associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC cancer 
6, 224. 
 
Zhuang, S., and Schnellmann, R.G. (2006). A death-promoting role for extracellular signal-
regulated kinase. J Pharmacol Exp Ther 319, 991-997. 
Zhuang, S., and Simon, G. (2000). Peroxynitrite-induced apoptosis involves activation of multiple 
caspases in HL-60 cells. American journal of physiology Cell physiology 279, C341-351. 
 
Zinkewich-Peotti, K., and Andrews, P.A. (1992). Loss of cis-diamminedichloroplatinum(II) 
resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer 
research 52, 1902-1906. 
 
Zong, W.X., and Thompson, C.B. (2006). Necrotic death as a cell fate. Genes & development 20, 
1-15. 
 
Zou, W., Liu, X., Yue, P., Zhou, Z., Sporn, M.B., Lotan, R., Khuri, F.R., and Sun, S.Y. (2004). c-
Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of 
apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate 
in human lung cancer cells. Cancer Res 64, 7570-7578. 
 
 
 
